U.S. patent number RE47,741 [Application Number 16/009,020] was granted by the patent office on 2019-11-26 for antibacterial aminoglycoside analogs.
This patent grant is currently assigned to Achaogen, Inc.. The grantee listed for this patent is Achaogen, Inc.. Invention is credited to James Bradley Aggen, Paola Dozzo, Adam Aaron Goldblum, Martin Sheringham Linsell.
![](/patent/grant/RE047741/USRE047741-20191126-C00001.png)
![](/patent/grant/RE047741/USRE047741-20191126-C00002.png)
![](/patent/grant/RE047741/USRE047741-20191126-C00003.png)
![](/patent/grant/RE047741/USRE047741-20191126-C00004.png)
![](/patent/grant/RE047741/USRE047741-20191126-C00005.png)
![](/patent/grant/RE047741/USRE047741-20191126-C00006.png)
![](/patent/grant/RE047741/USRE047741-20191126-C00007.png)
![](/patent/grant/RE047741/USRE047741-20191126-C00008.png)
![](/patent/grant/RE047741/USRE047741-20191126-C00009.png)
![](/patent/grant/RE047741/USRE047741-20191126-C00010.png)
![](/patent/grant/RE047741/USRE047741-20191126-C00011.png)
View All Diagrams
United States Patent |
RE47,741 |
Dozzo , et al. |
November 26, 2019 |
Antibacterial aminoglycoside analogs
Abstract
Compounds having antibacterial activity are disclosed. The
compounds have the following structure (I): ##STR00001## including
stereoisomers, pharmaceutically acceptable salts and prodrugs
thereof, wherein Q.sub.1, Q.sub.2, Q.sub.3, R.sub.11 and R.sub.12
are as defined herein. Methods associated with preparation and use
of such compounds, as well as pharmaceutical compositions
comprising such compounds, are also disclosed.
Inventors: |
Dozzo; Paola (San Francisco,
CA), Goldblum; Adam Aaron (Berkeley, CA), Aggen; James
Bradley (Burlingame, CA), Linsell; Martin Sheringham
(San Mateo, CA) |
Applicant: |
Name |
City |
State |
Country |
Type |
Achaogen, Inc. |
South San Francisco |
CA |
US |
|
|
Assignee: |
Achaogen, Inc. (South San
Francisco, CA)
|
Family
ID: |
42244665 |
Appl.
No.: |
16/009,020 |
Filed: |
June 14, 2018 |
Related U.S. Patent Documents
|
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
Issue Date |
|
|
PCT/US2010/034896 |
May 14, 2010 |
|
|
|
|
61312356 |
Mar 10, 2010 |
|
|
|
|
61178834 |
May 15, 2009 |
|
|
|
Reissue of: |
13295227 |
Nov 14, 2011 |
8492354 |
Jul 23, 2013 |
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
C07H
15/236 (20130101); C07H 15/236 (20130101); A61P
31/04 (20180101) |
Current International
Class: |
A01N
43/04 (20060101); A61K 31/70 (20060101); C07H
17/00 (20060101); C07H 15/00 (20060101); C07H
15/236 (20060101) |
Field of
Search: |
;514/40 |
References Cited
[Referenced By]
U.S. Patent Documents
Foreign Patent Documents
|
|
|
|
|
|
|
1 034 573 |
|
Jul 1978 |
|
CA |
|
1 105 452 |
|
Jul 1981 |
|
CA |
|
1 105 454 |
|
Jul 1981 |
|
CA |
|
1 397 562 |
|
Feb 2003 |
|
CN |
|
24 37 160 |
|
Feb 1975 |
|
DE |
|
24 40 956 |
|
Mar 1975 |
|
DE |
|
24 58 921 |
|
Jun 1975 |
|
DE |
|
25 55 405 |
|
Jun 1976 |
|
DE |
|
27 48 257 |
|
May 1978 |
|
DE |
|
28 18 822 |
|
Nov 1978 |
|
DE |
|
29 36 120 |
|
Mar 1980 |
|
DE |
|
31 00 739 |
|
Aug 1982 |
|
DE |
|
31 08 068 |
|
Sep 1982 |
|
DE |
|
34 05 326 |
|
Aug 1985 |
|
DE |
|
0 001 643 |
|
May 1979 |
|
EP |
|
0 002 450 |
|
Jun 1979 |
|
EP |
|
0 009 670 |
|
Apr 1980 |
|
EP |
|
0 056 575 |
|
Jul 1982 |
|
EP |
|
1 470 329 |
|
Apr 1977 |
|
GB |
|
1 473 733 |
|
May 1977 |
|
GB |
|
1 494 129 |
|
Dec 1977 |
|
GB |
|
1 535 215 |
|
Dec 1978 |
|
GB |
|
2 030 141 |
|
Apr 1980 |
|
GB |
|
1 583 366 |
|
Jan 1981 |
|
GB |
|
1 598 294 |
|
Sep 1981 |
|
GB |
|
54-46770 |
|
Apr 1979 |
|
JP |
|
54-61151 |
|
May 1979 |
|
JP |
|
55-000329 |
|
May 1980 |
|
JP |
|
55-17397 |
|
Jun 1980 |
|
JP |
|
56-15298 |
|
Feb 1981 |
|
JP |
|
1-254694 |
|
Oct 1989 |
|
JP |
|
623524 |
|
Dec 1975 |
|
SU |
|
WO 2005/070945 |
|
Aug 2005 |
|
WO |
|
WO 2006/052930 |
|
May 2006 |
|
WO |
|
WO 2007/028012 |
|
Mar 2007 |
|
WO |
|
WO 2007/064954 |
|
Jun 2007 |
|
WO |
|
WO 2008/124821 |
|
Oct 2008 |
|
WO |
|
WO 2009/067692 |
|
May 2009 |
|
WO |
|
WO 2010/030690 |
|
Mar 2010 |
|
WO |
|
WO 2010/030704 |
|
Mar 2010 |
|
WO |
|
WO 2010/042850 |
|
Apr 2010 |
|
WO |
|
WO 2010/042851 |
|
Apr 2010 |
|
WO |
|
WO 2010/132757 |
|
Nov 2010 |
|
WO |
|
WO 2010/132759 |
|
Nov 2010 |
|
WO |
|
WO 2010/132760 |
|
Nov 2010 |
|
WO |
|
WO 2010/132765 |
|
Nov 2010 |
|
WO |
|
WO 2010/132768 |
|
Nov 2010 |
|
WO |
|
WO 2010/132770 |
|
Nov 2010 |
|
WO |
|
WO 2010/132777 |
|
Nov 2010 |
|
WO |
|
WO 2010/132839 |
|
Nov 2010 |
|
WO |
|
WO 2010/147836 |
|
Dec 2010 |
|
WO |
|
WO 2011/044498 |
|
Apr 2011 |
|
WO |
|
WO 2011/044501 |
|
Apr 2011 |
|
WO |
|
WO 2011/044502 |
|
Apr 2011 |
|
WO |
|
WO 2011/044503 |
|
Apr 2011 |
|
WO |
|
WO 2011/044538 |
|
Apr 2011 |
|
WO |
|
WO 2012/067978 |
|
May 2012 |
|
WO |
|
Other References
Kotretsou et al., "Synthesis and Antimicrobial and Toxicological
Studies of Amino Acid and Peptide Derivatives of Kanamycin A and
Netilmicin", J. Med. Chem., 1995, 38, 4710-4719 (Year: 1995). cited
by examiner .
U.S. Appl. No. 15/837,995, filed Dec. 11, 2017, Aggen et al. cited
by applicant .
Wolff, Manfred E. "Burger's Medicinal Chemistry, 5ed, Part I", John
Wiley & Sons, 1995, pp. 975-977. cited by examiner .
Banker, G.S. et al, "Modern Pharmaceutics, 3ed.", Marcel Dekker,
New York, 1996, p. 596. cited by examiner .
Centron et al., Antimicrobial Agents and Chemotherapy , Jun. 1998,
vol. 42, No. 6, pp. 1506-1508. cited by examiner .
Adachi et al., "Synthesis and Evaluation of Aminoglycosides as
Inhibitors for Rev binding to Rev Responsive Element," Letters in
Drug Design & Discovery 3:71-75, 2006. cited by applicant .
Afonso et al., "Synthesis of 1-N-Peptidyl Derivatives of
Sisomicin," Current Chemotherapy and Infectious Disease,
Proceedings of the 11.sup.th International Congress of Chemotherapy
and the 19.sup.th Interscience Conference on Antimicrobial Agents
and Chemotherapy 1:405-406, 1980 (7 pages total). cited by
applicant .
Aggen et al., "Synthesis, Structure, and In Vitro Activity of the
Neoglycoside ACHN-490," Poster No. FI-840 presented at 49.sup.th
Interscience Conference on Antimicrobial Agents and Chemotherapy
(ICAAC), San Francisco, California, Sep. 12-15, 2009 (+ Abstract
085(F1) p. 185) (3 pages). cited by applicant .
Ahsen et al., "Non-competitive Inhibition of Group I Intron RNA
Self-splicing by Aminoglycoside Antibiotics," J. Mol. Biol.
226(4):935-941, 1992. cited by applicant .
Alhambra et al., "In vitro susceptibility of recent
antibiotic-resistant urinary pathogens to ertapenem and 12 other
antibiotics," Journal of Antimicrobial Chemotherapy 53:1090-1094,
2004. cited by applicant .
Alper et al., "Probing the Specificity of Aminoglycoside--Ribosomal
RNA Interactions with Designed Synthetic Analogs," J. Am. Chem.
Soc. 120(9):1965-1978, 1998. cited by applicant .
Andes et al., "Pharmacodynamics of the New Fluoroquinolone
Gatifloxacin in Murine Thigh and Lung Infection Models,"
Antimicrobial Agents and Chemotherapy 46(6):1665-1670, Jun. 2002.
cited by applicant .
Armstrong et al., "Surveying Aminoglycoside-Resistance Mechanisms:
A Tool for the Development of Neoglycosides," Presented at
19.sup.th European Congress of Clinical Microbiology and Infectious
Diseases (ECCMID), Helsinki, Finland, May 16-19, 2009 (+ Abstract
P643, p. S149). cited by applicant .
Bailey et al., "Comparison of single dose netilmicin with a
five-day course of co-trimoxazole for uncomplicated urinary tract
infections," New Zealand Medical Journal 97:262-264, 1984. cited by
applicant .
Bassaris et al., "Once-Daily High-Dose Netilmicin--A New Short-Term
Treatment Regimen for Patients with Moderate to Severe
Gram-Negative Infections," Clin. Drug Invest. 15(3):205-216, 1998.
cited by applicant .
Beauchamp et al., "Pharmacologic Basis for the Treatment of
Pyelonephritis," Current Infectious Disease Reports 1:371-378,
1999. cited by applicant .
Benenson et al., "Carbapenem-resistant Klebsiella pneumoniae
endocarditis in a young adult Successful treatment with gentamicin
and colistin," International Journal of Infectious Diseases
13:e295-e298, 2009. cited by applicant .
Bergeron, "Treatment of Pyelonephritis in Adults," Medical Clinics
of North America 79(3):619-649, May 1995. cited by applicant .
Biedenbach et al., "Ten Year Trend in Aminoglycoside Resistance
from a Worldwide Collection of Gram-Negative Pathogens
(1998-2007)," Poster No. 636 presented at 19th European Congress of
Clinical Microbiology and Infectious Diseases (ECCMID), Helsinki,
Finland, May 16-19, 2009 (+ Abstract P636, p. S147). cited by
applicant .
Biedenbach et al., "Activity of ACHN-490 Against Complicated
Urinary Tract Infection (cUTI) Pathogens From the United States and
Europe," ICAAC 2009, Poster # F1-843, 1 page. cited by applicant
.
Blaser et al., "Multicenter Quality Control Study of Amikacin Assay
for Monitoring Once-Daily Dosing Regimens," Therapeutic Drug
Monitoring 17:133-136, 1995. cited by applicant .
Bonfiglio et al., "In vitro Activity of Piperacillin/Tazobactam
against 615 Pseudomonas aeruginosa Strains Isolated in Intensive
Care Units," Chemotherapy 44:305-312, 1998. cited by applicant
.
Boxler et al., "Semisynthetic Aminoglycoside Antibacterials. Part
9. Synthesis of Novel 1- and 3-Substituted and 1- and
3-epi-Substituted Derivatives of Sisomicin and Gentamicin from the
1-and 3-Oxo-derivatives," J.C.S. Perkin I:2168-2185, 1981. cited by
applicant .
Bratu et al., "Carbapenemase-producing Klebsiella pneumoniae in
Brooklyn, NY: molecular epidemiology and in vitro activity of
polymyxin B and other agents," Journal of Antimicrobial
Chemotherapy 56:128-132, 2005. cited by applicant .
Brummett et al., "Ototoxicity of tobramycin, gentamicin, amikacin
and sisomicin in the guinea pig," Journal of Antimicrobial
Chemotherapy 4(Suppl. A):73-83, 1978. cited by applicant .
Buijk et al., "Experience with a once-daily dosing program of
aminoglycosides in critically ill patients," Intensive Care
Med.28:936-942, 2002. cited by applicant .
Carapetis et al., "Randomized, controlled trial comparing once
daily and three times daily gentamicin in children with urinary
tract infections," Pediatr. Infect. Dis. J. 20(3):240-246, 2001.
cited by applicant .
Cass et al., "Pharmacokinetics of the Novel Neoglycoside ACHN-490
in Mouse, Rat, and Dog," ICAAC 2009, Poster # F1-846, 1 page. cited
by applicant .
Centron et al., "Characterization of the 6'-N-Aminoglycoside
Acetyltransferase Gene aac(6')-Iq from the Integron of a Natural
Multiresistance Plasmid," Antimicrobial Agents and Chemotherapy
42(6):1506-1508, Jun. 1998. cited by applicant .
Chambers, H. F., Goodman & Gilman's The Pharmcological Basis of
Therapeutics, Eleventh Edition, Brunton et al. (ed.), McGraw-Hill,
Inc., New York, 2006, Chapter 45, "Aminoglycosides," pp. 1155-1171
(+ 3 cover pages). cited by applicant .
Chanal et al., "Comparative Study of a Novel Plasmid-Mediated
.beta..-Lactamase, CAZ-2, and the CTX-1 and CAZ-1 Enzymes
Conferring Resistance to Broad-Spectrum Cephalosporins,"
Antimicrobial Agents and Chemotherapy 32(11):1660-1665, Nov. 1988.
cited by applicant .
Chow et al., "A Structural Basis for RNA-Ligand Interactions,"
Chem. Rev. 97(5):1489-1513, Jul./Aug. 1997. cited by applicant
.
Christenson et al., "In vitro activity of meropenem, imipenem,
cefepime and ceftazidime against Pseudomonas aeruginosa isolates
from cystic fibrosis patients," Journal of Antimicrobial
Chemotherapy 45:899-901, 2000. cited by applicant .
Conil et al., "Increased amikacin dosage requirements in burn
patients receiving a once-daily regimen," International Journal of
Antimicrobial Agents 28:226-230, 2006. cited by applicant .
Credito et al., "Activity of Daptomycin Alone and in Combination
with Rifampin and Gentamicin against Staphylococcus aureus Assessed
by Time-Kill Methodology," Antimicrobial Agents and Chemotherapy
51(4):1504-1507, Apr. 2007. cited by applicant .
Cunha, B.A., "Aminoglycosides in Urology," Urology 36(1):1-14, Jul.
1990. cited by applicant .
Daniels et al., "Semisynthetic Aminoglycoside Antibacterials. Part
11. Solution Conformations of Semisynthetic and Naturally Occurring
Aminoglycoside Antibiotics," J. Chem. Soc., Perkin Trans.
1:2209-2227, 1981. cited by applicant .
Daniels et al., "Some Recent Advances in the Chemistry of
Antibiotics of the Gentamicin Series," The Japanese Journal of
Antibiotics 32(S-195) (11 pages), Dec. 1979. cited by applicant
.
Davies et al., "Semisynthetic Aminoglycoside Antibacterials. 6.
Synthesis of Sisomicin, Antibiotic G-52, and Novel 6'-Substituted
Analogues of Sisomicin from Aminoglycoside 66-40C," 0 Journal of
Medicinal Chemistry 21(2):189-193, 1978. cited by applicant .
De Broe et al., "Influence of dosage schedule on renal cortical
accumulation of amikacin and tobramycin in man," Journal of
Antimicrobial Chemotherapy 27(Suppl. C):41-47, 1991. cited by
applicant .
de Vries et al., "Prospective Randomized Study of Once-Daily versus
Thrice-Daily Netilmicin Regimens in Patients with Intraabdominal
Infections," Eur. J. Clin. Microbiol. Infect. Dis. 9(3):161-168,
Mar. 1990. cited by applicant .
Doi et al., "16S Ribosomal RNA Methylation: Emerging Resistance
Mechanism against Aminoglycosides," Clinical Infectious Diseases
45:88-94, Jul. 1, 2007. cited by applicant .
Dozzo et al., "New aminoglycoside antibiotics," Expert Opin. Ther.
Patents 20(10):1-21, 2010. cited by applicant .
Drusano et al., "Back to the Future: Using Aminoglycosides Again
and How to Dose Them Optimally," Clinical Infectious Diseases
45:753-760, Sep. 15, 2007. cited by applicant .
Echols et al., "Demographic, Clinical, and Treatment Parameters
Influencing the Outcome of Acute Cystitis," Clinical Infectious
Diseases 29(1):113-119, Jul. 1999. cited by applicant .
Endimiani et al., "Presence of Plasmid-Mediated Quinolone
Resistance in Klebsiella pneumoniae Isolates Possessing bla.sub.KPC
in the United States," Antimicrobial Agents and Chemotherapy
52(7):2680-2682, Jul. 2008. cited by applicant .
Endimiani et al., "Characterization of bla.sub.KPC-containing
Klebsiella pneumoniae isolates detected in different institutions
in the Eastern USA," Journal of Antimicrobial Chemotherapy
63:427-437, 2009. cited by applicant .
Endiamiani et al., "ACHN-490, a Neoglycoside with Potent in Vitro
Activity against Multidrug-Resistant Klebsiella pneumoniae
Isolates," Antimicrobial Agents and Chemotherapy 53(10):4504-4507,
Oct. 2009. cited by applicant .
Etra et al., "Sisomicin in Urinary Tract Infection. Tolerance and
Efficacy Study," Urology 7(2):160-164, Feb. 1976. cited by
applicant .
Food & Drug Administration, Center for Drug Evaluation and
Research (CDER), U.S. Department of Health and Human Services,
Guidance for Industry, Complicated Urinary Tract Infections and
Pyelonephritis--Developing Antimicrobial Drugs for Treatment, Draft
Guidance, Jul. 1998, 11 pages. cited by applicant .
Forge et al., "Aminoglycoside Antibiotics," Audiol. Neurootol.
5:3-22, 2000. cited by applicant .
Freeman et al., "Once-daily dosing of aminoglycosides: review and
recommendations for clinical practice," Journal of Antimicrobial
Chemotherapy 39:677-686, 1997. cited by applicant .
French, G. L., "Bactericidal agents in the treatment of MRSA
infections--the potential role of daptomycin," Journal of
Antimicrobial Chemotherapy 58:1107-1117, 2006. cited by applicant
.
Gaynes et al., "Overview of Nosocomial Infections Caused by
Gram-Negative Bacilli," Clinical Infectious Diseases 41:848-854,
Sep. 15, 2005. cited by applicant .
Georgescu et al., "Activity of ACHN-490, a Novel Neoglycoside
Antibiotic, Against Contemporary Gram-Negative Clinical Isolates
from Brooklyn, NY Hospitals," ICAAC 2009, Poster # F1-842, 1 page.
cited by applicant .
Giuliano et al., "The Effect of Dosing Strategy on Kidney Cortical
Accumulation of Aminoglycosides in Rats," American Journal of
Kidney Diseases 8(5):297-303, Nov. 1986. cited by applicant .
Giuliano et al., "In Vivo Uptake Kinetics of Aminoglycosides in the
Kidney Cortex of Rats," The Journal of Pharmacology and
Experimental Therapeutics 236(2):470-475, 1986. cited by applicant
.
Goldfarb et al., "Detection of Plasmid-Mediated KPC-Producing
Klebsiella pneumoniae in Ottawa, Canada: Evidence of Intrahospital
Transmission," Journal of Clinical Microbiology 47(6):1920-1922,
Jun. 2009. cited by applicant .
Goossens et al., "Prevalence and antimicrobial susceptibility data
for extended-spectrum .beta.-lactamase- and AmpC-producing
Enterobacteriaceae from the MYSTIC Program in Europe and the United
States (1997-2004)," Diagnostic Microbiology and Infectious Disease
53:257-264, 2005. cited by applicant .
Griebling, T. L., "Urinary Tract Infection in Women," in Litwin et
al. (eds.), Urologic Diseases in America, DHHS, PHS, NIH, NIDDK,
Washington, D.C.: GPO, 2007, NIH Publication 07-5512:587-619. cited
by applicant .
Grohs et al., "In Vitro Bactericidal Activities of Linezolid in
Combination with Vancomycin, Gentamicin, Ciprofloxacin, Fusidic
Acid, and Rifampin against Staphylococcus aureus," Antimicrobial
Agents and Chemotherapy 47(1):418-420, Jan. 2003. cited by
applicant .
Guan et al., "A biochemical basis for the inherited susceptibility
to aminoglycoside ototoxicity," Human Molecular Genetics
9(12):1787-1793, 2000. cited by applicant .
Gulmez et al., "Carbapenem-resistant Escherichia coli and
Klebsiella pneumoniae isolates from Turkey with OXA-48-like
carbapenemases and outer membrane protein loss," International
Journal of Antimicrobial Agents 31:523-526, 2008. cited by
applicant .
Hanessian et al., "Probing the functional requirements of the
L-haba side-chain of amikacin-synthesis, 16S A-site rRNA binding,
and antibacterial activity," Tetrahedron 59:995-1007, 2003. cited
by applicant .
Hare et al., "Evaluation of New 1-N-Substituted Aminoglycosides
Against Strains with Known Resistance Mechanisms," Current
Chemotherapy and Infectious Disease, Proceedings of the 11th
International Congress of Chemotherapy and the 19th Interscience
Conference on Antimicrobial Agents and Chemotherapy 1:403-405, 1980
(7 pages total). cited by applicant .
Harrison, L. H., "Treatment of Complicated Urinary Tract Infections
With Amikacin," Urology 10(2):110-113, Aug. 1977. cited by
applicant .
Hawkey et al., "The changing epidemiology of resistance," Journal
of Antimicrobial Chemotherapy 64(Suppl 1):i3-i10, 2009. cited by
applicant .
Hawser et al., "In vitro susceptibilities of aerobic and
facultative anaerobic Gram-negative bacilli from patients with
intra-abdominal infections worldwide from 2005-2007: results from
the SMART study," International Journal of Antimicrobial Agents
34:585-588, 2009. cited by applicant .
Hermann, T., "Biomedicine & Diseases: Review. Aminoglycoside
antibiotics: old drugs and new therapeutic approaches," Cell. Mol.
Life. Sci. 64:1841-1852, 2007. cited by applicant .
Hiraiwa et al., "Synthesis and antibacterial activity of
5-deoxy-5-episubstituted arbekacin derivatives," Bioorganic &
Medicinal Chemistry Letters 17:3540-3543, 2007. cited by applicant
.
Hirakata et al., "Regional variation in the prevalence of
extended-spectrum .beta.-lactamase-producing clinical isolates in
the Asia-Pacific region (SENTRY 1998-2002)," Diagnostic
Microbiology and Infectious Disease 52:323-329, 2005. cited by
applicant .
Hottendorf et al., "Nonparallel Nephrotoxicity Dose-Response Curves
of Aminoglycosides," Antimicrobial Agents and Chemotherapy
19(6):1024-1028, Jun. 1981. cited by applicant .
Hujer et al., "Analysis of Antibiotic Resistance Genes in
Multidrug-Resistant Acinetobacter sp. Isolates from Military and
Civilian Patients Treated at the Walter Reed Army Medical Center,"
Antimicrobial Agents and Chemotherapy 50(12):4114-4123, Dec. 2006.
cited by applicant .
International Preliminary Report on Patentability, for
International Application No. PCT/US2008/084399, mailed May 25,
2010, 6 pages. cited by applicant .
International Preliminary Report on Patentability, for
International Application No. PCT/US2010/038138, mailed Jan. 5,
2012, 11 pages. cited by applicant .
International Preliminary Report on Patentability, for
International Application No. PCT/US2010/035006, mailed Nov. 24,
2011, 26 pages. cited by applicant .
International Preliminary Report on Patentability, for
International Application No. PCT/US2010/034898, mailed Nov. 24.
2011, 13 pages. cited by applicant .
International Preliminary Report on Patentability, for
International Application No. PCT/US2010/034909, mailed Nov. 24,
2011. 17 pages. cited by applicant .
International Preliminary Report on Patentability, for
International Application No. PCT/US2010/034896, mailed Nov. 24,
2011, 14 pages. cited by applicant .
International Preliminary Report on Patentability, for
International Application No. PCT/US2010/034893, mailed Nov. 24,
2011, 14 pages. cited by applicant .
International Preliminary Report on Patentability, for
International Application No. PCT/US2010/034888, mailed Nov. 24,
2011, 15 pages. cited by applicant .
International Preliminary Report on Patentability, for
International Application No. PCT/US2010/034886, mailed Nov. 24,
2011, 15 pages. cited by applicant .
International Preliminary Report on Patentability, for
International Application No. PCT/US2010/034884, mailed Nov. 24,
2011, 12 pages. cited by applicant .
International Search Report and Written Opinion, for International
Application No. PCT/US2008/084399, mailed Apr. 21, 2009, 8 pages.
cited by applicant .
International Search Report and Written Opinion, for International
Application No. PCT/US2010/034886, mailed Aug. 25, 2010, 19 pages.
cited by applicant .
International Search Report and Written Opinion, for International
Application No. PCT/US2010/034888, mailed Aug. 25, 2010, 21 pages.
cited by applicant .
International Search Report and Written Opinion, for International
Application No. PCT/US2010/034893, mailed May 3, 2011, 20 pages.
cited by applicant .
International Search Report and Written Opinion for International
Application No. PCT/US2010/034896, mailed Sep. 6, 2010, 21 pages.
cited by applicant .
International Search Report and Written Opinion for International
Application No. PCT/US2010/034909, mailed Dec. 2, 2010, 31 pages.
cited by applicant .
International Search Report and Written Opinion, for International
Application No. PCT/US2010/034898, mailed Oct. 8, 2010, 23 pages.
cited by applicant .
International Search Report and Written Opinion for
PCT/US2010/035006, mailed Dec. 8, 2010, 39 pages. cited by
applicant .
International Search Report and Written Opinion for
PCT/US2010/038138, mailed Aug. 20, 2010, 18 pages. cited by
applicant .
International Search Report and Written Opinion for
PCT/US2010/034884, mailed Mar. 1, 2011, 19 pages. cited by
applicant .
Invitation to Pay Additional Fees and Partial International Search
Report for PCT/US2010/034884, mailed Oct. 26, 2010, 7 pages. cited
by applicant .
Invitation to Pay Additional Fees, and Partial International Search
Report, for International Application No. PCT/US2010/034886, mailed
Jul. 2, 2010, 4 pages. cited by applicant .
Invitation to Pay Additional Fees, and Partial International Search
Report, for International Application No. PCT/US2010/034888, mailed
Jun. 30, 2010, 5 pages. cited by applicant .
Invitation to Pay Additional Fees and, Where Applicable, Protest
Fee, for International Application No. PCT/US2010/034893, mailed
Mar. 2, 2011, 9 pages. cited by applicant .
Invitation to Pay Additional Fees, and Partial International Search
Report, for International Application No. PCT/US2010/034896, mailed
Jul. 12, 2010, 6 pages. cited by applicant .
Invitation to Pay Additional Fees, and Partial International Search
Report, for International Application No. PCT/US2010/034898, mailed
Aug. 4, 2010, 5 pages. cited by applicant .
Invitation to Pay Additional Fees, and Partial International Search
Report, for International Application No. PCT/US2010/034909, mailed
Aug. 25, 2010, 7 pages. cited by applicant .
Invitation to Pay Additional Fees, and Partial International Search
Report, for International Application No. PCT/US2010/035006, mailed
Aug. 18, 2010, 8 pages. cited by applicant .
Jana et al., "Molecular understanding of aminoglycoside action and
resistance," Appl Microbiol Biotechnol 70:140-150, 2006. cited by
applicant .
Johnson et al., "Urinary Tract Infections in Women: Diagnosis and
Treatment," Annals of Internal Medicine 111:906-917, 1989. cited by
applicant .
Jones et al., "Antimicrobial Activity of ACHN-490, a Neoglycoside,
Tested Against a Contemporary Collection of Clinical Isolates
Including Problematic Antimicrobial-Resistant Phenotypes," ICAAC
2009, Poster # F1-846a, 1 page. cited by applicant .
Jones et al., "Spectrum and activity of three contemporary
fluoroquinolones tested against Pseudomonas aeruginosa isolates
from urinary tract infections in the SENTRY Antimicrobial
Surveillance Program (Europe and the Americas; 2000): More alike
than different!" Diagnostic Microbiology and Infectious Disease
41:161-163, 2001. cited by applicant .
Kahlmeter et al., "Aminoglycoside toxicity--a review of clinical
studies published between 1975 and 1982," J. Antimicrob. Chemo.
13(Suppl. A):9-22, 1984. cited by applicant .
Kahlmeter et al., "Cross-resistance and associated resistance in
2478 Escherichia coli isolates from the Pan-European ECO.cndot.SENS
Project surveying the antimicrobial susceptibility of pathogens
from uncomplicated urinary tract infections," J. Antimirob. Chemo.
52(1):128-131, 2003. cited by applicant .
Karlowsky et al., "Trends in Antimicrobial Resistance among Urinary
Tract Infection Isolates of Escherichia coli from Female
Outpatients in the United States," Antimicrobial Agents and
Chemotherapy 46(8):2540-2545, Aug. 2002. cited by applicant .
Karlowsky et al., "Fluoroquinolone-Resistant Urinary Isolates of
Escherichia coli from Outpatients Are Frequently Multidrug
Resistant: Results from the North American Urinary Tract Infection
Collaborative Alliance-Quinolone Resistance Study," Antimicrobial
Agents and Chemotherapy 50(6):2251-2254, Jun. 2006. cited by
applicant .
Kishi et al., "Comparative Study on Intravenous Drip Infusion of
Dibekacin Once Daily and Twice Daily in Treatment of Complicated
Urinary Tract Infections," Hinyokika Kiyo 30(1):103-120, 1984.
cited by applicant .
Kitasato et al., "Reduction of Dibekacin-Induced Nephrotoxicty in
the Rat by the Formation of N-Alkylsulfonate Derivatives," Drugs
Exptl. Clin. Res. 15(6/7):239-247, 1989. cited by applicant .
Kitasato et al., "Comparative Ototoxicity of Ribostamycin,
Dactimicin, Dibekacin, Kanamycin, Amikacin, Tobramycin, Gentamicin,
Sisomicin and Netilmicin in the Inner Ear of Guinea Pigs,"
Chemotherapy 36:155-168, 1990. cited by applicant .
Klastersky et al., "Clinical Significance of In Vitro Synergism
Between Antibiotics in Gram-Negative Infections," Antimicrobial
Agents and Chemotherapy 2(6):470-475, Dec. 1972. cited by applicant
.
Klevens et al., "Estimating Health Care-Associated Infections and
Deaths in U.S. Hospitals, 2002," Public Health Reports 122:160-166,
Mar.-Apr. 2007. cited by applicant .
Kondo et al., "Synthesis of 2''-Amino-2''-Deoxyarbekacin and Its
Analogs Having Potent Activity Against Methicillin-Resistant
Staphylococcus aureus," The Journal of Antibiotics 47(7):821-832,
Jul. 1994. cited by applicant .
Kondo et al., "Semisynthetic aminoglycoside antibiotics:
Development and enzymatic modifications," J. Infect. Chemother.
5:1-9, 1999. cited by applicant .
Kotretsou et al., "Synthesis and Antimicrobial and Toxicological
Studies of Amino Acid and Peptide Derivatives of Kanamycin A and
Netilmicin," J. Med. Chem. 38:4710-4719, 1995. cited by applicant
.
Kotretsou et al., "Synthesis of Amino Acid and Peptide Derivatives
of Aminoglycosides Targeted Against Resistance of Bacteria," Topics
in Molecular Organization and Engineering 11:277-280, 1994. cited
by applicant .
Kostrub et al., "Quantitative Comparison of Aminoglycoside
Nephrotoxicity in Rats for Effective Screening and Evaluation of
New Derivatives, and Dosing Rationales That Minimise Toxicity,"
ECCMID 2009, Poster # P-1979, 1 page. cited by applicant .
Kostrub et al., "Ototoxic Potential of ACHN-490 Compared to
Gentamicin and Amikacin in the Guinea Pig," ECCMID 2010, Poster #
P-1249, 1 page. cited by applicant .
Lee et al., "Decreased Susceptibility to Polymyxin B during
Treatment for Carbapenem-Resistant Klebsiella pneumoniae
Infection," Journal of Clinical Microbiology 47(5):1611-1612, May
2009. cited by applicant .
Lee et al., "Selective reactions of reactive amino groups in
polyamino compounds by metal-chelated or -mediated methods,"
Tetrahedron 57:4801-4815, 2001. cited by applicant .
Li et al., "Tuning the Regioselectivity of the Staudinger Reaction
for the Facile Synthesis of Kanamycin and Neomycin Class
Antibiotics with N-1 Modification," Organic Letters
7(14):3061-3064, 2005. cited by applicant .
Li et al., "Colistin: the re-emerging antibiotic for
multidrug-resistant Gram-negative bacterial infections," Lancet
Infect. Dis. 6:589-601, Sep. 2006. cited by applicant .
Lin et al., "Activity of ACHN-490 in Combination with Daptomycin,
Ceftobiprole, or Linezolid against 47 Methicillin-resistant
Staphylococcus aureus by Synergy Time-kill," ICAAC 2009, Poster #
F1-844, 1 page. cited by applicant .
Lin et al., "Antistaphylococcal Activity of ACHN-490 Tested Alone
and in Combination With Other Agents by Time-Kill Assay,"
Antimicrobial Agents and Chemotherapy 54(5):2258-2261, May 2010.
cited by applicant .
Liu et al., Database WPI Accession No. 2003-713635 [68], retrieved
Feb. 23, 2011, 1 page. cited by applicant .
Madsen et al., "Treatment of Complicated Urinary Tract Infections,
Comparative Study of Sisomicin and Gentamicin," Urology
9(6):635-638, Jun. 1977. cited by applicant .
Magnet et al., "Molecular Insights into Aminoglycoside Action and
Resistance," Chem. Rev. 105:477-497, 2005. cited by applicant .
Maigaard et al., "Comparison of Netilmicin and Amikacin in
Treatment of Complicated Urinary Tract Infections," Antimicrobial
Agents and Chemotherapy 14(4):544-548, Oct. 1978. cited by
applicant .
Mallams et al., "Synthesis of Novel 1-N Aminoalkyloxycarbonyl and
1-N-Aminoalkylcarboxamido Derivatives of Sisomicin, Gentamicin B,
Gentamicin C-1a, and Kanamycin A," Current Chemotherapy and
Infectious Disease: Proceedings of the 11th International Congress
of Chemotherapy and the 19th Interscience Conference on
Antimicrobial Agents & Chemotherapy, Boston, MA, Oct. 1-5,
1979, vol. 1, Jan. 1, 1980, pp. 406-408. cited by applicant .
Mallams et al., "Semisynthetic Aminoglycoside Antibacterials. Part
10. Synthesis of Novel 1-N-Aminoalkoxycarbonyl and
1-N-Aminoalkylcarboxamido Derivatives of Sisomicin,Gentamicin B,
Gentamicin C, and Kanamycin A," J. Chem. Soc., Perkin Trans.
1:2186-2208, 1981. cited by applicant .
Maller et al., "Once- versus twice-daily amikacin regimen: efficacy
and safety in systemic Gram-negative infections," Journal of
Antimicrobial Chemotherapy 31:939-948, 1993. cited by applicant
.
Maltezou et al., "Outbreak of infections due to KPC-2-producing
Klebsiella pneumoniae in a hospital in Crete (Greece)," Journal of
Infection 58:213-219, 2009. cited by applicant .
Marrie et al., "Clinical and laboratory study of tobramycin in the
treatment of infections due to gram-negative organisms," Canadian
Medical Association Journal 117(2):138,141-143, Jul. 23, 1977.
cited by applicant .
Martino et al., "N-Formimidoyl-Thienamycin and Norfloxacin Against
Multiple-Resistant Pseudomonas aeruginosa Strains. Combined In
Vitro Activity and Comparison With 14 Other Antibiotics," Drugs
Exptl. Clin. Res. 11(4):247-251, 1985. cited by applicant .
Mentec et al., "Piperacillin, Tazobactam, and Gentamicin Alone or
Combined in an Endocarditis Model of Infection by a TEM-3-Producing
Strain of Klebsiella pneumoniae or Its Susceptible Variant,"
Antimicrobial Agents and Chemotherapy 36(9):1883-1889, Sep. 1992.
cited by applicant .
Miller et al., "The Most Frequent Aminoglycoside Resistance
Mechanisms--Changes with Time and Geographic Area: A Reflection of
Aminoglycoside Usage Patterns?" Clinical Infectious Diseases
24(Suppl 1):S46-S62, 1997. cited by applicant .
Miller et al., "The Most Frequently Occurring Aminoglycoside
Resistance Mechanisms--Combined Results of Surveys in Eight Regions
of the World," Journal of Chemotherapy 7(Supplement n. 2):17-30,
1995. cited by applicant .
Moazed et al., "Interaction of antibiotics with functional sites in
16S ribosomal RNA," Nature 327:389-394, Jun. 4, 1987. cited by
applicant .
Mori et al., Database WPI Accession No. 1980-11681C [07], retrieved
Apr. 27, 2011, 1 page. cited by applicant .
Nagabhushan et al., "Interaction of Vicinal and Nonvicinal
Amino-Hydroxy Group Pairs in Aminoglycoside--Aminocyclitol
Antibiotics with Transition Metal Cations. Selective N Protection,"
Journal of the American Chemical Society 100(16):5253-5254, Aug. 2,
1978. cited by applicant .
Nagabhushan et al., "Chemical Modification of Some Gentamicins and
Sisomicin at the 3''-Position," The Journal of Antibiotics
31(1):43-54, Jan. 1978. cited by applicant .
Nagabhushan et al., "The Syntheses and Biological Properties of
1-N-(S-4-Amino-2-Hydroxybutyryl)-Gentamicin B and
1-N-(S-3-Amino-2-Hydroxypropionyl)-Gentamicin B," The Journal of
Antibiotics 31(7):681-687, Jul. 1978. cited by applicant .
Nam et al., "An Efficient and Selective 1-N-Monoethylation of
Sisomicin: Process Development of Netilmicin," Organic Process
Research & Development 6(1):78-81, 2002. cited by applicant
.
National Center for Health Statistics. National Hospital Discharge
Survey: 2004 Annual Summary with Detailed Diagnosis and Procedure
Data. DHHS, Centers for Disease Control and Prevention,
Hyattsville, MD: GPO; 2006. DHHS publication 2006-1733, 218 pages.
cited by applicant .
Nicolau et al., "Experience with a Once-Daily Aminoglycoside
Program Administered to 2,184 Adult Patients," Antimicrobial Agents
and Chemotherapy 39(3):650-655, Mar. 1995. cited by applicant .
Nishimura et al., "A proof of the specificity of
kanamycin-ribosomal RNA interaction with designed synthetic analogs
and the antibacterial activity," Bioorganic & Medicinal
Chemistry Letters 15:2159-2162, 2005. cited by applicant .
Nordmann et al., "The real threat of Klebsiella pneumoniae
carbapenemase-producing bacteria," Lancet Infect. Dis. 9:228-236,
Apr. 2009. cited by applicant .
Odds, F.C., "Synergy, antagonism, and what the chequerboard puts
between them," Journal of Antimicrobial Chemotherapy 52:1, 2003.
cited by applicant .
O'Shea et al., "Physiochemical Properties of Antibacterial
Compounds: Implications for Drug Discovery," Journal of Medicinal
Chemistry 51(10):2871-2878, May 22, 2008. cited by applicant .
Pavez et al., "Early Dissemination of KPC-2-Producing Klebsiella
pneumoniae Strains in Brazil," Antimicrobial Agents and
Chemotherapy 53(6):2702, Jun. 2009. cited by applicant .
Peloquin et al., "Aminoglycoside Toxicity: Daily versus
Thrice-Weekly Dosing for Treatment of Mycobacterial Diseases,"
Clinical Infectious Diseases 38:1538-1544, Jun. 1, 2004. cited by
applicant .
Peterson, "A review of tigecycline--the first glycylcycline,"
International Journal of Antimicrobial Agents 32(S4):S215-S222,
2008. cited by applicant .
Queenan et al., "Carbapenemases: the Versatile .beta.-Lactamases,"
Clinical Microbiology Reviews 20(3):440-458, Jul. 2007. cited by
applicant .
Rai et al., "Novel Method for the Synthesis of 3',
4'-Dideoxygenated Pyranmycin and Kanamycin Compounds, and Studies
of Their Antibacterial Activity Against Aminoglycoside-Resistant
Bacteria," Journal of Carbohydrate Chemistry 24:131-143, 2005.
cited by applicant .
Rane et al., "Synthesis and In Vitro Microbiological Properties of
the 1-N-(3-Amino-2-Hydroxypropionyl) Derivatives of Sisomicin and
5-Episisomicin," Current Chemotherapy and Infectious Disease,
Proceedings of the 11th International Congress of Chemotherapy and
the 19th Interscience Conference on Antimicrobial Agents and
Chemotherapy 1:408-410, 1980 (7 pages total). cited by applicant
.
Reyes et al., "In Vivo Efficacy of the Neoglycoside ACHN-490
Against Enterobacteriaceae and MRSA," ICAAC 2009, Poster # F1-845,
1 page. cited by applicant .
Rodriguez-Banno et al., "Clinical significance of extended-spectrum
.beta.-lactamases," Expert Rev. Anti Infect. Ther. 6(5):671-683,
2008. cited by applicant .
Rossi et al., "In vitro susceptibilities of aerobic and
facultatively anaerobic Gram-negative bacilli isolated from
patients with intra-abdominal infections worldwide: 2004 results
from SMART (Study for Monitoring Antimicrobial Resistance Trends),"
Journal of Antimicrobial Chemotherapy 58:205-210, 2006. cited by
applicant .
Rybak et al., "Combination Antimicrobial Therapy for Bacterial
Infections," Drugs 52(3):390-405, Sep. 1996. cited by applicant
.
The Sanford Guide to Antimicrobial Therapy, 37.sup.th Edition,
Gilbert et al. (eds.), Antimicrobial Therapy: Sperryville, VA,
2007, p. 93. cited by applicant .
Santucci et al., "Gentamicin for the Practicing Urologist: Review
of Efficacy, Single Daily Dosing and "Switch" Therapy," The Journal
of Urology 163:1076-1084, Apr. 2000. cited by applicant .
Selimoglu, E., "Aminoglycoside-Induced Ototoxicity," Current
Pharmaceutical Design 13:119-126, 2007. cited by applicant .
Sepulchre et al., "The Chemical Ionisation Mass Spectrometry of
Aminocyclitol-Aminogylcoside Antibiotics," Nouveau Journal de
Chimie 2(4):405-409, Jul. 1978. cited by applicant .
Shaw et al., "Molecular Genetics of Aminoglycoside Resistance Genes
and Familial Relationships of the Aminoglycoside-Modifying
Enzymes," Microbiological Reviews 57(1):138-163, Mar. 1993. cited
by applicant .
Singh et al., "Microwave-Assisted Synthesis of Substituted
Tetrahydropyrans Catalyzed by ZrCl.sub.4 and Its Application in the
Asymmetric Synthesis of exo- and endo-brevicomin," J. Org. Chem.
74:5758-5761, 2009. cited by applicant .
Stamm, W. E., "Urinary Tract Infections and Pyelonephritis," in
Braunwald et al. (eds.), Harrison's 15.sup.th Edition Principles of
Internal Medicine, McGraw-Hill, New York, 2001, pp. 1620-1626.
cited by applicant .
Streicher et al., "Synthesis and Structure/Activity Relationships
of New Guanidino Derivatives of Aminoglycoside Antibiotics," Drugs
Exptl. Clin. Res. IX(8/9):591-598, 1983. cited by applicant .
Talan et al., "Prevalence and Risk Factor Analysis of
Trimethoprim-Sulfamethoxazole- and Fluoroquinolone-Resistant
Escherichia coli Infection among Emergency Department Patients with
Pyelonephritis," Clinical Infectious Diseases 47:1150-1158, 2008.
cited by applicant .
Tanabe et al., "Aminoglycoside Antibiotics: Synthesis of Nebramine,
Tobramycin and 4''-Epi-Tobramycin," Tetrahedron Letters
41:3607-3610, 1977. cited by applicant .
Theuretzbacher, Ursula, "Future antibiotics scenarios: is the tide
starting to turn?" International Journal of Antimicrobial Agents
34:15-20, 2009. cited by applicant .
Traczewski et al., "In Vitro Activity of Doripenem against
Pseudomonas aeruginosa and Burkholderia cepacia Isolates from both
Cystic Fibrosis and Non-Cystic Fibrosis Patients," Antimicrobial
Agents and Chemotherapy 50(2):819-821, Feb. 2006. cited by
applicant .
Urban et al., "Daily Dosage of Aminoglycosides," Current Clinical
Topics in Infectious Diseases 17:236-255, 1997. cited by applicant
.
Van der Auwera et al., "Pharmacodynamic Parameters and Toxicity of
Netilmicin (6 Milligrams/Kilogram/Day) Given Once Daily or in Three
Divided Doses to Cancer Patients with Urinary Tract Infection,"
Antimicrobial Agents and Chemotherapy 35(4):640-647, Apr. 1991.
cited by applicant .
Van Schepdael et al., "New Derivatives of Kanamycin B Obtained by
Modifications and Substitutions in Position 6''. 1. Synthesis and
Microbiological Evaluation," J. Med. Chem. 34:1468-1475, 1991.
cited by applicant .
Van Schepdael et al., "New Derivatives of Kanamycin B Obtained by
Combined Modifications in Positions 1 and 6''. Synthesis,
Microbiological Properties, and in Vitro and Computer-Aided
Toxicological Evaluation," J. Med. Chem. 34:1483-1492, 1991. cited
by applicant .
Verpooten et al., "Once-daily dosing decreases renal accumulation
of gentamicin and netilmicin," Clin. Pharmacol. Ther. 45:22-27,
Jan. 1989. cited by applicant .
Wachino et al., "Novel Plasmid-Mediated 16S rRNA m.sup.1 A1408
Methyltransferase, NpmA, Found in a Clinically Isolated Escherichia
coli Strain Resistant to Structurally Diverse Aminoglycosides,"
Antimicrobial Agents and Chemotherapy 51(12):4401-4409, Dec. 2007.
cited by applicant .
Waitz et al., "Chemotherapeutic Evaluation of 5-Episisomicin (Sch
22591), a New Semisynthetic Aminoglycoside," Antimicrobial Agents
and Chemotherapy 13(1):41-48, Jan. 1978. cited by applicant .
Wallis et al., "The Binding of Antibiotics to RNA," Prog. Biophys.
Molec. Biol., 67(2/3):141-154, 1997. cited by applicant .
Wang et al., "Design, Chemical Synthesis, And Antibacterial
Activity of Kanamycin And Neomycin Class Aminoglycoside
Antibiotics," in Dev P. Arya (ed.), Aminoglycoside Antibiotics,
From Chemical Biology to Drug Discovery, Wiley-Interscience, 2007,
pp. 141-180. cited by applicant .
Warren et al., "Guidelines From the Infectious Diseases Society of
America: Guidelines for Antimicrobial Treatment of Uncomplicated
Acute Bacterial Cystitis and Acute Pyelonephritis in Women,"
Clinical Infectious Diseases 29:745-758, Oct. 1999. cited by
applicant .
Widmer, Andreas F., "Ceftobiprole: A New Option for Treatment of
Skin and Soft-Tissue Infections due to Methicillin-Resistant
Staphylococcus aureus," Clinical Infectious Diseases 46:656-658,
Mar. 1, 2008. cited by applicant .
Woodford et al., "Arrival of Klebsiella pneumoniae producing KPC
carbapenemase in the United Kingdom," Journal of Antimicrobial
Chemotherapy 62:1261-1264, 2008. cited by applicant .
Wright, Gerard D., "Aminoglycoside-modifying enzymes," Current
Opinion in Microbiology 2(5):499-503, Oct. 1, 1999. cited by
applicant .
Wright et al., "Selective N-Acylation of Gentamicin
Antibiotics--Synthesis of 1-N-Acyl Derivatives," The Journal of
Antibiotics 29(7):714-719, Jul. 1976. cited by applicant .
Yamane et al., "Antimicrobial susceptibilities of organisms
isolated from patients with complicated urinary tract infections in
2004 and 2005," Japanese Journal of Chemotherapy 55(6):473-478,
Nov. 2007 (with English Abstract). cited by applicant .
Yamasaki et al., "Synthesis and Biological Activity of
1-N-[4-(Substituted)Amidino and
Guanidino-2-Hydroxybutyryl]Kanamycins A and B," The Journal of
Antibiotics 44(6):646-658, Jun. 1991. cited by applicant .
Zurenko et al., "The Bactericidal Activity of the Neoglycoside
ACHN-490 Against Aminoglycoside-Resistant Bacteria," ICAAC 2009,
Poster # F1-841, 1 page. cited by applicant .
Burgess, "Use of Pharmacokinetics and Pharmacodynamics to Optimize
Antimicrobial Treatment of Pseudomonas aeruginosa Infections," CID
Suppl. 2, S99-S104, 2005. cited by applicant .
Daptomycin Fact Sheet (Dec. 9, 2008)
http:"web.archive.org/web/20081209062636/http:clinicalpharmacy.ucsf.edu/i-
- dmp/whatsnew/dapto_monograph.htm" accessed Dec. 5, 2012. cited by
applicant .
Lim, T.K., "Emerging Pathogens for Pneumonia in Singpore," Annals
of the Academy of Medicine Singapore 26(5):651-658, Sep. 1997.
cited by applicant .
Obritsch et al., "Nosocomial Infections Due to Multidrug-Resistant
Pseudomonas aeruginosa: Epidemiology and Treatment Options,"
Pharmacotherapy 25(10):1353-1364, Oct. 2005. cited by applicant
.
Sanders et al., "Sisomicin: A Review of Eight Years'Experience,"
Reviews of Infectious Diseases 2(2):182-95, Mar.-Apr. 1980. cited
by applicant .
Office Action for U.S. Appl. No. 12/487,427 dated Aug. 29, 2012 (10
pages). cited by applicant .
Notice of Allowance and Fee(s) Due for U.S. Appl. No. 12/487,427
dated Dec. 20, 2012 (7 pages). cited by applicant .
Office Action for U.S. Appl. No. 13/295,247 dated Aug. 29, 2012 (8
pages). cited by applicant .
Office Action for U.S. Appl. No. 13/295,238 dated Aug. 28, 2012 (8
pages). cited by applicant .
Office Action for U.S. Appl. No. 13/295,233 dated Aug. 28, 2012 (8
pages). cited by applicant .
Office Action for U.S. Appl. No. 13/295,231 dated Sep. 13, 2012 (7
pages). cited by applicant .
Office Action for U.S. Appl. No. 13/294,425 dated Jan. 3, 2013 (7
pages). cited by applicant .
Office Action for U.S. Appl. No. 13/294,426 dated Dec. 19, 2012 (7
pages). cited by applicant .
Office Action for U.S. Appl. No. 13/294,429 dated Dec. 19, 2012 (19
pages). cited by applicant .
Restriction Requirement for U.S. Appl. No. 13/327,377 dated Aug.
30, 2012 (9 pages). cited by applicant .
Office Action for U.S. Appl. No. 13/327,377 dated Jan. 3, 2012 (20
pages). cited by applicant.
|
Primary Examiner: Kugel; Timothy J.
Attorney, Agent or Firm: Cooley LLP
Parent Case Text
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a continuation of International PCT Application
No. PCT/US2010/034896, filed May 14, 2010, now pending, which
claims the benefit under 35 U.S.C. .sctn.119(e) of U.S. Provisional
Patent Application No. 61/178,834 filed May 15, 2009 and U.S.
Provisional Patent Application No. 61/312,356 filed Mar. 10, 2010.
The foregoing applications are incorporated herein by reference in
their entireties.
Claims
What is claimed is:
1. A compound having the following structure (I): ##STR00157## or a
stereoisomer or pharmaceutically acceptable salt thereof, wherein:
Q.sub.1 is alkyl optionally substituted with hydroxyl or amino,
##STR00158## Q.sub.2 is hydrogen, optionally substituted alkyl,
optionally substituted aryl, optionally substituted aralkyl,
optionally substituted cycloalkyl, optionally substituted
cycloalkylalkyl, optionally substituted heterocyclyl, optionally
substituted heterocyclylalkyl, optionally substituted heteroaryl,
optionally substituted heteroarylalkyl,
--C(.dbd.NH)NR.sub.7R.sub.8, ##STR00159## Q.sub.3 is hydrogen,
optionally substituted alkyl, optionally substituted aryl,
optionally substituted aralkyl, optionally substituted cycloalkyl,
optionally substituted cycloalkylalkyl, optionally substituted
heterocyclyl, optionally substituted heterocyclylalkyl, optionally
substituted heteroaryl, optionally substituted heteroarylalkyl,
--C(.dbd.NH)NR.sub.7R.sub.8, ##STR00160## each R.sub.4, R.sub.5,
R.sub.7, R.sub.8 and R.sub.11 is, independently, hydrogen or
C.sub.1-C.sub.6 alkyl optionally substituted with one or more
halogen, hydroxyl or amino; each R.sub.6 is, independently,
hydrogen, halogen, hydroxyl, amino or C.sub.1-C.sub.6 alkyl; or
R.sub.4 and R.sub.5 together with the atoms to which they are
attached can form a heterocyclic ring having from 4 to 6 ring
atoms, or R.sub.5 and one R.sub.6 together with the atoms to which
they are attached can form a heterocyclic ring having from 3 to 6
ring atoms, or R.sub.4 and one R.sub.6 together with the atoms to
which they are attached can form a carbocyclic ring having from 3
to 6 ring atoms, or R.sub.7 and R.sub.8 together with the atom to
which they are attached can form a heterocyclic ring having from 3
to 6 ring atoms; each R.sub.9 and R.sub.12 is, independently,
hydrogen, hydroxyl, amino or C.sub.1-C.sub.6 alkyl optionally
substituted with one or more halogen, hydroxyl or amino; each
R.sub.10 is, independently, hydrogen, halogen, hydroxyl, amino or
C.sub.1-C.sub.6 alkyl; or R.sub.9 and one R.sub.10 together with
the atoms to which they are attached can form a heterocyclic ring
having from 3 to 6 ring atoms; and each n is, independently, an
integer from 0 to 4, and wherein (i) at least one of Q.sub.2 and
Q.sub.3 is other than hydrogen, and (ii) Q.sub.1 is not ethyl or
--C(.dbd.O)CH.sub.3.
2. A compound of claim 1 wherein Q.sub.2 is other than
hydrogen.
3. A compound of claim 2 wherein Q.sub.3 is hydrogen.
4. A compound of claim 2 wherein Q.sub.2 is optionally substituted
alkyl.
5. A compound of claim 4 wherein Q.sub.2 is substituted with
hydroxyl or amino.
6. A compound of claim 1 wherein R.sub.11 is hydrogen.
7. A compound of claim 1 wherein each R.sub.12 is methyl.
8. A pharmaceutical composition comprising a compound of claim 1,
or a stereoisomer or pharmaceutically acceptable salt thereof, and
a pharmaceutically acceptable carrier, diluent or excipient.
9. A method of treating a bacterial infection in a mammal in need
thereof, comprising administering to the mammal an effective amount
of a compound of claim 1 or a composition of claim 8.
10. A compound having the following structure (I): ##STR00161## or
a stereoisomer or pharmaceutically acceptable salt thereof,
wherein: Q.sub.1 is ##STR00162## Q.sub.2 is hydrogen, optionally
substituted alkyl, optionally substituted aryl, optionally
substituted aralkyl, optionally substituted cycloalkyl, optionally
substituted cycloalkylalkyl, optionally substituted heterocyclyl,
optionally substituted heterocyclylalkyl, optionally substituted
heteroaryl, optionally substituted heteroarylalkyl,
--C(.dbd.NH)NR.sub.7R.sub.8, ##STR00163## Q.sub.3 is hydrogen,
optionally substituted alkyl, optionally substituted aryl,
optionally substituted aralkyl, optionally substituted cycloalkyl,
optionally substituted cycloalkylalkyl, optionally substituted
heterocyclyl, optionally substituted heterocyclylalkyl, optionally
substituted heteroaryl, optionally substituted heteroarylalkyl,
--C(.dbd.NH)NR.sub.7R.sub.8, ##STR00164## each R.sub.4, R.sub.5,
R.sub.7, R.sub.8 and R.sub.11 is, independently, hydrogen or
C.sub.1-C.sub.6 alkyl optionally substituted with one or more
halogen, hydroxyl or amino; each R.sub.6 is, independently,
hydrogen, halogen, hydroxyl, amino or C.sub.1-C.sub.6 alkyl; or
R.sub.4 and R.sub.5 together with the atoms to which they are
attached can form a heterocyclic ring having from 4 to 6 ring
atoms, or R.sub.5 and one R.sub.6 together with the atoms to which
they are attached can form a heterocyclic ring having from 3 to 6
ring atoms, or R.sub.4 and one R.sub.6 together with the atoms to
which they are attached can form a carbocyclic ring having from 3
to 6 ring atoms, or R.sub.7 and R.sub.8 together with the atom to
which they are attached can form a heterocyclic ring having from 3
to 6 ring atoms; each R.sub.9 and R.sub.12 is, independently,
hydrogen, hydroxyl, amino or C.sub.1-C.sub.6 alkyl optionally
substituted with one or more halogen, hydroxyl or amino; each
R.sub.10 is, independently, hydrogen, halogen, hydroxyl, amino or
C.sub.1-C.sub.6 alkyl; or R.sub.9 and one R.sub.10 together with
the atoms to which they are attached can form a heterocyclic ring
having from 3 to 6 ring atoms; and each n is, independently, an
integer from 0 to 4, and wherein (i) at least one of Q.sub.2 and
Q.sub.3 is other than hydrogen, and (ii) for Q.sub.1, R.sub.5 and
one R.sub.6 together with the atoms to which they are attached form
a heterocyclic ring having 3 ring atoms, or R.sub.4 and one R.sub.6
together with the atoms to which they are attached form a
carbocyclic ring having 3 ring atoms, or R.sub.9 and one R.sub.10
together with the atoms to which they are attached form a
heterocyclic ring having 3 ring atoms.
11. A compound of claim 10 wherein Q.sub.2 is other than
hydrogen.
12. A compound of claim 11 wherein Q.sub.3 is hydrogen.
13. A compound of claim 11 wherein Q.sub.2 is optionally
substituted alkyl.
14. A compound of claim 13 wherein Q.sub.2 is substituted with
hydroxyl or amino.
15. A compound of claim 10 wherein R.sub.11 is hydrogen.
16. A compound of claim 10 wherein each R.sub.12 is methyl.
17. A pharmaceutical composition comprising a compound of claim 10,
or a stereoisomer or pharmaceutically acceptable salt thereof, and
a pharmaceutically acceptable carrier, diluent or excipient.
18. A method of treating a bacterial infection in a mammal in need
thereof, comprising administering to the mammal an effective amount
of a compound of claim 10 or a composition of claim 17.
.Iadd.19. A compound of claim 1 wherein Q.sub.1 is ##STR00165##
.Iaddend.
.Iadd.20. A compound of claim 1 wherein Q.sub.1 is ##STR00166##
.Iaddend.
.Iadd.21. A compound of claim 1 wherein Q.sub.1 is ##STR00167##
.Iaddend.
.Iadd.22. A compound of claim 1 wherein Q.sub.1 is ##STR00168## or
##STR00169## .Iaddend.
Description
BACKGROUND
1. Field
The present invention is directed to novel aminoglycoside
compounds, more specifically, novel sisomicin derivatives, and
methods for their preparation and use as therapeutic or
prophylactic agents.
2. Description of the Related Art
A particular interest in modern drug discovery is the development
of novel low molecular weight drugs that work by binding to RNA.
RNA, which serves as a messenger between DNA and proteins, was
thought to be an entirely flexible molecule without significant
structural complexity. Recent studies have revealed a surprising
intricacy in RNA structure. RNA has a structural complexity
rivaling proteins, rather than simple motifs like DNA. Genome
sequencing reveals both the sequences of the proteins and the mRNAs
that encode them. Since proteins are synthesized using an RNA
template, such proteins can be inhibited by preventing their
production in the first place by interfering with the translation
of the mRNA. Since both proteins and the RNAs are potential drug
targeting sites, the number of targets revealed from genome
sequencing efforts is effectively doubled. These observations
unlock a new world of opportunities for the pharmaceutical industry
to target RNA with small molecules.
Classical drug discovery has focused on proteins as targets for
intervention. Proteins can be extremely difficult to isolate and
purify in the appropriate form for use in assays for drug
screening. Many proteins require post-translational modifications
that occur only in specific cell types under specific conditions.
Proteins fold into globular domains with hydrophobic cores and
hydrophilic and charged groups on the surface. Multiple subunits
frequently form complexes, which may be required for a valid drug
screen. Membrane proteins usually need to be embedded in a membrane
to retain their proper shape. The smallest practical unit of a
protein that can be used in drug screening is a globular domain.
The notion of removing a single alpha helix or turn of a beta sheet
and using it in a drug screen is not practical, since only the
intact protein may have the appropriate 3-dimensional shape for
drug binding. Preparation of biologically active proteins for
screening is a major limitation in classical high throughput
screening. Quite often the limiting reagent in high throughput
screening efforts is a biologically active form of a protein which
can also be quite expensive.
For screening to discover compounds that bind RNA targets, the
classic approaches used for proteins can be superceded with new
approaches. All RNAs are essentially equivalent in their
solubility, ease of synthesis or use in assays. The physical
properties of RNAs are independent of the protein they encode. They
may be readily prepared in large quantity through either chemical
or enzymatic synthesis and are not extensively modified in vivo.
With RNA, the smallest practical unit for drug binding is the
functional subdomain. A functional subdomain in RNA is a fragment
that, when removed from the larger RNA and studied in isolation,
retains its biologically relevant shape and protein or RNA-binding
properties. The size and composition of RNA functional subdomains
make them accessible by enzymatic or chemical synthesis. The
structural biology community has developed significant experience
in identification of functional RNA subdomains in order to
facilitate structural studies by techniques such as NMR
spectroscopy. For example, small analogs of the decoding region of
16S rRNA (the A-site) have been identified as containing only the
essential region, and have been shown to bind antibiotics in the
same fashion as the intact ribosome.
The binding sites on RNA are hydrophilic and relatively open as
compared to proteins. The potential for small molecule recognition
based on shape is enhanced by the deformability of RNA. The binding
of molecules to specific RNA targets can be determined by global
conformation and the distribution of charged, aromatic, and
hydrogen bonding groups off of a relatively rigid scaffold.
Properly placed positive charges are believed to be important,
since long-range electrostatic interactions can be used to steer
molecules into a binding pocket with the proper orientation. In
structures where nucleobases are exposed, stacking interactions
with aromatic functional groups may contribute to the binding
interaction. The major groove of RNA provides many sites for
specific hydrogen bonding with a ligand. These include the aromatic
N7 nitrogen atoms of adenosine and guanosine, the O4 and O6 oxygen
atoms of uridine and guanosine, and the amines of adenosine and
cytidine. The rich structural and sequence diversity of RNA
suggests to us that ligands can be created with high affinity and
specificity for their target.
Although our understanding of RNA structure and folding, as well as
the modes in which RNA is recognized by other ligands, is far from
being comprehensive, significant progress has been made in the last
decade (see, e.g., Chow, C. S.; Bogdan, F. M., Chem. Rev., 1997,
97, 1489 and Wallis, M. G.; Schroeder, R., Prog. Biophys. Molec.
Biol. 1997, 67, 141). Despite the central role RNA plays in the
replication of bacteria, drugs that target these pivotal RNA sites
of these pathogens are scarce. The increasing problem of bacterial
resistance to antibiotics makes the search for novel RNA binders of
crucial importance.
Certain small molecules can bind and block essential functions of
RNA. Examples of such molecules include the aminoglycoside
antibiotics and drugs such as erythromycin which binds to bacterial
rRNA and releases peptidyl-tRNA and mRNA. Aminoglycoside
antibiotics have long been known to bind RNA. They exert their
antibacterial effects by binding to specific target sites in the
bacterial ribosome. For the structurally related antibiotics
neamine, ribostamycin, neomycin B, and paromomycin, the binding
site has been localized to the A-site of the prokaryotic 16S
ribosomal decoding region RNA (see Moazed, D.; Noller, H. F.,
Nature, 1987, 327, 389). Binding of aminoglycosides to this RNA
target interferes with the fidelity of mRNA translation and results
in miscoding and truncation, leading ultimately to bacterial cell
death (see Alper, P. B.; Hendrix, M.; Sears, P.; Wong, C., J. Am.
Chem. Soc., 1998, 120, 1965).
There is a need in the art for new chemical entities that work
against bacteria with broad-spectrum activity. Perhaps the biggest
challenge in discovering RNA-binding antibacterial drugs is
identifying vital structures common to bacteria that can be
disabled by small molecule drug binding. A challenge in targeting
RNA with small molecules is to develop a chemical strategy which
recognizes specific shapes of RNA. There are three sets of data
that provide hints on how to do this: natural protein interactions
with RNA, natural product antibiotics that bind RNA, and man-made
RNAs (aptamers) that bind proteins and other molecules. Each data
set, however, provides different insights to the problem.
Several classes of drugs obtained from natural sources have been
shown to work by binding to RNA or RNA/protein complexes. These
include three different structural classes of antibiotics:
thiostreptone, the aminoglycoside family and the macrolide family
of antibiotics. These examples provide powerful clues to how small
molecules and targets might be selected. Nature has selected RNA
targets in the ribosome, one of the most ancient and conserved
targets in bacteria. Since antibacterial drugs are desired to be
potent and have broad-spectrum activity, these ancient processes,
fundamental to all bacterial life, represent attractive targets.
The closer we get to ancient conserved functions the more likely we
are to find broadly conserved RNA shapes. It is important to also
consider the shape of the equivalent structure in humans, since
bacteria were unlikely to have considered the therapeutic index of
their RNAs while evolving them.
A large number of natural antibiotics exist, these include the
aminoglycosides, such as, kirromycin, neomycin, paromomycin,
thiostrepton, and many others. They are very potent, bactericidal
compounds that bind RNA of the small ribosomal subunit. The
bactericidal action is mediated by binding to the bacterial RNA in
a fashion that leads to misreading of the genetic code. Misreading
of the code during translation of integral membrane proteins is
thought to produce abnormal proteins that compromise the barrier
properties of the bacterial membrane.
Antibiotics are chemical substances produced by various species of
microorganisms (bacteria, fungi, actinomycetes) that suppress the
growth of other microorganisms and may eventually destroy them.
However, common usage often extends the term antibiotics to include
synthetic antibacterial agents, such as the sulfonamides, and
quinolines, that are not products of microbes. The number of
antibiotics that have been identified now extends into the
hundreds, and many of these have been developed to the stage where
they are of value in the therapy of infectious diseases.
Antibiotics differ markedly in physical, chemical, and
pharmacological properties, antibacterial spectra, and mechanisms
of action. In recent years, knowledge of molecular mechanisms of
bacterial, fungal, and viral replication has greatly facilitated
rational development of compounds that can interfere with the life
cycles of these microorganisms.
At least 30% of all hospitalized patients now receive one or more
courses of therapy with antibiotics, and millions of potentially
fatal infections have been cured. At the same time, these
pharmaceutical agents have become among the most misused of those
available to the practicing physician. One result of widespread use
of antimicrobial agents has been the emergence of
antibiotic-resistant pathogens, which in turn has created an
ever-increasing need for new drugs. Many of these agents have also
contributed significantly to the rising costs of medical care.
When the antimicrobial activity of a new agent is first tested, a
pattern of sensitivity and resistance is usually defined.
Unfortunately, this spectrum of activity can subsequently change to
a remarkable degree, because microorganisms have evolved the array
of ingenious alterations discussed above that allow them to survive
in the presence of antibiotics. The mechanism of drug resistance
varies from microorganism to microorganism and from drug to
drug.
The development of resistance to antibiotics usually involves a
stable genetic change, inheritable from generation to generation.
Any of the mechanisms that result in alteration of bacterial
genetic composition can operate. While mutation is frequently the
cause, resistance to antimicrobial agents may be acquired through
transfer of genetic material from one bacterium to another by
transduction, transformation or conjugation.
For the foregoing reasons, while progress has been made in this
field, there is a need for new chemical entities that possess
antibacterial activity. Further, in order to accelerate the drug
discovery process, new methods for synthesizing aminoglycoside
antibiotics are needed to provide an array of compounds that are
potentially new drugs for the treatment of bacterial infections.
The present invention fulfills these needs and provides further
related advantages.
BRIEF SUMMARY
In brief, the present invention is directed to novel aminoglycoside
compounds, more specifically, novel sisomicin derivatives, having
antibacterial activity, including stereoisomers, pharmaceutically
acceptable salts and prodrugs thereof, and the use of such
compounds in the treatment of bacterial infections.
In one embodiment, compounds having the following structure (I) are
provided:
##STR00002## or a stereoisomer, pharmaceutically acceptable salt or
prodrug thereof, wherein:
Q.sub.1 is alkyl optionally substituted with hydroxyl or amino,
##STR00003##
Q.sub.2 is hydrogen, optionally substituted alkyl, optionally
substituted aryl, optionally substituted aralkyl, optionally
substituted cycloalkyl, optionally substituted cycloalkylalkyl,
optionally substituted heterocyclyl, optionally substituted
heterocyclylalkyl, optionally substituted heteroaryl, optionally
substituted heteroarylalkyl, --C(.dbd.NH)NR.sub.7R.sub.8,
##STR00004##
Q.sub.3 is hydrogen, optionally substituted alkyl, optionally
substituted aryl, optionally substituted aralkyl, optionally
substituted cycloalkyl, optionally substituted cycloalkylalkyl,
optionally substituted heterocyclyl, optionally substituted
heterocyclylalkyl, optionally substituted heteroaryl, optionally
substituted heteroarylalkyl, --C(.dbd.NH)NR.sub.7R.sub.8,
##STR00005##
each R.sub.4, R.sub.5, R.sub.7, R.sub.8 and R.sub.11 is,
independently, hydrogen or C.sub.1-C.sub.6 alkyl optionally
substituted with one or more halogen, hydroxyl or amino;
each R.sub.6 is, independently, hydrogen, halogen, hydroxyl, amino
or C.sub.1-C.sub.6 alkyl;
or R.sub.4 and R.sub.5 together with the atoms to which they are
attached can form a heterocyclic ring having from 4 to 6 ring
atoms, or R.sub.5 and one R.sub.6 together with the atoms to which
they are attached can form a heterocyclic ring having from 3 to 6
ring atoms, or R.sub.4 and one R.sub.6 together with the atoms to
which they are attached can form a carbocyclic ring having from 3
to 6 ring atoms, or R.sub.7 and R.sub.8 together with the atom to
which they are attached can form a heterocyclic ring having from 3
to 6 ring atoms;
each R.sub.9 and R.sub.12 is, independently, hydrogen, hydroxyl,
amino or C.sub.1-C.sub.6 alkyl optionally substituted with one or
more halogen, hydroxyl or amino;
each R.sub.10 is, independently, hydrogen, halogen, hydroxyl, amino
or C.sub.1-C.sub.6 alkyl;
or R.sub.9 and one R.sub.10 together with the atoms to which they
are attached can form a heterocyclic ring having from 3 to 6 ring
atoms; and
each n is, independently, an integer from 0 to 4, and
wherein (i) at least one of Q.sub.2 and Q is other than hydrogen,
and (ii) .quadrature.1 is not ethyl or --C(.dbd.O)CH.sub.3.
In another embodiment, compounds having the following structure (I)
are provided:
##STR00006## or a stereoisomer, pharmaceutically acceptable salt or
prodrug thereof,
wherein:
Q.sub.1 is
##STR00007##
Q.sub.2 is hydrogen, optionally substituted alkyl, optionally
substituted aryl, optionally substituted aralkyl, optionally
substituted cycloalkyl, optionally substituted cycloalkylalkyl,
optionally substituted heterocyclyl, optionally substituted
heterocyclylalkyl, optionally substituted heteroaryl, optionally
substituted heteroarylalkyl, --C(.dbd.NH)NR.sub.7R.sub.8,
##STR00008##
Q.sub.3 is hydrogen, optionally substituted alkyl, optionally
substituted aryl, optionally substituted aralkyl, optionally
substituted cycloalkyl, optionally substituted cycloalkylalkyl,
optionally substituted heterocyclyl, optionally substituted
heterocyclylalkyl, optionally substituted heteroaryl, optionally
substituted heteroarylalkyl, --C(.dbd.NH)NR.sub.7R.sub.8,
##STR00009##
each R.sub.4, R.sub.5, R.sub.7, R.sub.8 and R.sub.11 is,
independently, hydrogen or C.sub.1-C.sub.6 alkyl optionally
substituted with one or more halogen, hydroxyl or amino;
each R.sub.6 is, independently, hydrogen, halogen, hydroxyl, amino
or C.sub.1-C.sub.6 alkyl;
or R.sub.4 and R.sub.5 together with the atoms to which they are
attached can form a heterocyclic ring having from 4 to 6 ring
atoms, or R.sub.5 and one R.sub.6 together with the atoms to which
they are attached can form a heterocyclic ring having from 3 to 6
ring atoms, or R.sub.4 and one R.sub.6 together with the atoms to
which they are attached can form a carbocyclic ring having from 3
to 6 ring atoms, or R.sub.7 and R.sub.8 together with the atom to
which they are attached can form a heterocyclic ring having from 3
to 6 ring atoms;
each R.sub.9 and R.sub.12 is, independently, hydrogen, hydroxyl,
amino or C.sub.1-C.sub.6 alkyl optionally substituted with one or
more halogen, hydroxyl or amino;
each R.sub.10 is, independently, hydrogen, halogen, hydroxyl, amino
or C.sub.1-C.sub.6 alkyl;
or R.sub.9 and one R.sub.10 together with the atoms to which they
are attached can form a heterocyclic ring having from 3 to 6 ring
atoms; and
each n is, independently, an integer from 0 to 4, and
wherein (i) at least one of Q.sub.2 and Q.sub.3 is other than
hydrogen, and (ii) for Q.sub.1, R.sub.5 and one R.sub.6 together
with the atoms to which they are attached form a heterocyclic ring
having 3 ring atoms, or R.sub.4 and one R.sub.6 together with the
atoms to which they are attached form a carbocyclic ring having 3
ring atoms, or R.sub.9 and one R.sub.10 together with the atoms to
which they are attached form a heterocyclic ring having 3 ring
atoms.
In another embodiment, a pharmaceutical composition is provided
comprising a compound having structure (I), or a stereoisomer,
pharmaceutically acceptable salt or prodrug thereof, and a
pharmaceutically acceptable carrier, diluent or excipient.
In another embodiment, a method of using a compound having
structure (I) in therapy is provided. In particular, the present
invention provides a method of treating a bacterial infection in a
mammal comprising administering to the mammal an effective amount
of a compound having structure (I), or a stereoisomer,
pharmaceutically acceptable salt or prodrug thereof.
These and other aspects of the invention will be apparent upon
reference to the following detailed description.
DETAILED DESCRIPTION
In the following description, certain specific details are set
forth in order to provide a thorough understanding of various
embodiments of the invention. However, one skilled in the art will
understand that the invention may be practiced without these
details.
Unless the context requires otherwise, throughout the present
specification and claims, the word "comprise" and variations
thereof, such as, "comprises" and "comprising" are to be construed
in an open, inclusive sense, that is as "including, but not limited
to".
Reference throughout this specification to "one embodiment" or "an
embodiment" means that a particular feature, structure or
characteristic described in connection with the embodiment is
included in at least one embodiment of the present invention. Thus,
the appearances of the phrases "in one embodiment" or "in an
embodiment" in various places throughout this specification are not
necessarily all referring to the same embodiment. Furthermore, the
particular features, structures, or characteristics may be combined
in any suitable manner in one or more embodiments.
As used in the specification and appended claims, unless specified
to the contrary, the following terms have the meaning
indicated.
"Amino" refers to the --NH.sub.2 radical.
"Cyano" refers to the --CN radical.
"Hydroxy" or "hydroxyl" refers to the --OH radical.
"Imino" refers to the .dbd.NH substituent.
"Nitro" refers to the --NO, radical.
"Oxo" refers to the .dbd.O substituent.
"Thioxo" refers to the .dbd.S substituent.
"Alkyl" refers to a straight or branched hydrocarbon chain radical
consisting solely of carbon and hydrogen atoms, which is saturated
or unsaturated (i.e., contains one or more double and/or triple
bonds), having from one to twelve carbon atoms (C.sub.1-C.sub.12
alkyl), preferably one to eight carbon atoms (C.sub.1-C.sub.8
alkyl) or one to six carbon atoms (C.sub.1-C.sub.6 alkyl), and
which is attached to the rest of the molecule by a single bond,
e.g., methyl, ethyl, n-propyl, 1-methylethyl (iso-propyl), n-butyl,
n-pentyl, 1,1-dimethylethyl (t-butyl), 3-methylhexyl,
2-methylhexyl, ethenyl, prop-1-enyl, but-1-enyl, pent-1-enyl,
penta-1,4-dienyl, ethynyl, propynyl, butynyl, pentynyl, hexynyl,
and the like. Unless stated otherwise specifically in the
specification, an alkyl group may be optionally substituted.
"Alkylene" or "alkylene chain" refers to a straight or branched
divalent hydrocarbon chain linking the rest of the molecule to a
radical group, consisting solely of carbon and hydrogen, which is
saturated or unsaturated (i.e., contains one or more double and/or
triple bonds), and having from one to twelve carbon atoms, e.g.,
methylene, ethylene, propylene, n-butylene, ethenylene,
propenylene, n-butenylene, propynylene, n-butynylene, and the like.
The alkylene chain is attached to the rest of the molecule through
a single or double bond and to the radical group through a single
or double bond. The points of attachment of the alkylene chain to
the rest of the molecule and to the radical group can be through
one carbon or any two carbons within the chain. Unless stated
otherwise specifically in the specification, an alkylene chain may
be optionally substituted.
"Alkoxy" refers to a radical of the formula --OR.sub.a where
R.sub.a is an alkyl radical as defined above containing one to
twelve carbon atoms. Unless stated otherwise specifically in the
specification, an alkoxy group may be optionally substituted.
"Alkylamino" refers to a radical of the formula --NHR.sub.a or
--NR.sub.aR.sub.a where each R.sub.a is, independently, an alkyl
radical as defined above containing one to twelve carbon atoms.
Unless stated otherwise specifically in the specification, an
alkylamino group may be optionally substituted.
"Thioalkyl" refers to a radical of the formula --SR.sub.a where
R.sub.a is an alkyl radical as defined above containing one to
twelve carbon atoms. Unless stated otherwise specifically in the
specification, a thioalkyl group may be optionally substituted.
"Aryl" refers to a hydrocarbon ring system radical comprising
hydrogen, 6 to 18 carbon atoms and at least one aromatic ring. For
purposes of this invention, the aryl radical may be a monocyclic,
bicyclic, tricyclic or tetracyclic ring system, which may include
fused or bridged ring systems. Aryl radicals include, but are not
limited to, aryl radicals derived from aceanthrylene,
acenaphthylene, acephenanthrylene, anthracene, azulene, benzene,
chrysene, fluoranthene, fluorene, as-indacene, s-indacene, indane,
indene, naphthalene, phenalene, phenanthrene, pleiadene, pyrene,
and triphenylene. Unless stated otherwise specifically in the
specification, the term "aryl" or the prefix "ar-" (such as in
"aralkyl") is meant to include aryl radicals that are optionally
substituted.
"Aralkyl" refers to a radical of the formula --R.sub.b--R.sub.c
where R.sub.b is an alkylene chain as defined above and R.sub.c is
one or more aryl radicals as defined above, for example, benzyl,
diphenylmethyl and the like. Unless stated otherwise specifically
in the specification, an aralkyl group may be optionally
substituted.
"Cycloalkyl" or "carbocyclic ring" refers to a stable non-aromatic
monocyclic or polycyclic hydrocarbon radical consisting solely of
carbon and hydrogen atoms, which may include fused or bridged ring
systems, having from three to fifteen carbon atoms, preferably
having from three to ten carbon atoms, and which is saturated or
unsaturated and attached to the rest of the molecule by a single
bond. Monocyclic radicals include, for example, cyclopropyl,
cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.
Polycyclic radicals include, for example, adamantyl, norbornyl,
decalinyl, 7,7-dimethyl-bicyclo[2.2.1]heptanyl, and the like.
Unless otherwise stated specifically in the specification, a
cycloalkyl group may be optionally substituted.
"Cycloalkylalkyl" refers to a radical of the formula
--R.sub.bR.sub.d where R.sub.d is an alkylene chain as defined
above and R.sub.g is a cycloalkyl radical as defined above. Unless
stated otherwise specifically in the specification, a
cycloalkylalkyl group may be optionally substituted.
"Fused" refers to any ring structure described herein which is
fused to an existing ring structure in the compounds of the
invention. When the fused ring is a heterocyclyl ring or a
heteroaryl ring, any carbon atom on the existing ring structure
which becomes part of the fused heterocyclyl ring or the fused
heteroaryl ring may be replaced with a nitrogen atom.
"Halo" or "halogen" refers to bromo, chloro, fluoro or iodo.
"Haloalkyl" refers to an alkyl radical, as defined above, that is
substituted by one or more halo radicals, as defined above, e.g.,
trifluoromethyl, difluoromethyl, trichloromethyl,
2,2,2-trifluoroethyl, 1,2-difluoroethyl, 3-bromo-2-fluoropropyl,
1,2-dibromoethyl, and the like. Unless stated otherwise
specifically in the specification, a haloalkyl group may be
optionally substituted.
"Heterocyclyl" or "heterocyclic ring" refers to a stable 3- to
18-membered non-aromatic ring radical which consists of two to
twelve carbon atoms and from one to six heteroatoms selected from
the group consisting of nitrogen, oxygen and sulfur. Unless stated
otherwise specifically in the specification, the heterocyclyl
radical may be a monocyclic, bicyclic, tricyclic or tetracyclic
ring system, which may include fused or bridged ring systems; and
the nitrogen, carbon or sulfur atoms in the heterocyclyl radical
may be optionally oxidized; the nitrogen atom may be optionally
quaternized; and the heterocyclyl radical may be partially or fully
saturated. Examples of such heterocyclyl radicals include, but are
not limited to, dioxolanyl, thienyl[1,3]dithianyl,
decahydroisoquinolyl, imidazolinyl, imidazolidinyl,
isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl,
octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl,
2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl,
4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl,
thiazolidinyl, tetrahydrofuryl, trithianyl, tetrahydropyranyl,
thiomorpholinyl, thiamorpholinyl, 1-oxo-thiomorpholinyl, and
1,1-dioxo-thiomorpholinyl. Unless stated otherwise specifically in
the specification, Unless stated otherwise specifically in the
specification, a heterocyclyl group may be optionally
substituted.
"N-heterocyclyl" refers to a heterocyclyl radical as defined above
containing at least one nitrogen and where the point of attachment
of the heterocyclyl radical to the rest of the molecule is through
a nitrogen atom in the heterocyclyl radical. Unless stated
otherwise specifically in the specification, a N-heterocyclyl group
may be optionally substituted.
"Heterocyclylalkyl" refers to a radical of the formula
--R.sub.bR.sub.c where R.sub.b is an alkylene chain as defined
above and R.sub.e is a heterocyclyl radical as defined above, and
if the heterocyclyl is a nitrogen-containing heterocyclyl, the
heterocyclyl may be attached to the alkyl radical at the nitrogen
atom. Unless stated otherwise specifically in the specification, a
heterocyclylalkyl group may be optionally substituted.
"Heteroaryl" refers to a 5- to 14-membered ring system radical
comprising hydrogen atoms, one to thirteen carbon atoms, one to six
heteroatoms selected from the group consisting of nitrogen, oxygen
and sulfur, and at least one aromatic ring. For purposes of this
invention, the heteroaryl radical may be a monocyclic, bicyclic,
tricyclic or tetracyclic ring system, which may include fused or
bridged ring systems; and the nitrogen, carbon or sulfur atoms in
the heteroaryl radical may be optionally oxidized; the nitrogen
atom may be optionally quaternized. Examples include, but are not
limited to, azepinyl, acridinyl, benzimidazolyl, benzothiazolyl,
benzindolyl, benzodioxolyl, benzofuranyl, benzooxazolyl,
benzothiazolyl, benzothiadiazolyl, benzo[b][1,4]dioxepinyl,
1,4-benzodioxanyl, benzonaphthofuranyl, benzoxazolyl,
benzodioxolyl, benzodioxinyl, benzopyranyl, benzopyranonyl,
benzofuranyl, benzofuranonyl, benzothienyl (benzothiophenyl),
benzotriazolyl, benzo[4,6]imidazo[1,2-a]pyridinyl, carbazolyl,
cinnolinyl, dibenzofuranyl, dibenzothiophenyl, furanyl, furanonyl,
isothiazolyl, imidazolyl, indazolyl, indolyl, indazolyl,
isoindolyl, indolinyl, isoindolinyl, isoquinolyl, indolizinyl,
isoxazolyl, naphthyridinyl, oxadiazolyl, 2-oxoazepinyl, oxazolyl,
oxiranyl, 1-oxidopyridinyl, 1-oxidopyrimidinyl, 1-oxidopyrazinyl,
1-oxidopyridazinyl, 1-phenyl-1H-pyrrolyl, phenazinyl,
phenothiazinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl,
pyrrolyl, pyrazolyl, pyridinyl, pyrazinyl, pyrimidinyl,
pyridazinyl, quinazolinyl, quinoxalinyl, quinolinyl, quinuclidinyl,
isoquinolinyl, tetrahydroquinolinyl, thiazolyl, thiadiazolyl,
triazolyl, tetrazolyl, triazinyl, and thiophenyl (i.e. thienyl).
Unless stated otherwise specifically in the specification, a
heteroaryl group may be optionally substituted.
"N-heteroaryl" refers to a heteroaryl radical as defined above
containing at least one nitrogen and where the point of attachment
of the heteroaryl radical to the rest of the molecule is through a
nitrogen atom in the heteroaryl radical. Unless stated otherwise
specifically in the specification, an N-heteroaryl group may be
optionally substituted.
"Heteroarylalkyl" refers to a radical of the formula
--R.sub.bR.sub.f where R.sub.b is an alkylene chain as defined
above and R.sub.f is a heteroaryl radical as defined above. Unless
stated otherwise specifically in the specification, a
heteroarylalkyl group may be optionally substituted.
The term "substituted" used herein means any of the above groups
(i.e., alkyl, alkylene, alkoxy, alkylamino, thioalkyl, aryl,
aralkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, heterocyclyl,
N-heterocyclyl, heterocyclylalkyl, heteroaryl. N-heteroaryl and/or
heteroarylalkyl) wherein at least one hydrogen atom is replaced by
a bond to a non-hydrogen atoms such as, but not limited to: a
halogen atom such as F, Cl, Br, and I; an oxygen atom in groups
such as hydroxyl groups, alkoxy groups, and ester groups; a sulfur
atom in groups such as thiol groups, thioalkyl groups, sulfone
groups, sulfonyl groups, and sulfoxide groups; a nitrogen atom in
groups such as amines, amides, alkylamines, dialkylamines,
arylamines, alkylarylamines, diarylamines, N-oxides, imides, and
enamines; a silicon atom in groups such as trialkylsilyl groups,
dialkylarylsilyl groups, alkyldiarylsilyl groups, and triarylsilyl
groups; and other heteroatoms in various other groups.
"Substituted" also means any of the above groups in which one or
more hydrogen atoms are replaced by a higher-order bond (e.g., a
double- or triple-bond) to a heteroatom such as oxygen in oxo,
carbonyl, carboxyl, and ester groups; and nitrogen in groups such
as imines, oximes, hydrazones, and nitriles. For example.
"substituted" includes any of the above groups in which one or more
hydrogen atoms are replaced with --NR.sub.gR.sub.h,
--NR.sub.gC(.dbd.O)R.sub.h, --NR.sub.gC(.dbd.O)NR.sub.gR.sub.h,
--NR.sub.gC(.dbd.O)OR.sub.h,
--NR.sub.gC(.dbd.NR.sub.g)NR.sub.gR.sub.h,
--NR.sub.gSO.sub.2R.sub.h, --OC(.dbd.O)NR.sub.gR.sub.h, --OR.sub.g,
--SR.sub.g, --SOR.sub.g, --SO.sub.2R.sub.g, --OSO.sub.2R.sub.g,
--SO.sub.2OR.sub.g, .dbd.NSO.sub.2R.sub.g, and
--SO.sub.2NR.sub.gR.sub.h. "Substituted" also means any of the
above groups in which one or more hydrogen atoms are replaced with
--C(.dbd.O)R.sub.g, --C(.dbd.O)OR.sub.g,
--C(.dbd.O)NR.sub.gR.sub.h, --CH.sub.2SO.sub.2R.sub.g,
--CH.sub.2SO.sub.2NR.sub.gR.sub.h. In the foregoing, R.sub.g and
R.sub.h are the same or different and independently hydrogen,
alkyl, alkoxy, alkylamino, thioalkyl, aryl, aralkyl, cycloalkyl,
cycloalkylalkyl, haloalkyl, heterocyclyl, N-heterocyclyl,
heterocyclylalkyl, heteroaryl, N-heteroaryl and/or heteroarylalkyl.
"Substituted" further means any of the above groups in which one or
more hydrogen atoms are replaced by a bond to an amino, cyano,
hydroxyl, imino, nitro, oxo, thioxo, halo, alkyl, alkoxy,
alkylamino, thioalkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl,
haloalkyl, heterocyclyl, N-heterocyclyl, heterocyclylalkyl,
heteroaryl, N-heteroaryl and/or heteroarylalkyl group. In addition,
each of the foregoing substituents may also be optionally
substituted with one or more of the above substituents.
The term "protecting group," as used herein, refers to a labile
chemical moiety which is known in the art to protect reactive
groups including without limitation, hydroxyl and amino groups,
against undesired reactions during synthetic procedures. Hydroxyl
and amino groups which protected with a protecting group are
referred to herein as "protected hydroxyl groups" and "protected
amino groups", respectively. Protecting groups are typically used
selectively and/or orthogonally to protect sites during reactions
at other reactive sites and can then be removed to leave the
unprotected group as is or available for further reactions.
Protecting groups as known in the art are described generally in
Greene and Wuts, Protective Groups in Organic Synthesis, 3rd
edition, John Wiley & Sons, New York (1999). Groups can be
selectively incorporated into aminoglycosides of the invention as
precursors. For example an amino group can be placed into a
compound of the invention as an azido group that can be chemically
converted to the amino group at a desired point in the synthesis.
Generally, groups are protected or present as a precursor that will
be inert to reactions that modify other areas of the parent
molecule for conversion into their final groups at an appropriate
time. Further representative protecting or precursor groups are
discussed in Agrawal, et al., Protocols for Oligonucleotide
Conjugates, Eds, Humana Press; New Jersey, 1994; Vol. 26 pp. 1-72.
Examples of "hydroxyl protecting groups" include, but are not
limited to, t-butyl, t-butoxymethyl, methoxymethyl,
tetrahydropyranyl, 1-ethoxyethyl, 1-(2-chloroethoxy)ethyl,
2-trimethylsilylethyl, p-chlorophenyl, 2,4-dinitrophenyl, benzyl,
2,6-dichlorobenzyl, diphenylmethyl, p-nitrobenzyl, triphenylmethyl,
trimethylsilyl, triethylsilyl, t-butyldimethylsilyl,
t-butyldiphenylsilyl, triphenylsilyl, benzoylformate, acetate,
chloroacetate, trichloroacetate, trifluoroacetate, pivaloate,
benzoate, p-phenylbenzoate, 9-fluorenylmethyl carbonate, mesylate
and tosylate. Examples of "amino protecting groups" include, but
are not limited to, carbamate-protecting groups, such as
2-trimethylsilylethoxycarbonyl (Teoc),
1-methyl-1-(4-biphenylyl)ethoxy-carbonyl (Bpoc), t-butoxycarbonyl
(BOC), allyloxycarbonyl (Allot), 9-fluorenylmethyloxycarbonyl
(Fmoc), and benzyloxycarbonyl (Cbz); amide protecting groups, such
as formyl, acetyl, trihaloacetyl, benzoyl, and nitrophenylacetyl;
sulfonamide-protecting groups, such as 2-nitrobenzenesulfonyl; and
imine and cyclic imide protecting groups, such as phthalimido and
dithiasuccinoyl.
"Prodrug" is meant to indicate a compound that may be converted
under physiological conditions or by solvolysis to a biologically
active compound of the invention. Thus, the term "prodrug" refers
to a metabolic precursor of a compound of the invention that is
pharmaceutically acceptable. A prodrug may be inactive when
administered to a subject in need thereof, but is converted in vivo
to an active compound of the invention. Prodrugs are typically
rapidly transformed in vivo to yield the parent compound of the
invention, for example, by hydrolysis in blood. The prodrug
compound often offers advantages of solubility, tissue
compatibility or delayed release in a mammalian organism (see,
Bundgard, H., Design of Prodrugs (1985), pp. 7-9, 21-24 (Elsevier,
Amsterdam)). A discussion of prodrugs is provided in Higuchi, T.,
et al., A.C.S. Symposium Series, Vol. 14, and in Bioreversible
Carriers in Drug Design, Ed. Edward B. Roche, American
Pharmaceutical Association and Pergamon Press, 1987.
The term "prodrug" is also meant to include any covalently bonded
carriers, which release the active compound of the invention in
vivo when such prodrug is administered to a mammalian subject.
Prodrugs of a compound of the invention may be prepared by
modifying functional groups present in the compound of the
invention in such a way that the modifications are cleaved, either
in routine manipulation or in vivo, to the parent compound of the
invention. Prodrugs include compounds of the invention wherein a
hydroxyl, amino or mercapto group is bonded to any group that, when
the prodrug of the compound of the invention is administered to a
mammalian subject, cleaves to form a free hydroxyl, free amino or
free mercapto group, respectively. Examples of prodrugs include,
but are not limited to, acetate, formate and benzoate derivatives
of alcohol or amide derivatives of amine functional groups in the
compounds of the invention and the like.
The invention disclosed herein is also meant to encompass all
pharmaceutically acceptable compounds of structure (I) being
isotopically-labelled by having one or more atoms replaced by an
atom having a different atomic mass or mass number. Examples of
isotopes that can be incorporated into the disclosed compounds
include isotopes of hydrogen, carbon, nitrogen, oxygen,
phosphorous, fluorine, chlorine, and iodine, such as .sup.2H,
.sup.3H, .sup.11C, .sup.13C, .sup.14C, .sup.13N, .sup.15N,
.sup.15O, .sup.17O, .sup.18O, .sup.31O, .sup.32P, .sup.35S,
.sup.18F, .sup.36Cl, .sup.123I and .sup.125I, respectively. These
radiolabelled compounds could be useful to help determine or
measure the effectiveness of the compounds, by characterizing, for
example, the site or mode of action, or binding affinity to
pharmacologically important site of action. Certain
isotopically-labelled compounds of structure (I), for example,
those incorporating a radioactive isotope, are useful in drug
and/or substrate tissue distribution studies. The radioactive
isotopes tritium, i.e. .sup.3H, and carbon-14, i.e. .sup.14C, are
particularly useful for this purpose in view of their ease of
incorporation and ready means of detection.
Substitution with heavier isotopes such as deuterium, i.e. .sup.2H,
may afford certain therapeutic advantages resulting from greater
metabolic stability, for example, increased in vivo half-life or
reduced dosage requirements, and hence may be preferred in some
circumstances.
Substitution with positron emitting isotopes, such as .sup.11C,
.sup.18F, .sup.15O and .sup.13N, can be useful in Positron Emission
Topography (PET) studies for examining substrate receptor
occupancy. Isotopically-labeled compounds of structure (I) can
generally be prepared by conventional techniques known to those
skilled in the art or by processes analogous to those described in
the Preparations and Examples as set out below using an appropriate
isotopically-labeled reagent in place of the non-labeled reagent
previously employed.
The invention disclosed herein is also meant to encompass the in
vivo metabolic products of the disclosed compounds. Such products
may result from, for example, the oxidation, reduction, hydrolysis,
amidation, esterification, and the like of the administered
compound, primarily due to enzymatic processes. Accordingly, the
invention includes compounds produced by a process comprising
administering a compound of this invention to a mammal for a period
of time sufficient to yield a metabolic product thereof. Such
products are typically identified by administering a radiolabelled
compound of the invention in a detectable dose to an animal, such
as rat, mouse, guinea pig, monkey, or to human, allowing sufficient
time for metabolism to occur, and isolating its conversion products
from the urine, blood or other biological samples.
"Stable compound" and "stable structure" are meant to indicate a
compound that is sufficiently robust to survive isolation to a
useful degree of purity from a reaction mixture, and formulation
into an efficacious therapeutic agent.
"Mammal" includes humans and both domestic animals such as
laboratory animals and household pets (e.g., cats, dogs, swine,
cattle, sheep, goats, horses, rabbits), and non-domestic animals
such as wildlife and the like.
"Optional" or "optionally" means that the subsequently described
event of circumstances may or may not occur, and that the
description includes instances where said event or circumstance
occurs and instances in which it does not. For example, "optionally
substituted aryl" means that the aryl radical may or may not be
substituted and that the description includes both substituted aryl
radicals and aryl radicals having no substitution.
"Pharmaceutically acceptable carrier, diluent or excipient"
includes without limitation any adjuvant, carrier, excipient,
glidant, sweetening agent, diluent, preservative, dye/colorant,
flavor enhancer, surfactant, wetting agent, dispersing agent,
suspending agent, stabilizer, isotonic agent, solvent, or
emulsifier which has been approved by the United States Food and
Drug Administration as being acceptable for use in humans or
domestic animals.
"Pharmaceutically acceptable salt" includes both acid and base
addition salts.
"Pharmaceutically acceptable acid addition salt" refers to those
salts which retain the biological effectiveness and properties of
the free bases, which are not biologically or otherwise
undesirable, and which are formed with inorganic acids such as, but
are not limited to, hydrochloric acid, hydrobromic acid, sulfuric
acid, nitric acid, phosphoric acid and the like, and organic acids
such as, but not limited to, acetic acid, 2,2-dichloroacetic acid,
adipic acid, alginic acid, ascorbic acid, aspartic acid,
benzenesulfonic acid, benzoic acid, 4-acetamidobenzoic acid,
camphoric acid, camphor-10-sulfonic acid, capric acid, caproic
acid, caprylic acid, carbonic acid, cinnamic acid, citric acid,
cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid,
ethanesulfonic acid, 2-hydroxyethanesulfonic acid, formic acid,
fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid,
gluconic acid, glucuronic acid, glutamic acid, glutaric acid,
2-oxo-glutaric acid, glycerophosphoric acid, glycolic acid,
hippuric acid, isobutyric acid, lactic acid, lactobionic acid,
lauric acid, maleic acid, malic acid, malonic acid, mandelic acid,
methanesulfonic acid, mucic acid, naphthalene-1,5-disulfonic acid,
naphthalene-2-sulfonic acid, 1-hydroxy-2-naphthoic acid, nicotinic
acid, oleic acid, orotic acid, oxalic acid, palmitic acid, pamoic
acid, propionic acid, pyroglutamic acid, pyruvic acid, salicylic
acid, 4-aminosalicylic acid, sebacic acid, stearic acid, succinic
acid, tartaric acid, thiocyanic acid, p-toluenesulfonic acid,
trifluoroacetic acid, undecylenic acid, and the like.
"Pharmaceutically acceptable base addition salt" refers to those
salts which retain the biological effectiveness and properties of
the free acids, which are not biologically or otherwise
undesirable. These salts are prepared from addition of an inorganic
base or an organic base to the free acid. Salts derived from
inorganic bases include, but are not limited to, the sodium,
potassium, lithium, ammonium, calcium, magnesium, iron, zinc,
copper, manganese, aluminum salts and the like. Preferred inorganic
salts are the ammonium, sodium, potassium, calcium, and magnesium
salts. Salts derived from organic bases include, but are not
limited to, salts of primary, secondary, and tertiary amines,
substituted amines including naturally occurring substituted
amines, cyclic amines and basic ion exchange resins, such as
ammonia, isopropylamine, trimethylamine, diethylamine,
triethylamine, tripropylamine, diethanolamine, ethanolamine,
deanol, 2-dimethylaminoethanol, 2-diethylaminoethanol,
dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine,
hydrabamine, choline, betaine, benethamine, benzathine,
ethylenediamine, glucosamine, methylglucamine, theobromine,
triethanolamine, tromethamine, purines, piperazine, piperidine,
N-ethylpiperidine, polyamine resins and the like. Particularly
preferred organic bases are isopropylamine, diethylamine,
ethanolamine, trimethylamine, dicyclohexylamine, choline and
caffeine.
Often crystallizations produce a solvate of the compound of the
invention. As used herein, the term "solvate" refers to an
aggregate that comprises one or more molecules of a compound of the
invention with one or more molecules of solvent. The solvent may be
water, in which case the solvate may be a hydrate. Alternatively,
the solvent may be an organic solvent. Thus, the compounds of the
present invention may exist as a hydrate, including a monohydrate,
dihydrate, hemihydrate, sesquihydrate, trihydrate, tetrahydrate and
the like, as well as the corresponding solvated forms. The compound
of the invention may be true solvates, while in other cases, the
compound of the invention may merely retain adventitious water or
be a mixture of water plus some adventitious solvent.
A "pharmaceutical composition" refers to a formulation of a
compound of the invention and a medium generally accepted in the
art for the delivery of the biologically active compound to
mammals, e.g., humans. Such a medium includes all pharmaceutically
acceptable carriers, diluents or excipients therefor.
"Effective amount" or "therapeutically effective amount" refers to
that amount of a compound of the invention which, when administered
to a mammal, preferably a human, is sufficient to effect treatment,
as defined below, of a bacterial infection in the mammal,
preferably a human. The amount of a compound of the invention which
constitutes a "therapeutically effective amount" will vary
depending on the compound, the condition and its severity, the
manner of administration, and the age of the mammal to be treated,
but can be determined routinely by one of ordinary skill in the art
having regard to his own knowledge and to this disclosure.
"Treating" or "treatment" as used herein covers the treatment of
the disease or condition of interest in a mammal, preferably a
human, having the disease or condition of interest, and
includes:
(i) preventing the disease or condition from occurring in a mammal,
in particular, when such mammal is predisposed to the condition but
has not yet been diagnosed as having it;
(ii) inhibiting the disease or condition, i.e., arresting its
development;
(iii) relieving the disease or condition, i.e., causing regression
of the disease or condition; or
(iv) relieving the symptoms resulting from the disease or
condition, i.e., relieving pain without addressing the underlying
disease or condition. As used herein, the terms "disease" and
"condition" may be used interchangeably or may be different in that
the particular malady or condition may not have a known causative
agent (so that etiology has not yet been worked out) and it is
therefore not yet recognized as a disease but only as an
undesirable condition or syndrome, wherein a more or less specific
set of symptoms have been identified by clinicians.
The compounds of the invention, or their pharmaceutically
acceptable salts may contain one or more asymmetric centers and may
thus give rise to enantiomers, diastereomers, and other
stereoisomeric forms that may be defined, in terms of absolute
stereochemistry, as (R)- or (S)- or, as (D)- or (L)- for amino
acids. The present invention is meant to include all such possible
isomers, as well as their racemic and optically pure forms.
Optically active (+) and (-), (R)- and (S)-, or (D)- and
(L)-isomers may be prepared using chiral synthons or chiral
reagents, or resolved using conventional techniques, for example,
chromatography and fractional crystallization. Conventional
techniques for the preparation/isolation of individual enantiomers
include chiral synthesis from a suitable optically pure precursor
or resolution of the racemate (or the racemate of a salt or
derivative) using, for example, chiral high pressure liquid
chromatography (HPLC). When the compounds described herein contain
olefinic double bonds or other centres of geometric asymmetry, and
unless specified otherwise, it is intended that the compounds
include both E and Z geometric isomers. Likewise, all tautomeric
forms are also intended to be included.
A "stereoisomer" refers to a compound made up of the same atoms
bonded by the same bonds but having different three-dimensional
structures, which are not interchangeable. The present invention
contemplates various stereoisomers and mixtures thereof and
includes "enantiomers", which refers to two stereoisomers whose
molecules are nonsuperimposeable mirror images of one another.
A "tautomer" refers to a proton shift from one atom of a molecule
to another atom of the same molecule. The present invention
includes tautomers of any said compounds.
As noted above, in one embodiment of the present invention,
compounds having antibacterial activity are provided, the compounds
having the following structure (I):
##STR00010## or a stereoisomer, pharmaceutically acceptable salt or
prodrug thereof,
wherein:
Q.sub.1 is alkyl optionally substituted with hydroxyl or amino,
##STR00011##
Q.sub.2 is hydrogen, optionally substituted alkyl, optionally
substituted aryl, optionally substituted aralkyl, optionally
substituted cycloalkyl, optionally substituted cycloalkylalkyl,
optionally substituted heterocyclyl, optionally substituted
heterocyclylalkyl, optionally substituted heteroaryl, optionally
substituted heteroarylalkyl, --C(.dbd.NH)NR.sub.7R.sub.8,
##STR00012##
Q.sub.3 is hydrogen, optionally substituted alkyl, optionally
substituted aryl, optionally substituted aralkyl, optionally
substituted cycloalkyl, optionally substituted cycloalkylalkyl,
optionally substituted heterocyclyl, optionally substituted
heterocyclylalkyl, optionally substituted heteroaryl, optionally
substituted heteroarylalkyl, --C(.dbd.NH)NR.sub.7R.sub.8,
##STR00013##
each R.sub.4, R.sub.5, R.sub.7, R.sub.8 and R.sub.11 is,
independently, hydrogen or C.sub.1-C.sub.6 alkyl optionally
substituted with one or more halogen, hydroxyl or amino;
each R.sub.6 is, independently, hydrogen, halogen, hydroxyl, amino
or C.sub.1-C.sub.6 alkyl;
or R.sub.4 and R.sub.5 together with the atoms to which they are
attached can form a heterocyclic ring having from 4 to 6 ring
atoms, or R.sub.5 and one R.sub.6 together with the atoms to which
they are attached can form a heterocyclic ring having from 3 to 6
ring atoms, or R.sub.4 and one R.sub.6 together with the atoms to
which they are attached can form a carbocyclic ring having from 3
to 6 ring atoms, or R.sub.7 and R.sub.8 together with the atom to
which they are attached can form a heterocyclic ring having from 3
to 6 ring atoms;
each R.sub.9 and R.sub.12 is, independently, hydrogen, hydroxyl,
amino or C.sub.1-C.sub.6 alkyl optionally substituted with one or
more halogen, hydroxyl or amino;
each R.sub.10 is, independently, hydrogen, halogen, hydroxyl, amino
or C.sub.1-C.sub.6 alkyl;
or R.sub.9 and one R.sub.10 together with the atoms to which they
are attached can form a heterocyclic ring having from 3 to 6 ring
atoms; and
each n is, independently, an integer from 0 to 4, and
wherein (i) at least one of Q.sub.2 and Q.sub.3 is other than
hydrogen, and (ii) Q.sub.1 is not ethyl or --C(.dbd.O)CH.sub.3.
In further embodiments:
Q.sub.1 is alkyl optionally substituted with hydroxyl or amino,
--C(.dbd.O)H,
##STR00014##
Q.sub.2 is hydrogen, optionally substituted alkyl, optionally
substituted aryl, optionally substituted aralkyl, optionally
substituted cycloalkyl, optionally substituted cycloalkylalkyl,
optionally substituted heterocyclyl, optionally substituted
heterocyclylalkyl, optionally substituted heteroaryl, optionally
substituted heteroarylalkyl, --C(.dbd.NH)NR.sub.7R.sub.8,
##STR00015##
Q.sub.3 is hydrogen, optionally substituted alkyl, optionally
substituted aryl, optionally substituted aralkyl, optionally
substituted cycloalkyl, optionally substituted cycloalkylalkyl,
optionally substituted heterocyclyl, optionally substituted
heterocyclylalkyl, optionally substituted heteroaryl, optionally
substituted heteroarylalkyl, --C(.dbd.NH)NR.sub.7R.sub.8,
##STR00016## each R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8 and
R.sub.11 is, independently, hydrogen or C.sub.1-C.sub.6 alkyl, or
R.sub.4 and R.sub.5 together with the atoms to which they are
attached can form a heterocyclic ring having from 4 to 6 ring
atoms, or R.sub.5 and R.sub.6 together with the atoms to which they
are attached can form a heterocyclic ring having from 4 to 6 ring
atoms, or R.sub.4 and R.sub.6 together with the atoms to which they
are attached can form a carbocyclic ring having from 3 to 6 ring
atoms, or R.sub.7 and R.sub.8 together with the atom to which they
are attached can form a heterocyclic ring having from 4 to 6 ring
atoms;
each R.sub.9, R.sub.10 and R.sub.12 is, independently, hydrogen,
hydroxyl, amino or C.sub.1-C.sub.6 alkyl, or R.sub.9 and R.sub.10
together with the atoms to which they are attached can form a
heterocyclic ring having from 4 to 6 ring atoms;
each n is, independently, an integer from 0 to 4; and
each m is, independently, an integer from 0 to 4, and
wherein (i) at least one of Q.sub.2 and Q.sub.3 is other than
hydrogen, and (ii) Q.sub.1 is not ethyl.
In other further embodiments, Q.sub.1 is:
##STR00017##
wherein: R.sub.4 is hydrogen; R.sub.7 is hydrogen; R.sub.8 is
hydrogen; and n is an integer from 1 to 4. In further embodiments,
each R.sub.6 is hydrogen. For example, in more specific embodiments
of the foregoing, Q.sub.1 is:
##STR00018## In other further embodiments, at least one R.sub.6 is
halogen.
In other further embodiments, Q.sub.1 is:
##STR00019## wherein: R.sub.4 and one R.sub.6 together with the
atoms to which they are attached form a carbocyclic ring having
from 3 to 6 ring atoms; R.sub.7 is hydrogen; R.sub.8 is hydrogen:
and n is an integer from 1 to 4. For example, in more specific
embodiments of the foregoing, Q.sub.1 is:
##STR00020## In other further embodiments, at least one R.sub.6 is
halogen.
In other further embodiments, Q.sub.1 is:
##STR00021## wherein R.sub.5 is hydrogen. In further embodiments,
each R.sub.6 is hydrogen. For example, in more specific embodiments
of the foregoing, Q.sub.1 is:
##STR00022## In other further embodiments, at least one R.sub.6 is
halogen.
In other further embodiments, Q.sub.1 is:
##STR00023## wherein: R.sub.7 is hydrogen; and R.sub.8 is hydrogen.
In further embodiments, each R.sub.6 is hydrogen. For example, in
more specific embodiments of the foregoing, Q.sub.1 is:
##STR00024## In other further embodiments, at least one R.sub.6 is
halogen.
In other further embodiments, Q.sub.1 is:
##STR00025## wherein: R.sub.7 is hydrogen; and R.sub.8 is hydrogen.
In further embodiments, each R.sub.6 is hydrogen. In other further
embodiments, at least one R.sub.6 is halogen.
In other further embodiments, Q.sub.1 is:
##STR00026## wherein R.sub.9 is hydrogen. In further embodiments,
each R.sub.10 is hydrogen. In other further embodiments, at least
one R.sub.10 is halogen.
In other further embodiments, Q.sub.1 is:
##STR00027## wherein: R.sub.7 is hydrogen; and R.sub.8 is hydrogen.
In further embodiments, each R.sub.10 is hydrogen. In other further
embodiments, at least one R.sub.10 is halogen.
In other further embodiments, Q.sub.1 is:
##STR00028## wherein R.sub.4 is hydrogen. In further embodiments,
each R.sub.6 is hydrogen. In other further embodiments, at least
one R.sub.6 is halogen. For example, in more specific embodiments
of the foregoing, Q.sub.1 is --C(.dbd.O)H.
In other further embodiments, Q.sub.1 is alkyl optionally
substituted with hydroxyl or amino. For example, in more specific
embodiments, Q.sub.1 is unsubstituted. In other more specific
embodiments, Q.sub.1 is substituted with hydroxyl or amino.
In other further embodiments, Q.sub.2 is other than hydrogen.
In other further embodiments, Q.sub.2 is optionally substituted
alkyl. For example, in more specific embodiments, Q.sub.2 is
unsubstituted. In other more specific embodiments, Q.sub.2 is
substituted with hydroxyl or amino.
In other further embodiments, Q.sub.2 is optionally substituted
cycloalkyl. For example, in more specific embodiments, Q.sub.2 is
unsubstituted. In other more specific embodiments, Q.sub.2 is
substituted with hydroxyl or amino.
In other further embodiments, Q.sub.2 is optionally substituted
cycloalkylalkyl. For example, in more specific embodiments, Q.sub.2
is unsubstituted. In other more specific embodiments, Q.sub.2 is
substituted with hydroxyl or amino.
In other further embodiments, Q.sub.2 is optionally substituted
heterocyclyl. For example, in more specific embodiments, Q.sub.2 is
unsubstituted. In other more specific embodiments, Q.sub.2 is
substituted with hydroxyl or amino.
In other further embodiments, Q.sub.2 is optionally substituted
heterocyclylalkyl. For example, in more specific embodiments,
Q.sub.2 is unsubstituted. In other more specific embodiments,
Q.sub.2 is substituted with hydroxyl or amino.
In other further embodiments. Q.sub.2 is hydrogen.
In other further embodiments, Q.sub.3 is other than hydrogen.
In other further embodiments, Q.sub.3 is optionally substituted
alkyl. For example, in more specific embodiments, Q.sub.3 is
unsubstituted. In other more specific embodiments, Q.sub.3 is
substituted with hydroxyl or amino.
In other further embodiments, Q.sub.3 is optionally substituted
cycloalkyl. For example, in more specific embodiments, Q.sub.3 is
unsubstituted. In other more specific embodiments, Q.sub.3 is
substituted with hydroxyl or amino.
In other further embodiments, Q.sub.3 is optionally substituted
cycloalkylalkyl. For example, in more specific embodiments, Q.sub.3
is unsubstituted. In other more specific embodiments, Q.sub.3 is
substituted with hydroxyl or amino.
In other further embodiments, Q.sub.3 is optionally substituted
heterocyclyl. For example, in more specific embodiments, Q.sub.3 is
unsubstituted. In other more specific embodiments, Q.sub.3 is
substituted with hydroxyl or amino.
In other further embodiments, Q.sub.3 is optionally substituted
heterocyclylalkyl. For example, in more specific embodiments,
Q.sub.3 is unsubstituted. In other more specific embodiments,
Q.sub.3 is substituted with hydroxyl or amino.
In other further embodiments, Q.sub.3 is --C(.dbd.NH)NH.sub.2.
In other further embodiments, Q.sub.3 is hydrogen.
In other further embodiments, R.sub.11 is hydrogen.
In other further embodiments, each R.sub.12 is methyl.
As further noted above, in another embodiment of the present
invention, compounds having antibacterial activity are provided,
the compounds having the following structure (I):
##STR00029## or a stereoisomer, pharmaceutically acceptable salt or
prodrug thereof,
wherein:
Q.sub.1 is
##STR00030##
Q.sub.2 is hydrogen, optionally substituted alkyl, optionally
substituted aryl, optionally substituted aralkyl, optionally
substituted cycloalkyl, optionally substituted cycloalkylalkyl,
optionally substituted heterocyclyl, optionally substituted
heterocyclylalkyl, optionally substituted heteroaryl, optionally
substituted heteroarylalkyl, --C(.dbd.NH)NR.sub.7R.sub.8,
##STR00031##
Q.sub.3 is hydrogen, optionally substituted alkyl, optionally
substituted aryl, optionally substituted aralkyl, optionally
substituted cycloalkyl, optionally substituted cycloalkylalkyl,
optionally substituted heterocyclyl, optionally substituted
heterocyclylalkyl, optionally substituted heteroaryl, optionally
substituted heteroarylalkyl, --C(.dbd.NH)NR.sub.7R.sub.8,
##STR00032##
each R.sub.4, R.sub.5, R.sub.7, R.sub.8 and R.sub.11 is,
independently, hydrogen or C.sub.1-C.sub.6 alkyl optionally
substituted with one or more halogen, hydroxyl or amino;
each R.sub.6 is, independently, hydrogen, halogen, hydroxyl, amino
or C.sub.1-C.sub.6 alkyl;
or R.sub.4 and R.sub.5 together with the atoms to which they are
attached can form a heterocyclic ring having from 4 to 6 ring
atoms, or R.sub.5 and one R.sub.6 together with the atoms to which
they are attached can form a heterocyclic ring having from 3 to 6
ring atoms, or R.sub.4 and one R.sub.6 together with the atoms to
which they are attached can form a carbocyclic ring having from 3
to 6 ring atoms, or R.sub.7 and R.sub.8 together with the atom to
which they are attached can form a heterocyclic ring having from 3
to 6 ring atoms;
each R.sub.9 and R.sub.12 is, independently, hydrogen, hydroxyl,
amino or C.sub.1-C.sub.6 alkyl optionally substituted with one or
more halogen, hydroxyl or amino;
each R.sub.10 is, independently, hydrogen, halogen, hydroxyl, amino
or C.sub.1-C.sub.6 alkyl;
or R.sub.9 and one R.sub.10 together with the atoms to which they
are attached can form a heterocyclic ring having from 3 to 6 ring
atoms; and
each n is, independently, an integer from 0 to 4, and
wherein (i) at least one of Q.sub.2 and Q.sub.3 is other than
hydrogen, and (ii) for Q.sub.1, R.sub.5 and one R.sub.6 together
with the atoms to which they are attached form a heterocyclic ring
having 3 ring atoms, or R.sub.4 and one R.sub.6 together with the
atoms to which they are attached form a carbocyclic ring having 3
ring atoms, or R.sub.9 and one R.sub.10 together with the atoms to
which they are attached form a heterocyclic ring having 3 ring
atoms.
In further embodiments,
Q.sub.1 is:
##STR00033##
Q.sub.2 is hydrogen, optionally substituted alkyl, optionally
substituted aryl, optionally substituted aralkyl, optionally
substituted cycloalkyl, optionally substituted cycloalkylalkyl,
optionally substituted heterocyclyl, optionally substituted
heterocyclylalkyl, optionally substituted heteroaryl, optionally
substituted heteroarylalkyl, --C(.dbd.NH)NR.sub.7R.sub.8,
##STR00034##
Q.sub.3 is hydrogen, optionally substituted alkyl, optionally
substituted aryl, optionally substituted aralkyl, optionally
substituted cycloalkyl, optionally substituted cycloalkylalkyl,
optionally substituted heterocyclyl, optionally substituted
heterocyclylalkyl, optionally substituted heteroaryl, optionally
substituted heteroarylalkyl, --C(.dbd.NH)NR.sub.7R.sub.8,
##STR00035##
each R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8 and R.sub.11 is,
independently, hydrogen or C.sub.1-C.sub.6 alkyl, or R.sub.4 and
R.sub.5 together with the atoms to which they are attached can form
a heterocyclic ring having from 4 to 6 ring atoms, or R.sub.5 and
R.sub.6 together with the atoms to which they are attached can form
a heterocyclic ring having from 4 to 6 ring atoms, or R.sub.4 and
R.sub.6 together with the atoms to which they are attached can form
a carbocyclic ring having from 3 to 6 ring atoms, or R.sub.7 and
R.sub.8 together with the atom to which they are attached can form
a heterocyclic ring having from 4 to 6 ring atoms;
each R.sub.9, R.sub.10 and R.sub.12 is, independently, hydrogen,
hydroxyl, amino or C.sub.1-C.sub.6 alkyl, or R.sub.9 and R.sub.10
together with the atoms to which they are attached can form a
heterocyclic ring having from 4 to 6 ring atoms;
each n is, independently, an integer from 0 to 4; and
each m is, independently, an integer from 0 to 4, and
wherein at least one of Q.sub.2 and Q.sub.3 is other than
hydrogen.
In other further embodiments, Q.sub.1 is:
##STR00036##
In other further embodiments, Q.sub.2 is other than hydrogen.
In other further embodiments, Q.sub.2 is optionally substituted
alkyl. For example, in more specific embodiments, Q.sub.2 is
unsubstituted. In other more specific embodiments, Q.sub.2 is
substituted with hydroxyl or amino.
In other further embodiments, Q.sub.2 is optionally substituted
cycloalkyl. For example, in more specific embodiments, Q.sub.2 is
unsubstituted. In other more specific embodiments, Q.sub.2 is
substituted with hydroxyl or amino.
In other further embodiments, Q.sub.2 is optionally substituted
cycloalkylalkyl. For example, in more specific embodiments, Q.sub.2
is unsubstituted. In other more specific embodiments, Q.sub.2 is
substituted with hydroxyl or amino.
In other further embodiments, Q.sub.2 is optionally substituted
heterocyclyl. For example, in more specific embodiments, Q.sub.2 is
unsubstituted. In other more specific embodiments, Q.sub.2 is
substituted with hydroxyl or amino.
In other further embodiments, Q.sub.2 is optionally substituted
heterocyclylalkyl. For example, in more specific embodiments,
Q.sub.2 is unsubstituted. In other more specific embodiments,
Q.sub.2 is substituted with hydroxyl or amino.
In other further embodiments, Q.sub.3 is hydrogen.
In other further embodiments, Q.sub.3 is other than hydrogen.
In other further embodiments, Q.sub.3 is optionally substituted
alkyl. For example, in more specific embodiments, Q.sub.3 is
unsubstituted. In other more specific embodiments, Q.sub.3 is
substituted with hydroxyl or amino.
In other further embodiments, Q.sub.3 is optionally substituted
cycloalkyl. For example, in more specific embodiments, Q.sub.3 is
unsubstituted. In other more specific embodiments, Q.sub.3 is
substituted with hydroxyl or amino.
In other further embodiments, Q.sub.3 is optionally substituted
cycloalkylalkyl. For example, in more specific embodiments, Q.sub.3
is unsubstituted. In other more specific embodiments, Q.sub.3 is
substituted with hydroxyl or amino.
In other further embodiments, Q.sub.3 is optionally substituted
heterocyclyl. For example, in more specific embodiments, Q.sub.3 is
unsubstituted. In other more specific embodiments, Q.sub.3 is
substituted with hydroxyl or amino.
In other further embodiments, Q.sub.3 is optionally substituted
heterocyclylalkyl. For example, in more specific embodiments,
Q.sub.3 is unsubstituted. In other more specific embodiments,
Q.sub.3 is substituted with hydroxyl or amino.
In other further embodiments, Q.sub.3 is --C(.dbd.NH)NH.sub.2.
In other further embodiments, Q.sub.3 is hydrogen.
In other further embodiments, R.sub.11 is hydrogen.
In other further embodiments, each R.sub.12 is methyl.
It is understood that any embodiment of the compounds of structure
(I), as set forth above, and any specific substituent set forth
herein for a Q.sub.1, Q.sub.2, Q.sub.3, R.sub.11 and R.sub.12 group
in the compounds of structure (I), as set forth above, may be
independently combined with other embodiments and/or substituents
of compounds of structure (I) to form embodiments of the invention
not specifically set forth above. In addition, in the event that a
list of substitutents is listed for any particular substituent
group in a particular embodiment and/or claim, it is understood
that each individual substituent may be deleted from the particular
embodiment and/or claim and that the remaining list of substituents
will be considered to be within the scope of the invention.
For the purposes of administration, the compounds of the present
invention may be administered as a raw chemical or may be
formulated as pharmaceutical compositions. Pharmaceutical
compositions of the present invention comprise a compound of
structure (I) and a pharmaceutically acceptable carrier, diluent or
excipient. The compound of structure (I) is present in the
composition in an amount which is effective to treat a particular
disease or condition of interest--that is, in an amount sufficient
to treat a bacterial infection, and preferably with acceptable
toxicity to the patient. The antibacterial activity of compounds of
structure (I) can be determined by one skilled in the art, for
example, as described in the Examples below. Appropriate
concentrations and dosages can be readily determined by one skilled
in the art.
The compounds of the present invention possess antibacterial
activity against a wide spectrum of gram positive and gram negative
bacteria, as well as enterobacteria and anaerobes. Representative
susceptible organisms generally include those gram positive and
gram negative, aerobic and anaerobic organisms whose growth can be
inhibited by the compounds of the invention such as Staphylococcus,
Lactobacillus, Streptococcus, Sarcina, Escherichia, Enterobacter,
Klebsiella, Pseudomonas, Acinetobacter, Mycobacterium, Proteus,
Campylobacter, Citrobacter, Nisseria, Baccillus, Bacteroides,
Peptococcus, Clostridium, Salmonella, Shigella, Serratia,
Haemophilus, Brucella, Francisella, Anthracis, Yersinia,
Corynebacterium, Moraxella, Enterococcus, and other organisms.
Administration of the compounds of the invention, or their
pharmaceutically acceptable salts, in pure form or in an
appropriate pharmaceutical composition, can be carried out via any
of the accepted modes of administration of agents for serving
similar utilities. The pharmaceutical compositions of the invention
can be prepared by combining a compound of the invention with an
appropriate pharmaceutically acceptable carrier, diluent or
excipient, and may be formulated into preparations in solid,
semi-solid, liquid or gaseous forms, such as tablets, capsules,
powders, granules, ointments, solutions, suppositories, injections,
inhalants, gels, microspheres, and aerosols. Typical routes of
administering such pharmaceutical compositions include, without
limitation, oral, topical, transdermal, inhalation, parenteral,
sublingual, buccal, rectal, vaginal, and intranasal. The term
parenteral as used herein includes subcutaneous injections,
intravenous, intramuscular, intrasternal injection or infusion
techniques. Pharmaceutical compositions of the invention are
formulated so as to allow the active ingredients contained therein
to be bioavailable upon administration of the composition to a
patient. Compositions that will be administered to a subject or
patient take the form of one or more dosage units, where for
example, a tablet may be a single dosage unit, and a container of a
compound of the invention in aerosol form may hold a plurality of
dosage units. Actual methods of preparing such dosage forms are
known, or will be apparent, to those skilled in this art; for
example, see Remington: The Science and Practice of Pharmacy, 20th
Edition (Philadelphia College of Pharmacy and Science, 2000). The
composition to be administered will, in any event, contain a
therapeutically effective amount of a compound of the invention, or
a pharmaceutically acceptable salt thereof, for treatment of a
disease or condition of interest in accordance with the teachings
of this invention.
A pharmaceutical composition of the invention may be in the form of
a solid or liquid. In one aspect, the carrier(s) are particulate,
so that the compositions are, for example, in tablet or powder
form. The carrier(s) may be liquid, with the compositions being,
for example, an oral syrup, injectable liquid or an aerosol, which
is useful in, for example, inhalatory administration.
When intended for oral administration, the pharmaceutical
composition is preferably in either solid or liquid form, where
semi-solid, semi-liquid, suspension and gel forms are included
within the forms considered herein as either solid or liquid.
As a solid composition for oral administration, the pharmaceutical
composition may be formulated into a powder, granule, compressed
tablet, pill, capsule, chewing gum, wafer or the like form. Such a
solid composition will typically contain one or more inert diluents
or edible carriers. In addition, one or more of the following may
be present: binders such as carboxymethylcellulose, ethyl
cellulose, microcrystalline cellulose, gum tragacanth or gelatin;
excipients such as starch, lactose or dextrins, disintegrating
agents such as alginic acid, sodium alginate, Primogel, corn starch
and the like; lubricants such as magnesium stearate or Sterotex;
glidants such as colloidal silicon dioxide; sweetening agents such
as sucrose or saccharin; a flavoring agent such as peppermint,
methyl salicylate or orange flavoring; and a coloring agent.
When the pharmaceutical composition is in the form of a capsule,
for example, a gelatin capsule, it may contain, in addition to
materials of the above type, a liquid carrier such as polyethylene
glycol or oil.
The pharmaceutical composition may be in the form of a liquid, for
example, an elixir, syrup, solution, emulsion or suspension. The
liquid may be for oral administration or for delivery by injection,
as two examples. When intended for oral administration, preferred
composition contain, in addition to the present compounds, one or
more of a sweetening agent, preservatives, dye/colorant and flavor
enhancer. In a composition intended to be administered by
injection, one or more of a surfactant, preservative, wetting
agent, dispersing agent, suspending agent, buffer, stabilizer and
isotonic agent may be included.
The liquid pharmaceutical compositions of the invention, whether
they be solutions, suspensions or other like form, may include one
or more of the following adjuvants: sterile diluents such as water
for injection, saline solution, preferably physiological saline,
Ringer's solution, isotonic sodium chloride, fixed oils such as
synthetic mono or diglycerides which may serve as the solvent or
suspending medium, polyethylene glycols, glycerin, propylene glycol
or other solvents; antibacterial agents such as benzyl alcohol or
methyl paraben; antioxidants such as ascorbic acid or sodium
bisulfite; chelating agents such as ethylenediaminetetraacetic
acid; buffers such as acetates, citrates or phosphates and agents
for the adjustment of tonicity such as sodium chloride or dextrose.
The parenteral preparation can be enclosed in ampoules, disposable
syringes or multiple dose vials made of glass or plastic.
Physiological saline is a preferred adjuvant. An injectable
pharmaceutical composition is preferably sterile.
A liquid pharmaceutical composition of the invention intended for
either parenteral or oral administration should contain an amount
of a compound of the invention such that a suitable dosage will be
obtained.
The pharmaceutical composition of the invention may be intended for
topical administration, in which case the carrier may suitably
comprise a solution, emulsion, ointment or gel base. The base, for
example, may comprise one or more of the following: petrolatum,
lanolin, polyethylene glycols, bee wax, mineral oil, diluents such
as water and alcohol, and emulsifiers and stabilizers. Thickening
agents may be present in a pharmaceutical composition for topical
administration. If intended for transdermal administration, the
composition may include a transdermal patch or iontophoresis
device.
The pharmaceutical composition of the invention may be intended for
rectal administration, in the form, for example, of a suppository,
which will melt in the rectum and release the drug. The composition
for rectal administration may contain an oleaginous base as a
suitable nonirritating excipient. Such bases include, without
limitation, lanolin, cocoa butter and polyethylene glycol.
The pharmaceutical composition of the invention may include various
materials, which modify the physical form of a solid or liquid
dosage unit. For example, the composition may include materials
that form a coating shell around the active ingredients. The
materials that form the coating shell are typically inert, and may
be selected from, for example, sugar, shellac, and other enteric
coating agents. Alternatively, the active ingredients may be
encased in a gelatin capsule.
The pharmaceutical composition of the invention in solid or liquid
form may include an agent that binds to the compound of the
invention and thereby assists in the delivery of the compound.
Suitable agents that may act in this capacity include a monoclonal
or polyclonal antibody, a protein or a liposome.
The pharmaceutical composition of the invention may consist of
dosage units that can be administered as an aerosol. The term
aerosol is used to denote a variety of systems ranging from those
of colloidal nature to systems consisting of pressurized packages.
Delivery may be by a liquefied or compressed gas or by a suitable
pump system that dispenses the active ingredients. Aerosols of
compounds of the invention may be delivered in single phase,
bi-phasic, or tri-phasic systems in order to deliver the active
ingredient(s). Delivery of the aerosol includes the necessary
container, activators, valves, subcontainers, and the like, which
together may form a kit. One skilled in the art, without undue
experimentation may determine preferred aerosols.
The pharmaceutical compositions of the invention may be prepared by
methodology well known in the pharmaceutical art. For example, a
pharmaceutical composition intended to be administered by injection
can be prepared by combining a compound of the invention with
sterile, distilled water so as to form a solution. A surfactant may
be added to facilitate the formation of a homogeneous solution or
suspension. Surfactants are compounds that non-covalently interact
with the compound of the invention so as to facilitate dissolution
or homogeneous suspension of the compound in the aqueous delivery
system.
The compounds of the invention, or their pharmaceutically
acceptable salts, are administered in a therapeutically effective
amount, which will vary depending upon a variety of factors
including the activity of the specific compound employed; the
metabolic stability and length of action of the compound; the age,
body weight, general health, sex, and diet of the patient; the mode
and time of administration; the rate of excretion; the drug
combination; the severity of the particular disorder or condition;
and the subject undergoing therapy.
Compounds of the invention, or pharmaceutically acceptable
derivatives thereof, may also be administered simultaneously with,
prior to, or after administration of one or more other therapeutic
agents. Such combination therapy includes administration of a
single pharmaceutical dosage formulation which contains a compound
of the invention and one or more additional active agents, as well
as administration of the compound of the invention and each active
agent in its own separate pharmaceutical dosage formulation. For
example, a compound of the invention and the other active agent can
be administered to the patient together in a single oral dosage
composition such as a tablet or capsule, or each agent administered
in separate oral dosage formulations. Where separate dosage
formulations are used, the compounds of the invention and one or
more additional active agents can be administered at essentially
the same time, i.e., concurrently, or at separately staggered
times, i.e., sequentially; combination therapy is understood to
include all these regimens.
It is understood that in the present description, combinations of
substituents and/or variables of the depicted formulae are
permissible only if such contributions result in stable
compounds.
It will also be appreciated by those skilled in the art that in the
synthetic processes described herein the functional groups of
intermediate compounds may need to be protected by suitable
protecting groups. Such functional groups include hydroxyl, amino,
mercapto and carboxylic acid. Suitable protecting groups for
hydroxyl include trialkylsilyl or diarylalkylsilyl (for example,
t-butyldimethylsilyl, t-butyldiphenylsilyl or trimethylsilyl),
tetrahydropyranyl, benzyl, and the like. Suitable protecting groups
for amino, amidino and guanidino include t-butoxycarbonyl,
benzyloxycarbonyl, and the like. Suitable protecting groups for
mercapto include --C(O)--R'' (where R'' is alkyl, aryl or
arylalkyl), p-methoxybenzyl, trityl and the like. Suitable
protecting groups for carboxylic acid include alkyl, aryl or
arylalkyl esters. Protecting groups may be added or removed in
accordance with standard techniques, which are known to one skilled
in the art and as described herein. The use of protecting groups is
described in detail in Green, T. W. and P. G. M. Wutz, Protective
Groups in Organic Synthesis (1999), 3rd Ed., Wiley. As one of skill
in the art would appreciate, the protecting group may also be a
polymer resin such as a Wang resin, Rink resin or a
2-chlorotrityl-chloride resin.
It will also be appreciated by those skilled in the art, although a
protected derivative of compounds of this invention may not possess
pharmacological activity as such, they may be administered to a
mammal and thereafter metabolized in the body to form compounds of
the invention which are pharmacologically active. Such derivatives
may therefore be described as "prodrugs". All prodrugs of compounds
of this invention are included within the scope of the
invention.
Furthermore, all compounds of the invention which exist in free
base or acid form can be converted to their pharmaceutically
acceptable salts by treatment with the appropriate inorganic or
organic base or acid by methods known to one skilled in the art.
Salts of the compounds of the invention can be converted to their
free base or acid form by standard techniques.
The following Examples illustrate various methods of making
compounds of this invention, i.e., compounds of structure (I):
##STR00037## wherein Q.sub.1, Q.sub.2, Q.sub.3, R.sub.11 and
R.sub.12 are as defined herein. It is understood that one skilled
in the art may be able to make these compounds by similar methods
or by combining other methods known to one skilled in the art. It
is also understood that one skilled in the art would be able to
make, in a similar manner as described below, other compounds of
structure (I) not specifically illustrated below by using the
appropriate starting components and modifying the parameters of the
synthesis as needed. In general, starting components may be
obtained from sources such as Sigma Aldrich, Lancaster Synthesis,
Inc., Maybridge, Matrix Scientific, TCI, and Fluorochem USA, etc.
or synthesized according to sources known to those skilled in the
art (see, e.g., Advanced Organic Chemistry: Reactions, Mechanisms,
and Structure, 5th edition (Wiley, December 2000)) or prepared as
described herein.
The following examples are provided for purposes of illustration,
not limitation.
EXAMPLES
##STR00038## ##STR00039## ##STR00040##
##STR00041## ##STR00042## ##STR00043##
Example 1
N-1 Acylation
Method A:
##STR00044## Method B:
##STR00045##
Example 2
N-1 Epoxide Opening
##STR00046##
Example 3
N-1 Sulfonylation
##STR00047##
Example 4
N-1 Reductive Amination
##STR00048##
Example 5
N-6' Reductive Amination
##STR00049##
Example 6
N-6' Epoxide Opening
##STR00050##
Example 7
N-1 Acylation
Method A:
##STR00051## Method B:
##STR00052##
Example 8
N-1 Epoxide Opening
##STR00053##
Example 9
N-1 Sulfonylation
##STR00054##
Example 10
N-1 Reductive Amination
##STR00055##
Example 11
N-2' Reductive Amination
##STR00056##
Example 12
N-2' Epoxide Opening
##STR00057##
Example 13
N-2' Guanidinium
##STR00058##
Example 14
N-2' Acylation
##STR00059##
Representative Coupling Agents
As one of skill in the art will appreciate, other representative
coupling agents that may be utilized in the above examples include,
but are not limited to, the following.
Representative N-1 Coupling Reagents
##STR00060## ##STR00061## ##STR00062## ##STR00063## ##STR00064##
##STR00065## ##STR00066##
General Synthetic Procedures
Procedure 1: Reductive Amination
Method A: To a stirring solution of the aminoglycoside derivative
(0.06 mmol) in MeOH (2 mL) was added the aldehyde (0.068 mmol),
silica supported cyanoborohydride (0.1 g, 1.0 mmol/g), and the
reaction mixture was heated by microwave irradiation to 100.degree.
C. (100 watts power) for 15 minutes. The reaction was checked by MS
for completeness, and once complete all solvent was removed by
rotary evaporation. The resulting residue was dissolved in EtOAc
(20 ml), and washed with 5% NaHCO.sub.3 (2.times.5 mL), followed by
brine (5 mL). The organic phase was then dried over
Na.sub.2SO.sub.4, filtered and the solvent was removed by rotary
evaporation.
Method B: To a solution of aminoglycoside derivative (0.078 mmol)
in DMF (1 ml) were added 3 .ANG. molecular sieves (15-20), followed
by the aldehyde (0.15 mmol) and the reaction was shaken for 2.5
hours. The reaction was checked by MS for completeness and, if
needed, more aldehyde (0.5 eq) was added, The reaction mixture was
then added dropwise to a stirring solution of NaBH.sub.4 (0.78
mmol) in MeOH (2 mL) at 0.degree. C., and the reaction was stirred
for 1 hour. The reaction was diluted with H.sub.2O (2 mL) and EtOAc
(2 ml). The organic layer was separated and the aqueous layer was
extracted with EtOAc (3.times.3 mL). The combined organic layers
were dried over Na.sub.2SO.sub.4, filtered and concentrated to
dryness.
Procedure 2: PNZ Deprotection
To a stirring solution of the PNZ protected aminoglyco side
derivative (0.054 mmol) in EtOH (1.5 mL) and H.sub.2O (1 mL) was
added 1N NaOH (0.3 mL), followed by Na.sub.2S.sub.2O.sub.4 (0.315
mmol), and the reaction mixture was heated at 70.degree. C. for 12
hours. The reaction progress was monitored by MS. Once complete,
the reaction mixture was diluted with H.sub.2O (5 mL) and then
extracted with EtOAc (2.times.10 mL). The combined organic layers
were washed with H.sub.2O (2.times.5 mL), brine (5 mL), dried over
Na.sub.2SO.sub.4, filtered and concentrated to dryness.
Procedure 3: Boc Deprotection (tert-butyl Dimethyl Silyl Protecting
Group is Removed Under these Conditions)
Important: Before Boc deprotection a sample must be dried well by
pumping at high vacuum for 3 h.
Method A: To a stirring solution of the Boc protected
aminoglycoside (0.054 mmol) in DCM (1 mL) were added 3 .ANG.
molecular sieves (4-6), and trifluoroacetic acid (0.6 mL), The
reaction was stirred at room temperature for 1 h, and checked for
completeness by MS. Upon completion the reaction mixture was
diluted with ether (15 mL) to induce precipitation. The vial was
centrifuged and the supernatant was decanted. The precipitate was
washed with ether (2.times.15 ml), decanted and dried under
vacuum.
Method B: To a stirring solution of Boc-protected aminoglycoside
derivative (0.078 mmol) in DCM (1.5 mL) at 0.degree. C. was added
trifluoroacetic acid (1.5 mL). The reaction was stirred for 45
minutes, and checked for completeness by MS. Upon completion, the
reaction was diluted with dichloroethane (10 ml) and concentrated
to dryness. The last dilution/concentration step was repeated
twice.
Procedure 4: PyBOP Coupling
To a stirring solution of aminoglycoside derivative (0.078 mmol) in
DMF (1 mL) at -40.degree. C. was added the acid (0.16 mmol),
followed by PyBOP (0.16 mmol) and DIPEA (0.31 mmol) and the
reaction was stirred. The reaction mixture was diluted with EtOAc
(3 mL) and H.sub.2O (3 mL), and the aqueous layer was separated and
extracted with EtOAc (3.times.3 mL). The combined organic layers
were dried over Na.sub.2SO.sub.4, filtered and concentrated to
dryness.
Procedure 5: Epoxide Opening
To a stirring solution of the aminoglycoside derivative (0.06 mmol)
in MeOH (2 mL) was added the epoxide (0.07 mmol), LiClO.sub.4 (0.15
mmol), and the reaction mixture was heated by microwave irradiation
to 100.degree. C. for 90 minutes. The reaction progress was
monitored by MS. Upon completion, the solvent was removed by rotary
evaporation. The resulting residue was dissolved in EtOAc (20 mL),
washed with H.sub.2O (2.times.5 mL) and brine (5 mL), dried over
Na.sub.2SO.sub.4, filtered and concentrated to dryness.
Procedure 6: Phthalimido Deprotection
To a stirring solution of the phthalimido protected aminoglyco side
(0.064 mmol) in EtOH (3 mL) was added hydrazine (0.32 mmol), and
the reaction mixture was heated to reflux for 2 h. The reaction
progress was monitored by MS. Upon cooling to room temperature, the
cyclic by-product precipitated and was removed by filtration. The
filtrate was concentrated to dryness to yield a residue, which was
dissolved in EtOAc (20 mL), washed with 5% NaHCO.sub.3 (2.times.5
mL) and brine (5 mL), dried over Na.sub.2SO.sub.4, filtered and
concentrated to dryness.
Procedure 7: Addition of Guanidinium Group
To a stirring solution of the aminoglycoside derivative (0.063
mmol) in DMF (1 mL) was added 1H-pyrazole-1-carboxamidine
hydrochloride (0.09 mmol), followed by DIPEA (0.862 ml) and the
reaction mixture was heated to 80.degree. C. and stirred overnight.
The reaction progress was monitored by MS. Upon completion, the
reaction mixture was cooled to room temperature and diluted with
water (3 mL). The aqueous phase was separated and extracted with
EtOAc (2.times.5 mL), and the combined organics were washed with
brine (5 mL), dried over Na.sub.2SO.sub.4, filtered and
concentrated to dryness.
Procedure 8: Sulfonylation
To a stirring solution of the aminoglyco side scaffold (0.067 mmol)
in DCM (3 mL) was added DIPEA (0.128 mol) and the sulfonyl chloride
(0.07 mmol). The reaction mixture was stirred at room temperature
and its progress was monitored by MS. Once complete, the solvent
was removed by rotary evaporation and the residue was dissolved in
ethyl acetate (20 mL), washed with 5% NaHCO.sub.3 (2.times.5 mL)
and brine (5 mL), dried over Na.sub.2SO.sub.4, filtered and
concentrated to dryness.
Procedure 9: N-Boc Protection
To a stirring solution of the amine (4.64 mmol) in THF (10 mL) was
added 1N NaOH (10 mL), followed by Boc-anhydride (5.57 mmol) and
the reaction progress was checked by MS. Once complete, the THF was
removed by rotary evaporation and water (40 mL) was added. The
aqueous phase was separated and extracted with Et.sub.2O
(2.times.30 ml). The aqueous phase was acidified to pH 3 by the
addition of dilute H.sub.3PO.sub.4 and was then extracted with
EtOAc (2.times.60 ml). The combined organic layers were washed with
H.sub.2O (2.times.30 mL) and brine (30 mL), dried over
Na.sub.2SO.sub.4, filtered and concentrated to dryness.
Procedure 10: Syntheses of Epoxides
To a stirring solution of the alkene (5.16 mmol) in chloroform (20
mL) at 0.degree. C. was added m-chloroperbenzoic acid (8.0 mmol)
and the reaction mixture was stirred for 30 minutes at 0.degree. C.
and was then allowed to warm to room temperature. The reaction
progress was monitored by MS and TLC, and additional portions of
m-CPBA were added as needed. Upon completion, the reaction mixture
was diluted with chloroform (50 mL) and washed with 10% aq.
Na.sub.2SO.sub.3 (2.times.30 mL), 10% aq. NaHCO.sub.3 (2.times.50
mL) and brine (50 mL). The organic layer was dried over
Na.sub.2SO.sub.4, filtered and concentrated to yield a crude
product, which was purified by flash choromatography (silica
gel/hexanes:ethyl acetate 0-25%).
Procedure 11: General Procedure for Synthesis of .alpha.-Hydroxy
Carboxylic Acids
Step #1. O-(Trimethylsilyl)cyanohydrines: A 50-mL flask equipped
with a magnetic stirring bar and drying tube was charged with the
ketone or aldehyde
(0.010 mmol), followed by THF (50 mL), trimethylsilyl cyanide (1.39
g, 14 mmol), and zinc iodide (0.090 g, 0.28 mmol), and the reaction
mixture was stirred at room temperature for 24 hr. Solvent
evaporation gave a residue, which was dissolved in EtOAc (60 mL),
washed with 5% aq. NaHCO.sub.3 (2.times.30 mL), H.sub.2O (30 mL),
and brine (30 mL), dried over Na.sub.2SO.sub.4, filtered and
concentrated to dryness to yield a crude, which was carried through
to the next step without further purification.
Step #2. Acid hydrolysis to .alpha.-hydroxy carboxylic acid: AcOH
(25 ml) and conc. HCl (25 ml) were added to the unpurified material
from step #1 and the reaction mixture was refluxed for 2-3 hr. The
reaction mixture was then concentrated to dryness to give a white
solid, which was carried through to the next step without further
purification.
Step #3. Boc protection: To a stirring solution of solid from step
#2 in 2 M NaOH (20 mL) and i-PrOH (20 mL) at 0.degree. C. was added
Boc.sub.2O (6.6 g, 3 mmol) in small portions, and the reaction
mixture was allowed to warm to room temperature over 4 h. i-PrOH
was then evaporated, and H.sub.2O (50 mL) was added, and the
aqueous phase was separated and extracted with Et.sub.2O
(2.times.30 ml). The aqueous layer was acidified to pH 3 by
addition of dilute H.sub.3PO.sub.4 and was extracted with EtOAc
(2.times.60 ml). The combined organic layers were washed with
H.sub.2O (2.times.30 mL) and brine (30 mL), dried over
Na.sub.2SO.sub.4, filtered and concentrated to yield the desired
N-Boc-.alpha.-hydroxy carboxylic acids in 56-72% yield.
Procedure 12: Protection of Amine by Fmoc Group
To a stirring solution of the amine (0.049 mol) in DCM (100 mL),
was added DIPEA (16 mL, 0.099 mol) and the reaction mixture was
cooled to 0.degree. C. Fmoc-Cl (12.8 g, 0.049 mol) was then added
portion-wise over several minutes, and the reaction was allowed to
warm to room temperature for 2 hr. The organic layer was washed
with water (2.times.50 mL) and brine (50 mL), dried over
Na.sub.2SO.sub.4, filtered and concentrated to dryness to yield the
Fmoc protected amine (90-95% yield).
Procedure 13: Synthesis of Aldehydes Via TEMPO/Bleach Oxidation
To a vigorously stirring solution of the alcohol (1.54 mmol) in DCM
(4 mL) was added TEMPO (0.007 g, 0.045 mmol, 0.03 mol %) and a 2M
aqueous KBr solution (75 mL, 0.15 mmol, 10 mol %) and the reaction
mixture was cooled to -10.degree. C. In a separate flask
NaHCO.sub.3 (0.5 g, 9.5 mmol) was dissolved in bleach (25 mL,
Chlorox 6.0% NaOCl) to yield a 0.78 M buffered NaOCl solution, This
freshly prepared 0.78 M NaOCl solution (2.3 mL, 1.8 mmol, 117 mol
%) was added to the reaction mixture over 5 min and the reaction
was stirred for an additional 30 min at 0.degree. C. The organic
phase was separated and the aqueous layer was extracted with
dichloromethane (2.times.4 mL). The combined organic layers were
washed with 10% aq. Na.sub.2S.sub.2O.sub.3 (4 mL), sat. aq.
NaHCO.sub.3 (2.times.4 mL), brine (5 mL), dried over
Na.sub.2SO.sub.4 and concentrated to dryness.
Procedure 14: Synthesis of Alcohols Via Borane Reduction
To a stirring solution of the acid (1.5 mmol) in THF (5 mL) at
-10.degree. C. was slowly added 1.0 M BH.sub.3-THF (2.98 mL, 2.98
mmol). The reaction mixture was stirred vigorously for an
additional 3 min at -10.degree. C., and was then allowed to warm to
room temperature overnight. The reaction was quenched by the
dropwise addition of a solution of HOAc/H.sub.2O (1:1 v/v, 2.0 mL).
The THF was removed by rotary evaporation and sat. aq. NaHCO.sub.3
(15 mL) was added. The aqueous layer was extracted with DCM
(3.times.5 mL) and the combined organic layers were washed with
sat. aq. NaHCO.sub.3 (2.times.5 mL), brine (10 mL), dried over
Na.sub.2SO.sub.4, filtered and concentrated to dryness.
Procedure 15: Ozonolysis and Pinnick Oxidation
The substrate olefin (0.5 to 0.75 mmol) was dissolved in DCM (30
mL) and the reaction was cooled to -78.degree. C. Ozone was bubbled
through until a blue color persisted (3 to 5 min), and the reaction
was stirred for 1 hr. Argon was then bubbled through to remove
excess ozone for 10 minutes. The reaction was further quenched by
the addition of dimethyl sulfide (10 equiv.), and was stirred for
30 min with warming to rt. The solvent was reduced under vacuum to
yield the crude aldehyde, which was dried under high-vacuum for 10
min, and used without further purification. To a stirring solution
of the aldehyde in THF, tBuOH and H.sub.2O (3:3:2, 10 mL), was
added NaH.sub.2PO.sub.4 (4 equiv.) followed by 2-methyl-2-butene
(10 equiv.) and sodium chlorite (2 equiv.), and the reaction was
stirred for 4 hr. The reaction mixture was then added to sat. aq.
NaCl (10 mL) and extracted with DCM (3.times.). The combined
organic layers were dried over Na.sub.2SO.sub.4, filtered and
reduced under vacuum to yield a crude, which was purified by flash
chromatography (silica gel, 0.fwdarw.0.5 or 1% MeOH/DCM).
Procedure 16: Hydrogenolysis
To a stirring solution of aminoglycoside (0.031 mmol) in AcOH (2
mL), was added H.sub.2O (1 mL), followed by Pd(OH).sub.2/C (40 mg)
and the reaction was stirred under a hydrogen atmosphere for 3
hours. The catalyst was removed by filtration, and the reaction was
diluted with water and lyophilized to yield a crude, which was
purified on a 1-inch reverse phase HPLC column (buffered with 10 mM
NH.sub.4OH) to yield the desired product.
General Purification Procedures
Method #1: Purification by Basic Condition
Mobile Phases:
A--Water with 10 mM NH.sub.4OH B--Acetonitrile with 10 mM
NH.sub.4OH Columns: A: Waters-XBridge Prep Shield RP18 Column
19.times.250 mm, 5 .mu.m Gradient: 20 min at 0%, then 0-20% in 200
min at a flow of 20 ml/min B: Waters-XBridge Prep Shield RP18
Column 50.times.100 mm, 5 .mu.m Gradient: 20 min at 0%, then 0-20%
in 200 min at a flow of 20 ml/min Method #2: Purification by Acidic
Condition Mobile Phases: A--Water with 0.1% TFA B--Acetonitrile
with 0.1% TFA Columns: A: Phenomenex Luna C18 21.4.times.250 mm, 10
.mu.m Gradient: 0-100%, flow 25 ml/min B: Phenomenex Luna C18
50.times.250 mm, 10 .mu.m Gradient: 0-100%, flow 45 ml/min
Representative Intermediates
Aminoglycoside Freebasing
Amberlite IRA-400 (OH form) (200 g) was washed with MeOH
(3.times.200 ml). To a stirring suspension of the washed resin in
MeOH (150 mL) was added aminoglycoside sulfate (20 g) and the
mixture was stirred overnight. The resin was then filtered and
washed with MeOH (100 mL) and the combined organic layers were
concentrated to dryness to yield the desired aminoglycoside.
(N-Hydroxy-5-norbornene-2,3-dicarboxyl-imido)-4-nitro-benzoate
##STR00067##
To a stirring solution of 4-nitrobenzyl chloroformate (5.0 g, 0.023
mol) in THF (90 mL) at 0.degree. C. was added
N-hydroxy-5-norbornene-2,3-dicarboximide (4.16 g, 0.023 mol),
followed by the dropwise addition of a solution of Et.sub.3N (3.2
mL, 0.02 mol) in THF (50 mL) and the reaction was stirred for 4
hours with gradual warming to room temperature. The reaction vessel
was then placed in the freezer (-5.degree. C.) for 1 hour to induce
precipitation of triethylamine hydrochloride, which was removed by
filtration. The filtrate was concentrated to dryness to yield a
residue, which was vigorously stirred in MeOH (80 mL) for 1 h and
then filtered to yield
(N-hydroxy-5-norbornene-2,3-dicarboxyl-imido)-4-nitro-benzoate as a
white solid (7.98 g, 0.022 mol, 96% yield): TLC (hexanes:EtOAc v/v
1:1) Rf=0.35.
2,5-Dioxo-pyrrolidin-1-yl-4-nitrobenzyl carbonate
(PNZ-succinimide)
##STR00068##
To a stirring solution of N-hydroxysuccinimide (5.35 g, 46.5 mmol)
in anhydrous THF (100 mL) was added para-nitrobenzylchloroformate
(10.0 g, 46.5 mmol), and the solution was cooled in an ice bath.
Triethylamine (6.5 mL, 4.89 g, 46.5 mmol) was added over 10
minutes, and, after 30 minutes, the reaction mixture was allowed to
warm to room temperature and stir overnight. The slurry was cooled
in an ice-bath, and was filtered, followed by rinsing with ethyl
acetate. The filtrate was concentrated in vacuo, and the residue
was triturated with methanol. The solids were isolated by
filtration to give 2,5-dioxopyrrolidin-1-yl-4-nitrobenzyl
carbonate.
N,N'-bis-Cbz-2(S)-hydroxy-4-guanidino-butyric acid
##STR00069##
To a stirring solution of 2(S)-hydroxy-4-amino-butyric acid (0.059
g, 0.50 mmol) in DMF (2 ml) was added
N,N'-bis(benzyloxycarbonyl)-1H-pyrazole-1-carboxamidine (0.26 g,
0.70 mmol) followed by DIPEA (0.87 mL, 4.99 mmol) and the reaction
was heated to 80.degree. C. and stirred overnight. The crude
mixture was purified on a 2-inch reverse-phase HPLC column to yield
N,N'-bis-Cbz-2(S)-hydroxy-4-guanidino-butyric acid: MS: m/z
(M+H).sup.+ calcd. 430.15, found 430.1.
Benzyl-2-(benzoyloxyamino)ethyl carbamate
##STR00070##
To a solution of benzyl-N-(2-aminoethyl)carbamate chloride salt (1,
540 mg, 2.34 mmol) in sat. aq. NaHCO.sub.3 (45 mL) was added 1 M
NaOH (15 mL) and the reaction was stirred vigorously. DCM (30 mL)
was added, followed by benzoylperoxide (1.13 g, 4.68 mmol) and the
reaction was stirred overnight. The organic layer was separated and
washed with brine, dried over MgSO.sub.4, filtered and concentrated
to a crude, which was purified on a 1-inch reverse-phase HPLC
column to yield benzyl-2-(benzoyloxyamino)ethyl carbamate (2, 252
mg, 0.80 mmol, 34.2%): MS: m/z (M+H).sup.+ calc. 315.13, obs.
315.0.
Succinimidyl benzoyloxy(2-Cbz-aminoethyl)carbamate
##STR00071##
To a stirring solution of disuccinimidyl carbonate (525 mg, 2.05
mmol) in CH.sub.3CN (16 mL) was added
benzyl-2-(benzoyloxyamino)ethyl carbamate (2, 252 mg, 0.80 mmol) as
a solution in CH.sub.3CN (12 mL) over 4 hours, and the reaction was
stirred overnight. Additional disuccinimidyl carbonate (251 mg,
0.98 mmol) was added and the reaction was heated at 60.degree. C.
overnight. Solvent removal gave a crude, which was purified on a
2-inch reverse-phase HPLC column to yield succinimidyl
benzoyloxy(2-Cbz-aminoethyl)carbamate (3, 81 mg, 0.18 mmol, 22.5%
yield).
N-Boc-3-amino-2(S)-hydroxy-propionic acid
##STR00072##
To a stirring solution of S-isoserine (4.0 g, 0.038 mol) in
dioxane: H.sub.2O (100 mL, 1:1 v/v) at 0.degree. C. was added
N-methylmorpholine (4.77 mL, 0.043 mol), followed by Boc.sub.2O
(11.28 mL, 0.049 mol) and the reaction was stirred overnight with
gradual warming to room temperature. Glycine (1.0 g, 0.013 mol) was
then added and the reaction was stirred for 20 min. The reaction
was cooled to 0.degree. C. and sat aq. NaHCO.sub.3 (75 mL) was
added. The aqueous layer was washed with ethyl acetate (2.times.60
mL) and then acidified to pH 1 with NaHSO.sub.4. This solution was
then extracted with ethyl acetate (3.times.70 mL) and these
combined organic layers were dried over Na.sub.2SO.sub.4, filtered
and concentrated to dryness to give the desired
N-Boc-3-amino-2(S)-hydroxy-propanoic acid (6.30 g, 0.031 mmol,
81.5% yield): .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.45 (bs,
1H), 5.28 (bs, 1H), 4.26 (m, 1H), 3.40-3.62 (m, 2H), 2.09 (s, 1H),
1.42 (s, 9H); .sup.13C NMR (100 MHz, CDCl3) .delta. 174.72, 158.17,
82, 71.85, 44.28, 28.45.
(N-Hydroxy-5-norbornene-2,3-dicarboxyl-imido)-tert-butyl-carbonate
##STR00073##
To a stirring solution of N-hydroxy-5-norbornene-2,3-dicarboximide
(20.0 g, 0.112 mol) in THF (200 mL) at 0.degree. C. was added
triethylamine (0.65 mL, 4.8 mmol), followed by the dropwise
addition of a solution of Boc.sub.2O (29.23 g, 0.134 mol) in THF
(30 mL) and the reaction was allowed to stir overnight with gradual
warming to room temperature. A precipitate formed, which was
filtered and washed with cold THF (200 mL). The crude solid was
then vigorously stirred in MeOH (100 mL) for 1 hour, before being
filtered, washed with MeOH (50 mL), and dried under high vacuum to
yield the desired
(N-hydroxy-5-norbornene-2,3-dicarboxyl-imido)-tert-butylcarbonate
as a white solid (28.0 g, 0.1 mol, 89.3% yield): TLC (hexanes:ethyl
acetate, 1:1 v/v) R.sub.f=0.44; NMR (400 MHz, DMSO-d.sub.6) .delta.
6.10 (bs, 2H), 3.48 (bs, 2H), 3.29-3.32 (m, 2 H), 1.58-1.62 (m,
1H), 1.50-1.55 (m, 1H), 1.47 (s, 9H).
N-Boc-4-amino-2(S)-hydroxy-butyric acid
##STR00074##
To a stirring solution of S-4-amino-2-hydroxy-butyric acid (51.98
g, 0.44 mol) in dioxane: H.sub.2O (2 L, 1:1 v/v) was added
K.sub.2CO.sub.3 (106 g, 0.91 mol) followed by a solution of
Boc-anhydride (100 g, 0.46 mol) in dioxane (100 mL), and the
reaction was stirred overnight. The reaction was washed with DCM
(2.times.300 mL), and the aqueous layer was acidified to pH 2 with
H.sub.3PO.sub.4. The aqueous layer was extracted with DCM
(2.times.300 mL), and the combined organic layers were dried over
MgSO.sub.4, filtered and concentrated to dryness to yield the
desired N-Boc-4-amino-2(S)-hydroxybutyric acid (48.2 g, 50%
yield).
N-Boc-3-amino-propanal
##STR00075##
To a stirring solution of 3-(Boc-amino)-1-propanol (25 mL, 0.144
mol) in water saturated DCM (1.0 L) was added Dess-Martin reagent
(99.2 g, 233.9 mmol) and the reaction mixture was stirred for 1
hour. The reaction was then diluted with ether (1.0 L), followed by
a solution of Na.sub.2S.sub.2O.sub.3 (250 g) in 80% NaHCO.sub.3
(450 g in 1.0 L H.sub.2O). The reaction was stirred vigorously for
30 minutes until two layers formed, the top layer was clear. The
reaction was filtered to remove the precipitated solids and the
aqueous layer was extracted with ether (1.0 L). The organic layer
was washed with sat. NaHCO.sub.3 (1.0 L), H.sub.2O (1.0 L), and
brine (1 L), dried over Na.sub.2SO.sub.4 and concentrated to a
clear oil. The crude oil was dissolved in EtOAc:hexanes (1:1 v/v,
1.0 L) and filtered through a short silica gel column to yield the
desired N-Boc-3-amino-propanal (21.7 g, 0.125 mol, 85.6% yield):
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 9.77 (s, 1H, CHO), 4.85
(hs, 1H, NH), 336-3.42 (m, 2H, CH.sub.2), 2.67 (t, 2H, CH.sub.2),
1.39 (s, 9H, (CH.sub.3).sub.3).
N-Boc-1-oxa-6-azaspiro[2.5]octane
##STR00076##
4-Methylene-piperidine (0.222 g, 1.12 mmol) was submitted to
Procedure 10 to form the desired N-Boc-1-oxa-6-azaspiro[2.5]octane
(0.215 g, 1.01 mmol, 90.2% yield): .sup.1H NMR (250 MHz,
DMSO-d.sub.6) .delta. 3.29-3.61 (m, 6H), 1.56-1.70 (m, 2H),
1.30-1.54 (m, 11H).
2-(Pent-4-enyl)-isoindoline-1,3-dione
##STR00077##
To a stirring solution of 5-bromo-pentene (6.0 g, 0.040 mol) in DMF
(30 mL) was added K.sub.2CO.sub.3 (4.7 g, 0.034 mol) and potassium
phthalimide (6.21 g, 0.033 mmol) and the reaction mixture was
heated at 100.degree. C. for 1 hr. The reaction mixture was cooled
to room temperature, and water (50 mL) was added. The aqueous layer
was then extracted with ethyl acetate (2.times.50 mL), and the
combined organic layers were washed with 5% aq. NaHCO.sub.3
(2.times.20 mL), brine (30 mL) and dried over Na.sub.2SO.sub.4.
Filtration and solvent evaporation gave an oil, which was purified
by flash chromatography (silica gel/hexanes:ethyl acetate 0-35%) to
yield the desired 2-(pent-4-enyl)-isoindoline-1,3-dione as a solid
(6.36 g, 0.029 mmol, 72.5% yield): MS m/e [M+H].sup.+ calcd 216.1,
found 216.1; NMR (250 MHz, DMSO-d.sub.6) .delta. 7.79-7.95 (m, 4H),
5.70-5.91 (m, 1H), 4.90-5.11 (m, 2H), 3.58 (t, 2H), 1.98-2.10 (m,
2H), 1.59-1.78 (m, 2H).
2-(3-(Oxiran-2-yl)-propyl)-isoindoline-1,3-dione
##STR00078##
2-(Pent-4-enyl)-isoindoline-1,3-dione (6.36 g, 0.029 mmol) was
submitted to Procedure 10 for epoxide formation to yield
2-(3-(oxiran-2-yl)-propyl-isoindoline-1,3-dione (5.8 g, 0.025 mmol,
86.2% yield): MS m/e [M+H].sup.+ calcd 232.1, found 232.1; .sup.1H
NMR (250 MHz, DMSO-d.sub.6) .delta. 7.75-7.90 (m, 4H, Ar), 3.52 (t,
2H, CH.sub.2), 2.87-2.96 (m, 1H, CH), 2.70 (t, 1H), 2.30-2.45 (m,
1H), 1.36-1.80 (m, 4H).
N-Boc-3-hydroxypyrrolidine-3-carboxylic acid
##STR00079##
N-Boc-3-pyrrolidone (0.010 mmol) was submitted to Procedure 11 to
yield the desired N-Boc-3-hydroxy-pyrrolidine-3-carboxylic
acid.
N-Boc-1-amino-but-3-ene
##STR00080##
3-Buten-1-amine (4.93 g, 0.069 mol) was submitted to Procedure 9
for Boc protection to yield a crude, which was purified by flash
chromatography (silica gel/hexanes:ethyl acetate 0-30%) to yield
N-Boc-1-amino-but-3-ene (6.47 g, 0.038 mol, 55.1% yield).
N-Boc-2-(oxiran-2-yl)-ethyl carbamate
##STR00081##
N-Boc-1-amino-but-3-ene (6.47 g, 0.038 mol) was submitted to
Procedure 10 for epoxide formation to yield a crude, which was
purified by flash chromatography (silica gel/hexanes:ethyl acetate
0-45%) to yield N-Boc-2-(oxiran-2-yl)-ethyl carbamate (6.0 g, 0.032
mol, 84.2% yield): .sup.1H NMR (250 MHz, DMSO-d.sub.6) .delta.
2.98-3.09 (m, 2H), 2.83-2.92 (m, 1H), 2.65 (t, 1H), 2.42 (dd, 1H),
1.44-1.66 (m, 2H), 1.36 (s, 9H, (CH.sub.3).sub.3).
N-Boc-3-hydroxy-azetidin-3-carboxylic acid
##STR00082##
N-Boc-3-azetidinone (21.9 g, 0.128 mol) was submitted to Procedure
11 to yield the desired N-Boc-3-hydroxy-azetidin-3-carboxylic acid
(18.7 g, 0.086 mol, 67.0% yield): MS m/e [M+H].sup.+ calcd 218.1,
found 218.2.
3-Methylene-1-methylamino-cyclobutane
##STR00083##
To a stirring solution of 3-methylene-1-cyano-cyclobutane (2.5 g,
0.026 mol) in THF (35 ml) at 0.degree. C. was slowly added 2M
LiAlH.sub.4 (22 mL, 0.044 mmol) and the reaction was allowed to
warm to room temperature. The reaction was then quenched by the
addition of sat. aq. NH.sub.4Cl (10 mL), and THF (10 mL). The
organic layer was separated and concentrated to dryness to yield a
residue, which was dissolved in ethyl acetate (100 mL). The organic
layer was washed with 5% NaHCO.sub.3 (2.times.20 mL), brine (20
mL), dried over Na.sub.2SO.sub.4, filtered and concentrated to
yield the desired 3-methylene-1-methylamino-cyclobutane as an oil,
which was carried through to the next step without further
purification.
3-Methylene-1-N-Boc-methylamino-cyclobutane
##STR00084##
To a stirring solution of 3-methylene-1-methylamino-cyclobutane
(2.52 g, 0.026 mol) in 1N NaOH (15 ml) and THF (15 mL), was added
Boc.sub.2O (6.7 g, 0.030 mol) and the reaction mixture was stirred
overnight. THF was evaporated and the aqueous layer was extracted
with ethyl acetate (2.times.40 mL). The combined organic layers
were washed with 5% NaHCO.sub.3 (2.times.20 mL) brine (20 mL),
dried over Na.sub.2SO.sub.4, filtered and concentrated to dryness
to yield a crude, which was purified by flash chromatography
(silica gel/hexanes:ethyl acetate 0%-60%) to yield the desired
3-methylene-1-N-Boc-methylamino-cyclobutane (1.9 g, 0.0096 mol,
36.9% yield): .sup.1H NMR (250 MHz, DMSO-d.sub.6) .delta. 6.88 (bs,
1H), 4.72 (s, 2H), 2.95-3.05 (m, 2H), 2.56-2.71 (m, 2H), 2.21-2.40
(m, 3H), 1.20 (s, 9H).
N-Boc-1-oxaspiro[2.3]hexan-5-yl-methanamine
##STR00085##
3-Methylene-1-N-Boc-methylamino-cyclobutane (1.9 g, 0.0096 mol) was
submitted to Procedure 10 for epoxide formation to yield
N-Boc-1-oxaspiro[2.3]hexan-5-yl-methanamine (1.34 g, 6.27 mol,
65.3% yield): .sup.1H NMR (250 MHz, DMSO-d.sub.6) .delta. 2.99-3.10
(m, 2H), 2.60-2.66 (m, 2H), 1.99-2.47 (m, 5H), 1.40 (s, 9H).
N-Fmoc-4-amino-butyraldehyde diethyl acetal
##STR00086##
4-Amino-butyraldehyde diethyl acetal (8.0 g, 0.050 mol) was Fmoc
protected following Procedure 12 to give the desired
N-Fmoc-4-amino-butyraldehyde diethyl acetal (22.08 g, MS m/e
[M+Na].sup.+ calcd 406.2, found 406.1), which was carried through
to the next step without further purification.
N-Fmoc-4-amino-butyraldehyde
##STR00087##
To a stirring solution of N-Fmoc-4-amino-butyraldehyde diethyl
acetal (0.050 mmol) in 1,4-dioxane (100 mL) was added aq. HCl (100
ml, 1:1 v/v, H.sub.2O:conc. HCl) and the reaction progress was
monitored by MS. Upon completion, the organic solvent was removed
by rotary evaporation, and the aqueous layer was extracted with
ethyl acetate (2.times.200 mL). The combined organic layers were
washed with 5% NaHCO.sub.3 (2.times.75 mL), brine (75 mL), dried
over Na.sub.2SO.sub.4, filtered and concentrated to dryness to
yield the desired N-Fmoc-4-amino-butyraldehyde (15.35 g, 0.049 mol,
90.0% yield), which was carried through to the next step without
further purification: MS m/e [M+Na].sup.+ calcd 332.1, found
332.0.
3-Methylene-cyclobutane carboxylic acid
##STR00088##
To a stirring solution of KOH (70.0 g, 1.25 mol) in EtOH/H.sub.2O
(500 mL, 1:1 v/v) was added 3-methylenecyclobutane carbonitrile
(25.0 g, 0.26 mol) and the reaction mixture was refluxed for 6 h.
The reaction progress was monitored by TLC and, upon completion,
the mixture was cooled and acidified to pH 3-4 with HCl. The
ethanol was evaporated, and the remaining aqueous layer was
extracted with Et.sub.2O (200 mL). The organic layer was washed
with water (2.times.20 mL), brine (30 ml), dried over
Na.sub.2SO.sub.4, filtered and concentrated to dryness to yield
3-methylene-cyclobutane carboxylic acid, which was carried through
to the next step without further purification: .sup.1H NMR (250
MHz, CDCl.sub.3) .delta. 10.75 (bs, 1H), 4.80 (s, 2H), 2.85-3.26
(m, 5H).
N-Boc-3-Methylene-cyclobutanamine
##STR00089##
To a stirring solution of 3-methylene-cyclobutane carboxylic acid
(1.0 g, 8.9 mmol) in THF (90 mL) was added NaN.sub.3 (2.0 g, 31.1
mmol), followed by tetrabutyl ammonium bromide (0.48 g, 1.5 mmol)
and Zn(OTf).sub.2 (0.1 g, 0.3 mmol), and the reaction mixture was
heated to 40.degree. C. Boc.sub.2O (2.1 g, 9.8 mmol) was then added
at once, and the reaction was heated at 45.degree. C. overnight.
The reaction was then cooled to 0.degree. C. and was quenched with
10% aq. NaNO.sub.2 (180 mL). The THF was evaporated and the aqueous
layer was extracted with EtOAc (180 mL). The organic layer was
washed with 5% aq. NaHCO.sub.3 (2.times.20 mL), brine (30 ml),
dried over Na.sub.2SO.sub.4, filtered and concentrated to dryness
to yield a crude, which was purified by flash chromatography
(silica gel/hexanes:ethyl acetate: 0-90%) to yield the desired
N-Boc-3-methylene-cyclobutanamine (0.57 g, 3.1 mmol, 34.9% yield):
.sup.1H NMR (250 MHz, CDCl.sub.3) .delta. 4.83 (s, 2H), 4.79 (bs,
1H), 4.05-4.23 (m, 1H), 2.92-3.11 (m, 2H), 2.50-2.65 (m, 2H), 1.44
(s, 9H).
N-Boc-1-oxaspiro[2.3]hexan-5-amine
##STR00090##
N-Boc-3-methylene-cyclobutanamine (1.65 g, 9.0 mmol) was submitted
to Procedure 10 for epoxide formation to yield
N-Boc-1-oxaspiro[2.3]hexan-5-amine (1.46 g, 7.33 mmol, 81.5%
yield): .sup.1H NMR (250 MHz, CDCl.sub.3) .delta. 4.79 (bs, 1H),
4.13-4.31 (m, 1H), 2.66-2.83 (m, 4H), 2.31-2.47 (m, 2H), 1.45 (s,
9H).
N-Boc-2,2-dimethyl-3-amino-propionaldehyde
##STR00091##
N-Boc-3-amino-2,2-dimethyl propanol (0.415 g, 2.04 mmol) was
submitted to Procedure 13 to yield
N-Boc-2,2-dimethyl-3-amino-propionaldehyde (0.39 g, 1.94 mmol,
95.1% yield): .sup.1H NMR (250 MHz, CDCl.sub.3) .delta. 9.42 (s,
1H), 4.80 (bs, 1H), 3.11 (d, 2H), 1.39 (s, 9H), 1.06 (s, 6H).
N-Boc-3-amino-3-cyclopropyl propionaldehyde
##STR00092##
N-Boc-3-amino-propanol (0.130 g, 0.60 mmol) was submitted to
Procedure 13 for oxidation to the corresponding
N-Boc-3-amino-3-cyclopropyl propionaldehyde, which was carried
through to the next step without further purification.
4(S)-tert-Butyldimethylsilyloxy-N-Boc-pyrrolidin-2(R)-carboxaldehyde
##STR00093##
4(S)-tert-Butyldimethylsilyloxy-N-Boc-pyrrolidin-2(R)-methanol
(0.50 g, 1.50 mmol) was submitted to Procedure 13 for oxidation to
the corresponding
4(S)-tert-butyldimethylsilyloxy-N-Boc-pyrrolidin-2(R)-carboxaldehyde,
which was carried through to the next step without further
purification.
3-tert-Butyldimethylsilyloxy-propanal
##STR00094##
3-tert-Butyldimethylsilyloxy-propanol (0.50 g, 2.62 mmol) was
submitted to Procedure 13 for oxidation to the corresponding
3-tert-butyldimethylsilyloxy-propanal, which was carried through to
the next step without further purification.
2-Methyl-N-Boc-2-amino-propanal
##STR00095##
2-Methyl-N-Boc-2-amino-propanol (0.83 g, 4.38 mmol) was submitted
to Procedure 13 for oxidation to the corresponding
2-methyl-N-Boc-2-amino-propanal (0.706 g, 3.77 mmol, 86.1% yield):
.sup.1H NMR (250 MHz, CDCl.sub.3) .delta. 9.40 (s, 1H), 1.57 (s,
1H), 1.41 (s, 9H), 1.30 (s, 6H).
N-Boc-1-amino-cyclobutane carboxylic acid
##STR00096##
1-Amino-cyclobutane carboxylic acid ethyl ester (1.0 g, 6.28 mmol)
was dissolved in 1N HCl (10 mL) and the reaction was heated to a
reflux for 2 hours. The reaction mixture was then concentrated to
dryness to yield a crude which was submitted to Procedure 9 for Boc
protection to yield the desired N-Boc-1-Amino-cyclobutane
carboxylic acid.
N-Boc-1-amino-cyclobutyl-methanol
##STR00097##
N-Boc-1-amino-cyclobutane carboxylic acid (6.28 mmol) was submitted
to Procedure 14 for reduction to the corresponding
N-Boc-1-Amino-cyclobutyl-methanol.
N-Boc-1-amino-cyclobutane carboxaldehyde
##STR00098##
N-Boc-1-amino-cyclobutyl-methanol (0.25 g, 1.24 mmol) was submitted
to Procedure 13 to yield the corresponding
N-Boc-1-amino-cyclobutane carboxaldehyde (0.24 g, 1.20 mmol, 96.8%
yield): .sup.1H NMR (250 MHz, CDCl.sub.3) .delta. 9.0 (s, 1H), 4.91
(bs, 1H), 3.74 (bs, 2H), 1.71-2.20 (m, 4H), 1.42 (s, 9H).
N-Boc-3-amino-cyclobutanone
##STR00099##
To a vigorously stirring solution of
N-Boc-3-methylene-cyclobutanamine (9.8 g, 53.5 mmol) in DCM (160
mL) and H.sub.2O (160 mL) was added K.sub.2CO.sub.3 (3 g, 21.7
mmol), followed by NaIO.sub.4 (35 g, 163.5 mmol),
tetrabutylammonium chloride (0.2 g, 0.72 mmol) and RuCl.sub.3 (0.6
g, 7.6 mmol). During the course of the reaction, the organic
solution turned dark brown, the catalyst turned black, while the
upper aqueous layer turned white. The reaction was monitored by
TLC, and upon completion, the reaction mixture was filtered through
a pad of celite. The filtrates were transferred to a reparatory
funnel, and the aqueous layer was extracted with DCM (2.times.50
mL). The combined organic layers were washed with 5% NaHCO.sub.3
(2.times.30 mL), brine (30 mL), dried over Na.sub.2SO.sub.4,
filtered and evaporated to dryness to yield a crude, which was
purified by flash chromatography (silica gel/hexanes:ethyl acetate
0-60%) to yield the desired N-Boc-3-amino-cyclobutanone (7.13 g,
38.53 mmol, 72% yield): NMR (250 MHz, CDCl.sub.3) .delta. 4.88 (bs,
1H), 4.13-4.29 (m, 1H), 3.23-3.41 (m, 2H), 2.9-3.05 (m, 2H), 1.39
(s, 9H).
N-Boc-1-hydroxy-3-amino-cyclobutyl-carboxylic acid
##STR00100##
N-Boc-3-amino-cyclobutanone (7.13 g, 38.53 mmol) was submitted to
Procedure 11 to yield the desired
N-Boc-1-hydroxy-3-amino-cyclobutyl-carboxylic acid (MS m/e
[M+H].sup.+ calcd 232.1, found 232.2.
N,N-diBoc-4(S)-amino-2(S)-methanol-pyrrolidine
##STR00101##
N,N-diBoc-4(S)-amino-pyrrolidine-2(S)-carboxylic acid (1.03 g, 3.12
mmol) was submitted to Procedure 14 to yield the corresponding
N,N-diBoc-4(S)-amino-2(S)-methanol pyrrolidine (0.605 g, 1.91 mmol,
61.2% yield), which was carried through to the next step without
further purification.
N,N-diBoc-4(S)-amino-pyrrolidine-2(S)-carbaldehyde
##STR00102##
N,N-diBoc-4(S)-amino-2(S)-methanol pyrrolidine (0.486 g, 1.53 mmol)
was submitted to Procedure 13 for oxidation to the corresponding
N,N-diBoc-4(S)-amino-pyrrolidine-2(S)-carbaldehyde, which was
carried through to the next step without further purification.
N-Boc-1-aminomethyl-cyclopropyl-methanol
##STR00103##
N-Boc-1-aminomethyl-cyclopropane carboxylic acid (1.0 g, 4.64 mmol)
was submitted to Procedure 14 to yield the corresponding
N-Boc-1-aminomethyl-cyclopropyl-methanol (0.99 g, MS m/e
[M+H].sup.+ calcd 202.1, found 202.1), which was carried through to
the next step without further purification.
N-Boc-1-aminomethyl-cyclopropane carboxaldehyde
##STR00104##
N-Boc-1-aminomethyl-cyclopropyl-methanol (0.87 g, 4.32 mmol) was
submitted to Procedure 13 for oxidation to the corresponding
N-Boc-1-aminomethyl-cyclopropane carboxaldehyde, which was carried
through to the next step without further purification.
N-Boc-1-amino-cyclopropyl-methanol
##STR00105##
N-Boc-1-amino-cyclopropane carboxylic acid (0.25 g, 1.24 mmol) was
submitted to Procedure 14 to yield the corresponding
N-Boc-1-amino-cyclopropyl-methanol (0.051 g, 0.27 mmol, 21.8%
yield), which was carried through to the next step without further
purification.
N-Boc-1-amino-cyclopropane carboxaldehyde
##STR00106##
N-Boc-1-amino-cyclopropyl-methanol (0.051 g, 0.27 mmol) was
submitted to Procedure 13 for oxidation to the corresponding
N-Boc-1-amino-cyclopropane carboxaldehyde, which was carried
through to the next step without further purification.
N-Boc-1(R)-amino-2(S)-tert-butyldimethylsilyloxy-cyclopentane-4(S)-carboxy-
lic acid
##STR00107##
To a stirring solution of
N-Boc-1(R)-amino-2(S)-hydroxy-cyclopentane-4(S)-carboxylic acid
methyl ester (0.622 g, 2.40 mmol) in DCM (1.9 mL) was added
imidazole (0.164 g, 2.41 mmol), DMAP (0.047 g, 0.35 mmol) and TBSCl
(0.363 g, 2.40 mmol) and the reaction was stirred at room
temperature for 18 hours, followed by heating at 40.degree. C. for
1 hour. The reaction mixture was cooled to room temperature, and
was quenched with H.sub.2O (3 mL). The organic layer was separated
and was concentrated to dryness to yield a residue, which was
dissolved in isopropanol (6 mL) and 1M NaOH (2.9 mL), and the
reaction was heated at 60.degree. C. for 1 hour. The reaction was
cooled to 0.degree. C. and slowly acidified to pH 3 with 1M HCl (3
mL). After adding chloroform (18 mL), the organic layer was
separated, dried over Na.sub.2SO.sub.4, and concentrated to dryness
to yield the desired acid (0.75 g, 2.09 mmol, 87.1% yield).
N-Boc-1(R)-amino-2(S)-tert-butyldimethylsilyloxy-4(S)-hydroxymethyl-cyclop-
entane
##STR00108##
N-Boc-1(R)-amino-2(S)-tert-butyldimethylsilyloxy-cyclopentane-4(S)-carbox-
ylic acid (0.53 g, 1.47 mmol) was submitted to Procedure 14 for
reduction to the corresponding
N-Boc-1(R)-amino-2(S)-tert-butyldimethyl
silyloxy-4(S)-hydroxymethyl-cyclopentane (0.44 g, 1.27 mmol, 86.4%
yield): .sup.1H NMR (250 MHz, CDCl.sub.3) .delta. 4.69-4.79 (m,
1H), 4.08-4.13 (m, 1H), 3.88 (bs, 1H), 3.52-3.61 (m, 2H), 2.16-2.30
(m, 2H), 1.96-2.14 (m, 2H), 1.48-1.53 (m, 2H), 1.47 (s, 9H), 0.91
(s, 9H), 0.09 (s, 6H).
N-Boc-1(R)-amino-2(S)-tert-butyldimethylsilyloxy-cyclopentane-4(S)-carboxa-
ldehyde
##STR00109##
N-Boc-1(R)-amino-2(S)-tert-butyldimethylsilyloxy-4(S)-hydroxy
methyl-cyclopentane (0.44 g, 1.27 mmol) was submitted to Procedure
13 for oxidation to the corresponding
N-Boc-1(R)-amino-2(S)-tert-butyldimethylsilyloxy-cyclopentane-4(S)-carbox-
aldehyde (0.42 g, 1.22 mmol, 96.1% yield).
tert-Butyl-2-(N-Boc-3-hydroxy-azetidin-3-yl)acetate
##STR00110##
To a stirring solution of N-Boc-3-azetidinone (0.45 g, 2.64 mmol)
in THF (5 mL) was slowly added a 0.5 M solution of
2-tert-butoxy-2-oxoethyl-zinc chloride in Et.sub.2O (10 mL, 5.0
mmol), and the reaction mixture was stirred for 5 h. The reaction
was then quenched with sat. aq. NH.sub.4Cl (10 mL), and the aqueous
layer was separated and extracted with ethyl acetate (2.times.30
mL). The combined organic layers were washed with 5% aq.
NaHCO.sub.3 (2.times.10 mL), brine (15 mL), dried over
Na.sub.2SO.sub.4, filtered and concentrated to dryness to yield
tert-butyl-2-(N-Boc-3-hydroxy-azetidin-3-yl)-acetate (MS m/e
[M+H].sup.+ calcd 288.2, found 287.7).
2-(N-Boc-3-hydroxy-azetidin-3-yl)-acetic acid
##STR00111##
To a stirring solution of
tert-butyl-2-(N-Boc-3-hydroxy-azetidin-3-yl)-acetate (0.86 g, 2.99
mmol) in dioxane (18 mL) was added 3M HCl (5 mL), and the mixture
was heated at 70.degree. C. for 1 h. The reaction mixture was then
cooled to 0.degree. C. and it was basified with 2 M NaOH (8 mL),
followed by addition of BOC.sub.2O (1.0 g, 4.6 mmol). The reaction
mixture was allowed to warm to room temperature for 2 h, and was
then concentrated to half its total volume on the rotary
evaporator. Isopropanol (3 mL) and chloroform (12 mL) were then
added and the mixture was cooled to 0.degree. C. and slowly
acidified to pH 3 with 1M HCl. The organic layer was then
separated, dried over Na.sub.2SO.sub.4, and concentrated to dryness
to yield 2-(N-Boc-3-hydroxy-azetidin-3-yl)-acetic acid (0.65 g,
2.81 mmol, 94.0% yield).
N-Boc-3-(2-hydroxy-ethyl)-azetidin-3-ol
##STR00112##
2-(N-Boc-3-hydroxy-azetidin-3-yl)-acetic acid (0.44 g, 1.90 mmol)
was submitted to Procedure 14 for reduction to yield the
corresponding N-Boc-3-(2-hydroxy-ethyl)-azetidin-3-ol (0.29 g, 1.33
mmol, 70.0% yield).
2-(N-Boc-3-hydroxy-azetidin-3-yl)-acetaldehyde
##STR00113##
N-Boc-3-(2-hydroxy-ethyl)-azetidin-3-ol (0.29 g, 1.33 mmol) was
submitted to Procedure 13 for oxidation to the corresponding
2-(N-Boc-3-hydroxy-azetidin-3-yl)-acetaldehyde, which was carried
through to the next step without further purification.
N-Boc-3-hydroxymethyl-azetidine
##STR00114##
N-Boc-azetidine-3-carboxylic acid (1.94 g, 9.64 mmol) was submitted
to Procedure 14 for reduction to the corresponding
N-Boc-3-hydroxymethyl-azetidine, which was carried through to the
next step without further purification.
N-Boc-azetidine-3-carboxaldehyde
##STR00115##
N-Boc-3-hydroxymethyl-azetidine (9.64 mmol) was submitted to
Procedure 13 for oxidation to the desired
N-Boc-azetidine-3-carboxaldehyde, which was carried through to the
next step without further purification.
2-(N-Boc-azetidin-3-yl)-2-hydroxy-acetic acid
##STR00116##
N-Boc-azetidine-3-carboxaldehyde (1.60 g, 8.64 mmol) was submitted
to Procedure 11 to yield the desired
2-(N-Boc-azetidin-3-yl)-2-hydroxy-acetic acid (MS m/e [M+H].sup.+
calcd 232.1, found 231.8).
Synthesis of (2R,3R)-4-azido-2-benzyloxy-3-fluorobutanoic acid
(5)
##STR00117##
Molecular sieves (4 .ANG., 4 g) were added to a round bottom flask,
and were activated by heating with a Bunsen burner under high
vacuum. DCM (100 mL) was then added and the flask was cooled to
-35.degree. C. with a cryocooler. Titanium tetraisopropoxide (1.75
mL, 5.95 mmol) and (R,R)-(-)-diisopropyl tartrate (1.65 mL, 7.75
mmol) were added and the reaction was stirred for 30 min.
Penta-1,4-dienol (5 g, 59.4 mmol) and excess cumene hydroperoxide
(80%, 17.5 mL) were added in small portions, and stirring was
continued at -35.degree. C. for 48 hr. The reaction was quenched by
addition of sat. aq. Na.sub.2SO.sub.4 (5 mL) immediately followed
by Et.sub.2O (50 mL) and the reaction was stirred for 2 hr with
warming to rt. The reaction mixture was filtered through Celite,
and washed with Et.sub.2O. Solvent removal under vacuum without
heating resulted in approximately 30 mL of a yellow solution.
Excess cumene alcohol and hydroperoxide were removed by flash
chromatography (silica gel, 40% Et.sub.2O/hex). Finally solvent
removal under vacuum without heating yielded a mixture of
(2S,3R)-1,2-epoxy-4-penten-3-ol (1) (Rf=0.47, 1:1 EtOAc/hex) and
diisopropyl tartrate (Rf=0.6), which was used in the next step
without further purification.
To a stirring solution of epoxide (1) in THF (100 mL) under an
argon atmosphere was added tetrabutylammonium iodide (2.2 g, 5.96
mmol), followed by benzyl bromide (8.6 mL, 71.9 mmol) and the
reaction was cooled to -15.degree. C. Sodium hydride (60% in
mineral oil, 2.65 g, 66.1 mmol) was added in small portions and the
reaction was stirred overnight with warming to rt. The reaction was
quenched with MeOH, filtered through Celite, and washed with
Et.sub.2O, Solvent removal gave an oily residue which was purified
by flash chromatography (silica gel, 5.fwdarw.10% Et.sub.2O/hex) to
yield (2S,3R)-1,2-epoxy-3-benzyloxy-4-pentene (2) as a clear
non-volatile liquid (5.3 g, 47.6% yield): Rf=0.69 (1:4 EtOAc/hex);
[.alpha.].sub.D=-36.7.degree. (c 1.52, CHCl.sub.3); HRMS (ESI)
(M+H).sup.+ calc. for C.sub.12H.sub.14O.sub.2 191.1067, obs.
191.1064; .sup.1H NMR (CDCl.sub.3, 300 MHz) .delta. 7.38-7.33 (m,
5H), 5.92-5.78 (m, 1H), 5.41-5.39 (m, 1H), 5.37-5.33 (m, 1H), 4.66
(d, J=11.95 Hz, 1H), 4.49 (d, J=11.96 Hz, 1H), 3.83 (dd, J=7.34,
4.20 Hz, 1H), 3.10 (dt, J=4.07, 4.06, 2.70 Hz, 1H). 2.79 (dd,
J=5.21, 4.00 Hz, 1H), 2.70 (dd, J=5.23, 2.64 Hz, 1H). .sup.13C NMR
(CDCl.sub.3, 100 MHz) .delta. 138.32, 134.67, 128.56 (2C), 127.87
(2C), 127.82, 119.73, 79.54, 70.83, 53.41, 45.00.
##STR00118##
NaN.sub.3 (3.38 g, 52 mmol) and NH.sub.4Cl (2.78 g, 52 mmol) in
H.sub.2O (10 mL) were heated until a clear solution was obtained.
This solution was then added dropwise to a solution of
(2S,3R)-1,2-epoxy-3-benzyloxy-4-pentene (2) (3.3 g, 17.4 mmol) in
MeOH (200 mL) and the reaction mixture was stirred for 4 days. The
organic solvent was removed under vacuum, and the aqueous layer was
extracted with DCM (3.times.). The combined organic layers were
dried over Na.sub.2SO.sub.4, filtered and reduced under vacuum to
yield a crude, which was purified by flash chromatography (silica
gel, 10.fwdarw.20% Et.sub.2O/hex) to yield
(2S,3R)-1-azido-3-benzyloxy-4-penten-2-ol (3) (2.66 g, 66% yield)
as a non-volatile clear liquid: Rf=4.8 (1:4 EtOAc/hex); HRMS (ESI)
(M+Na).sup.+ calc. for C.sub.12H.sub.15N.sub.3O.sub.2 256.1056,
obs. 256.1057; [.alpha.].sub.D=-46.3.degree. (c 1.50, CHCl.sub.3);
.sup.1H NMR (CDCl.sub.3, 300 MHz) .delta. 7.42-7.28 (m, 5H),
5.91-5.76 (m, 1H), 5.46 (dd, J=17.16, 1.42 Hz, 1H), 5.42 (dd,
J=24.00, 1.37 Hz, 1H), 4.65 (d, J=11.67 Hz, 1H), 4.39 (d, J=11.67
Hz, 1H), 3.88-3.80 (m, 2H), 3.44-3.40 (m, 2H), 2.22 (d, J=3.60 Hz,
1H); .sup.13C NMR (CDCl.sub.3, 100 MHz) .delta. 137.88, 134.60,
128.66 (2C), 128.08 (2C), 728.05, 121.40, 81.39, 72.61, 70.70,
53.0; FTIR (NaCl): 3435, 2870, 2102, 1642, 1454, 1070
cm.sup.-1.
##STR00119##
To a stifling solution of DAST (900 .mu.L, 6.87 mmol) in benzene
(3.2 mL) and pyridine (400 .mu.L) in a plastic container at
-10.degree. C. was added (2S,3R)-1-azido-3-benzyloxy-4-penten-2-ol
(3) (750 mg, 3.21 mmol) in small portions, and the reaction was
stirred at this temperature for 48 hr followed by 6 hr at rt. The
reaction mixture was slowly added to sat. aq. NaHCO.sub.3 (20 mL)
at 0.degree. C. and was stirred for 10 min. The resulting aqueous
mixture was extracted with DCM (3.times.) and the combined organic
layers were washed with 2 N HCl, dried over MgSO.sub.4, filtered
and reduced under vacuum to yield a crude, which was purified by
flash chromatography (silica gel, 1% Et.sub.2O/hex) to yield
(3R,4R)-5-azido-4-fluoro-3-benzyloxy-pent-1-ene (4) (128 mg, 16.9%
yield) as a nonvolatile clear liquid: Rf=0.63 (1:9 EtOAC/Hex);
[.alpha.].sub.D=-11.9.degree. (c 1.50, CHCl.sub.3); .sup.1H NMR
(CDCl.sub.3, 400 MHz) .delta. 7.44-7.29 (m, 5H), 4.63 (dddd,
J=47.64, 7.07, 4.99, 3.32 Hz, 1H), 5.49-5.42 (m, 2H), 4.70 (d,
J=11.95 Hz, 1H), 4.57 (ddd, J=7.07, 4.99, 3.32 Hz, 1H), 4.44 (d,
J=11.90 Hz, 1H), 4.03 (ddd, J=16.87, 7.57, 5.04 Hz, 1H), 3.64-3.52
(m, 1H), 3.45 (ddd, J=27.45, 13.63, 3.27 Hz, 1H). .sup.19F NMR
(CDCl.sub.3, 282 MHz) -196.66 (dddd, J=47.27, 27.08, 19.84, 16.89
Hz); .sup.13C NMR (CDCl.sub.3, 100 MHz) .delta. 137.80, 133.09 (d,
J=5.30 Hz), 128.70 (2C), 128.09 (3C), 121.04, 93.33 (d, J=181.54
Hz), 79.08 (d, J=20.39 Hz), 70.92, 51.46 (d, J=22.25 Hz). FTIR
(NaCl): 2930, 2104, 1643, 1454, 1281, 1115, 1069 cm.sup.-1.
##STR00120##
(3R,4R)-5-azido-4-fluoro-3-benzyloxy-pent-1-ene (4) (128 mg, 0.543
mmol) was submitted to Procedure 15, followed by recrystallization
from hot hexanes (2.times.) to yield
(2R,3R)-4-azido-2-benzyloxy-3-fluorobutanoic acid (5) (120 mg,
90%): [.alpha.].sub.D=-56.9.degree. (c 0.68, CHCl.sub.3); HRMS (ESI
negative mode) (M-H) calc. for C.sub.11H.sub.12FN.sub.3O.sub.3
252.0790, obs. 252.0782; .sup.1H NMR (CDCl.sub.3, 400 MHz), .delta.
10.55 (s, 1H), 7.46-7.34 (m, 5H), 4.98 (dddd, J=46.40, 7.57, 4.91,
2.92 Hz, 1H), 4.94 (d, J=11.47 Hz, 1H), 4.55 (d, J=11.51 Hz, 1H),
4.17 (dd, J=27.26, 2.86 Hz, 1H), 3.77 (dt, J=13.89, 13.66, 7.27 Hz,
1H), 3.42 (ddd, J=24.28, 13.20, 4.92 Hz, 1H); .sup.19F NMR
(CDCl.sub.3, 376 MHz) .delta. -198.36 (dddd, J=46.28, 27.22, 24.46,
14.15 Hz); .sup.13C NMR (CDCl.sub.3, 100 MHz) .delta. 174.63 (d,
J=4.21 Hz), 136.37, 129.15 (2C), 129.07, 128.98 (2C), 91.53 (d,
J=182.59 Hz), 76.40 (d, J=19.90 Hz), 73.96 (s), 50.87 (d, J=25.13
Hz); FTIR (NaCl): 3151, 2098, 1753, 1407, 1283, 1112 cm.sup.-1.
Synthesis of ent-5
##STR00121##
Starting from penta-1,4-dienol (5 g, 59.4 mmol) and using
(S,S)-(+)-diisopropyl tartrate under the same reaction conditions
as described above the enantiomer ent-2 was obtained (4.9 g, 43%
yield): [.alpha.].sub.D=+35.7.degree. (c 1.76, CHCl.sub.3).
(2R,3S)-1,2-Epoxy-3-benzyloxy-4-pentene (ent-2, 3.9 g, 20.5 mmol)
was submitted to the same reaction conditions described above to
yield the enantiomer (2R,3S)-1-azido-3-benzyloxy-4-penten-2-ol
(ent-3, 2.75 g, 57% yield): [.alpha.].sub.D=+47.3.degree. (c 1.30,
CHCl.sub.3). (2R,3S)-1-Azido-3-benzyloxy-4-penten-2-ol (ent-3) (500
mg, 2.14 mmol) was submitted to the same reactions as described
above to yield the enantiomer
(3S,4S)-5-azido-4-fluoro-3-benzyloxy-pent-1-ene (ent-4, 75.5 mg,
0.32 mmol, 15% yield, [.alpha.].sub.D=+10.7.degree., c 1.50,
CHCl.sub.3), which was submitted to the same reaction conditions as
described above to yield ent-5 (59 mg, 73% yield):
[.alpha.].sub.D=+ 58.6.degree. (c 0.73, CHCl.sub.3).
Synthesis of (R)-4-Azido-3,3-difluoro-2-benzyloxy-butanoic acid
(3)
##STR00122##
To a stirring solution of DMSO (690 .mu.L, 9.65 mmol) in DCM (25
mL) at -78.degree. C. was added oxalyl chloride (3.21 mL of a 2.0 M
solution in DCM, 6.43 mmol) and the reaction was stirred for 1 hr.
A solution of (2S,3R)-1-azido-3-benzyloxy-4-penten-2-ol (1) (750
mg, 3.21 mmol) in DCM (1 mL) was added dropwise and the reaction
mixture was stirred for 1 hr at -78.degree. C. N-Methyl morpholine
(1.41 mL, 12.9 mmol) was added dropwise, and the reaction was
stirred at -15.degree. C. for 2 hr. The reaction was quenched with
phosphate buffer (0.1 M, pH 6.0) and the aqueous layer was
separated. The organic layer was washed with the phosphate buffer
(3.times.), dried over Na.sub.2SO.sub.4, filtered and reduced under
vacuum to give a brown residue. The residue was dissolved in
Et.sub.2O, dried over MgSO.sub.4, filtered through a cotton plug,
and reduced under vacuum to yield the crude ketone, which was
dissolved in DCM (1 mL) and was added to a stirring solution of
DAST (2 mL, 15.3 mmol) in DCM (3 mL) in a plastic vial at
-25.degree. C. The reaction was allowed to slowly warm to rt and
was stirred for 48 hr. The reaction mixture was then slowly poured
into stirring sat. aq. NaHCO.sub.3 (20 mL) at 0.degree. C., and was
stirred for 10 min. The resulting aqueous mixture was extracted
with DCM (3.times.), and the combined organic layers were dried
over Na.sub.2SO.sub.4, filtered and reduced under vacuum to yield a
crude, which was purified by flash chromatography (silica gel, 1%
Et.sub.2O/hex) followed by preparative TLC purification (silica
gel, 0.5 mm, 5% Et.sub.2O/hex) to yield
(R)-5-azido-4,4-difluoro-3-benzyloxy-pent-1-ene (2, 193 mg, 0.76
mmol, 24% yield), as a non-volatile clear liquid: Rf=0.72 (1:4
EtOAc/hex); [.alpha.].sub.D=-23.8.degree. (c 1.52, CHCl.sub.3);
.sup.1H NMR (CDCl.sub.3, 300 MHz) .delta. 7.44-7.31 (m, 5H), 5.89
(dddd, J=16.88, 10.61, 7.11, 0.62 Hz, 1H), 5.59-5.56 (m, 1H), 5.53
(d, J=10.74 Hz, 1H), 4.71 (d, J=11.67 Hz, 1H), 4.50 (d, J=11.66 Hz,
1H), 4.14 (td, J=14.25, 7.13, 7.13 Hz, 1H), 3.64 (tq, J=13.67,
13.67, 13.67, 11.19, 11.19 Hz, 2H); .sup.19F NMR (CDCl.sub.3, 282
MHz) 6-116.63 (dtd, J=257.62, 13.91, 13.90, 8.72 Hz), -111.27 (dtd,
J=257.59, 16.18, 16.16, 7.04 Hz); .sup.13C NMR (CDCl.sub.3, 75 MHz)
.delta. 137.14, 130.33 (t, J=3.06, 3.06 Hz), 128.71 (2C), 128.27,
128.20 (2C), 122.78, 120.69 (dd, J=249.89, 246.83 Hz), 78.87 (dd,
J=30.35, 25.35 Hz), 71.48 (d, J=0.48 Hz), 51.47 (dd, J=30.26, 25.92
Hz); FTIR (NaCl): 2928, 2108, 1455, 1292, 1091 cm.sup.-1.
##STR00123##
(R)-5-Azido-4,4-difluoro-3-benzyloxy-pent-1-ene (2, 193 mg, 0.76
mmol) was submitted to Procedure 15, followed by washing with cold
hexanes (3.times.) at -20.degree. C. to yield (3) (139 mg, 67.6%
yield): [.alpha.].sub.D=-32.4.degree. (c 0.80, CHCl.sub.3); HRMS
(ESI negative mode) (M-H) for C.sub.11H.sub.11F.sub.2N.sub.3O.sub.3
270.0696, obs. 270.06924; .sup.1H NMR (CDCl.sub.3, 400 MHz) .delta.
7.46-7.32 (m, 5H), 6.48 (s, 1H), 4.84 (d, J=11.30 Hz, 1H), 4.67 (d,
J=11.30 Hz, 1H), 4.37 (dd, J=12.23, 9.78 Hz, 1H), 3.75 (dd,
J=14.67, 12.35 Hz, 2H); .sup.19F NMR (CDCl.sub.3, 376 MHz) .delta.
-112.61 J=260.95, 12.30, 12.29, 12.29 Hz), -109.68 (dtd, J=260.79,
14.75, 14.68, 9.94 Hz); .sup.13C NMR (CDCl.sub.3, 100 MHz) .delta.
170.84, 135.48, 129.01, 128.94 (2C), 128.78 (2C), 119.59 (t,
J=251.58, 251.58 Hz), 76.56 (dd, J=29.86, 27.24 Hz), 74.34, 51.58
(dd, J=28.94, 26.76 Hz). FTIR (NaCl): 3337, 2929, 2112, 1738, 1455,
1292, 1210, 1119 cm.sup.-1.
Synthesis of ent-3
##STR00124##
(2R,3S)-1-Azido-3-benzyloxy-4-penten-2-ol (ent-1, 500 mg, 2.14
mmol) was submitted to the same reaction conditions described above
to yield (S)-5-azido-4,4-difluoro-3-benzyloxy-pent-1-ene (ent-2,
114 mg, 21% yield, [.alpha.].sub.D=+27.9.degree. (c 3.14,
CHCl.sub.3)). Ent-2 (75.5 mg, 0.32 mmol) was submitted to Procedure
15 to yield (S)-4-azido-2-benzyloxy-3,3-difluorobutanoic acid
(ent-3, 34.8 mg, 43% yield, [.alpha.].sub.D=+36.4.degree. (c 0.80,
CHCl.sub.3).
Synthesis of (2S,3S)-4-azido-2,3-bis-benzyloxybutanoic acid (3)
##STR00125##
To a stirring solution of (2S,3R)-1-azido-3-benzyloxy-4-penten-2-ol
(1) (250 .mu.L, 1.07 mmol) in THF (50 mL) under argon was added
tetrabutylammonium iodide (42 mg, 0.11 mmol) followed by benzyl
bromide (155 .mu.L, 1.27 mmol) and the reaction was cooled to
0.degree. C. Sodium hydride (60% in mineral oil, 47 mg, 1.18 mmol)
was added in small portions and the reaction was stirred overnight
with warming to rt. The reaction was quenched with MeOH, filtered
through Celite, and washed with Et.sub.2O. The organic solvent was
removed under vacuum to give an oily residue, which was purified by
flash chromatography (silica gel, 2% Et.sub.2O/hex) to yield
(3R,4S)-5-azido-3,4-bisbenzyloxy-pent-1-ene (2, 237 mg, 65% yield)
as a clear non-volatile liquid: Rf=0.62 (1:4 EtOAc/hex);
[.alpha.].sub.D=-6.1.degree. (c 1.50, CHCl.sub.3); .sup.1H NMR
(CDCl.sub.3, 300 MHz) .delta. 7.35-7.24 (m, 10H), 5.81 (ddd,
J=17.15, 10.58, 7.45 Hz, 1H), 5.37 (ddd, J=5.70, 1.65, 0.86 Hz,
1H), 5.33 (ddd, J=12.07, 1.44, 0.81 Hz. 1H), 4.63 (s, 2H), 4.61 (d,
J=11.87 Hz, 1H), 4.35 (d, J=11.78 Hz, 1H), 3.90 (tdd, J=7.37, 5.65,
0.79, 0.79 Hz, 1H), 3.60 (ddd, J=6.39, 5.69, 3.64 Hz, 1H), 3.43
(dd, J=12.93, 6.42 Hz, 1H), 3.35 (dd, J=12.93, 3.60 Hz, 1H);
.sup.13C NMR (CDCl.sub.3, 75 MHz) .delta. 138.25, 138.01, 135.43,
128.60 (4C), 128.29 (2C), 128.02, 127.99 (2C), 127.87, 119.97,
80.76, 80.23, 73.33, 70.79, 51.69; FTIR (NaCl): 2867, 2100, 1606,
1454, 1286, 1095, 1073.
##STR00126##
(3R,4S)-5-azido-3,4-bis-benzyloxy-pent-1-ene (2, 237 mg, 0.69 mmol)
was submitted to Procedure 15 to yield
(2S,3S)-4-azido-2,3-bis-benzyloxybutanoic acid (3, 187.7 mg, 75%
yield): [.alpha.].sub.D=-15.1.degree. (c 1.05, CHCl.sub.3); HRMS
(ESI negative mode) (M-H) calc. for C.sub.18H.sub.19N.sub.3O.sub.4
340.1303, obs. 340.1296; .sup.1H NMR (CDCl.sub.3, 300 MHz) .delta.
7.24 (s, 1H), 7.38-7.33 (m, 10H), 4.79 (d, J=11.61 Hz, 1H), 4.66
(s, 2H), 4.56 (d, J=11.61 Hz, 1H), 4.20 (d, J=4.24 Hz, 1H), 3.98
(td, J=6.56, 4.30, 4.30 Hz, 1H), 3.58 (dd, J=13.04, 6.62 Hz, 1H),
3.42 (dd, J=13.04, 4.31 Hz, 1H); .sup.13C NMR (CDCl.sub.3, 75 MHz)
.delta. 175.57, 137.92, 137.34, 129.44 (2C), 129.36 (2C), 129.15,
129.04 (2C), 128.98 (2C), 128.94, 79.71, 77.651, 74.04, 73.89,
51.65; FTIR (NaCl): 3000, 2918, 2103, 1722, 1455, 1284, 1110
cm.sup.-1.
Synthesis of ent-3
##STR00127##
(2R,3S)-1-azido-3-benzyloxy-4-penten-2-ol (ent-1, 250 mg, 1.07
mmol) was submitted to the same reaction conditions as described
above to yield (3S,4R)-5-azido-3,4-bis-benzyloxy-pent-1-ene (ent-2,
322 mg, 59% yield): [.alpha.].sub.D=+7.9.degree. (c 1.50,
CHCl.sub.3). Ent-2 (178 mg, 0.55 mmol) was submitted to Procedure
15 to yield ent-3 (144 mg, 77% yield): [.alpha.].sub.D=+
15.2.degree. (c 0.81, CHCl.sub.3).
Synthesis of Compound 9
##STR00128## ##STR00129## Synthesis of Epoxy Alcohol Ent-2
A 3-neck, 5 liter round bottomed flask equipped with an overhead
mechanical stirrer, a thermocouple probe and a nitrogen
inlet/outlet was charged with powdered, freshly activated molecular
sieves (4 .ANG., 84 g, 0.8 wt. equiv), followed by anhydrous
dichloromethane (2.1 L, 20 vol). The resulting suspension was
cooled to approximately -42.degree. C. using an
acetonitrile/CO.sub.2 bath, then titanium tetraisopropoxide (37 mL,
0.125 mol, 10 mol %) was charged into the batch, followed by
(S,S)-(+)-diisopropyl tartrate (35 mL, 0.166 mol, 13.3 mol %). The
reaction mixture was stirred for 30 minutes, then divinyl alcohol 1
(105 g, 1.25 mol, 1.0 equiv) was added over 3 minutes using an
addition funnel (minor exotherm, 2.degree. C.). Cumene
hydroperoxide (370 mL, 80% titer, 1.99 mol, 1.59 equiv) was then
added to the batch over 5 minutes using an addition funnel
(10.degree. C. exotherm). The reaction was allowed to proceed for
18 hours, holding the temperature between -45 and -30.degree. C.
When complete as determined by TLC analysis (R.sub.f 0.42 for
divinyl alcohol, and 0.18 for epoxy alcohol, 50% MTBE in Heptanes),
the reaction was quenched with saturated aqueous sodium sulfate
(105 mL, 1 vol), diluted with MTBE (1.05 L, 10 vol) and the batch
allowed to warm to ambient temperature, with vigorous stirring.
Diatomaceous earth, Celite.RTM. (105 g, 1 wt. equiv) was added to
the batch, which was then filtered through a pad of Celite.RTM..
The filter cake was washed with MTBE (0.5 L) and the filtrate
concentrated in vacuo on a rotary evaporator (with water bath held
at 10-20.degree. C.) to afford a yellow/brownish oil. A portion of
the crude product [311 g] was subjected to silica plug (1 kg silica
gel) using 0-60% MTBE/petroleum ether. The fractions containing the
product were collected and concentrated to obtain a colorless oil
(48.3 g). This material was then purified via column chromatography
(300 g silica gel, 5-30% MTBE/petroleum ether) to afford ent-2 as a
clear liquid [22.6 g, 36% overall mass recovery]: R.sub.f=0.59 (1:1
MTBE/petroleum ether); .sup.1H NMR (CDCl.sub.3, 500 MHz) .delta.
5.85 (ddd, J=17.0, 10.5, 6.2 Hz, 1H), 5.40 (dt, J=17.3, 1.3 Hz,
1H), 5.27 (dt, J=10.5, 1.3 Hz, 1H), 4.36-4.33 (m, 1H), 3.10 (ddd,
J=3.8, 3.8, 3.0 Hz, 1H), 2.81 (dd, J=2.9, 5.0 Hz, 1H), 2.76 (dd,
4.1, 5.0 Hz, 1H), 2.07 (d, J=3.0 Hz, 1H).
Synthesis of Compound 3
The reaction was carried out at 20-g scale of alcohol following a
literature procedure (J. Org. Chem. 2009, 74(15), 5758-5761). A 2-L
round-bottomed flask equipped with a mechanical stirrer, a
thermocouple probe, and an addition funnel was charged with a
solution of epoxy alcohol ent-2 [20 g, 200 mmol, 1 equiv] in
tetrahydrofuran (400 mL, 20 vol) along with Ph.sub.3P (105 g, 400
mmol, 2 equiv), and 4-nitrobenzoic acid (67 g, 400 mmol, 2 equiv)
under a nitrogen atmosphere. DIAD (81 g, 400 mmol, 2 equiv) was
added to the reaction mixture using an addition funnel while
maintaining the reaction mixture at 0.degree. C. (ice bath). Once
the addition of DIAD was complete, the cold bath was removed and
the reaction mixture was allowed to come to ambient temperature
(23.degree. C.). The reaction mixture was stirred for 1.5 h (all
starting material consumed) and then quenched with aqueous
NaHCO.sub.3 solution (100 ml, 5 vol) followed by the addition of
MTBE (1000 mL, 50 vol). The resulting solution was transferred into
a separatory funnel. Brine (100 mL, 5 vol) was added to obtain
phase separation. The organic phase was washed with brine
(2.times.20 vol), dried (MgSO.sub.4), and concentrated under vacuum
to obtain an oil (296 g). The oil was passed through a silica plug
(1 kg) using 10-20% MTBE/heptanes. The crude solid (46 g) was then
dissolved into MTBE (20 vol) and washed with NaHCO.sub.3 (3.times.5
vol), water (2.times.2 vol), brine (2.times.2 vol), dried
(MgSO.sub.4), concentrated, and further dried to obtain the
benzoate ester as a white solid [29 g, 59%: R.sub.f=0.56 (1:1
MTBE/heptanes)]; .sup.1H NMR (CDCl.sub.3, 500 MHz) .delta. 8.35 (d,
J=10.8 Hz, 2H), 8.25 (d, J=10.8 Hz, 2H), 5.97 (ddd, J=17.2, 10.6,
6.2 Hz, 1H), 5.48 (td, J=17.3, 1.2 Hz, 1H), 5.40 (td, J=10.7, 1.1
Hz, 1H), 5.34 (dd, J=5.0, 1.3 Hz, 1H), 3.31 (ddd, J=6.5, 4.1, 2.6
Hz, 1H), 2.93 (dd, J=4.2, 4.2 Hz, 1H), 2.76 (dd, J=4.8, 2.6 Hz,
1H).
The hydrolysis of the benzoate ester was carried out following the
literature procedure (J. Org. Chem. 2009, 74(15), 5758-5761). Thus
solution of the ester (22.7 g, 91 mmol, 1 equiv) in methanol (340
mL, 15 vol) was treated with an aqueous solution of K.sub.2CO.sub.3
(13.8 g, 100 mmol, 1.1 equiv, in 34 mL, 1.5 vol water) at
10-15.degree. C. The solution immediately turned into a thick
slurry. The slurry was stirred at ambient temperature (23.degree.
C.) for 3 h (starting material consumed). The reaction mixture was
concentrated on a rotary evaporator (at ambient water bath
temperature) to .about.2 vol (45 mL). The thick solution was then
reslurried in DCM (454 mL, 20 vol). The slurry was filtered and the
solids were washed with DCM (2.times.5 vol, 2.times.114 mL). The
combined organic filtrate was dried (MgSO.sub.4), filtered, and
concentrated to obtain a solid (31 g). The crude material was then
purified by column chromatography (silica gel, 10-30%
MTBE/petroleum ether) to obtain the desired alcohol 3 as a clear
oil [9.24 g, quantitative yield, R.sub.f=0.31 (1:1 MTBE/heptanes)];
.sup.1H NMR (CDCl.sub.3, 300 MHz) .delta. 5.94 (ddd, J=16.2, 10.6,
5.5, 1H), 5.40 (d, J=17.3 Hz, 1H), 5.26 (d, J=10.6 Hz, 1H), 4.0 (t,
J=5.3 Hz, 1H), 3.07 (m, 1H), 2.84 (t, J=4.8 Hz, 1H), 2.77-2.74 (m,
1H), 2.57 (br s, 1H).
Synthesis of Compound 4
A 1-L three-necked round-bottomed flask equipped with an addition
funnel, an overhead mechanical stirrer, a nitrogen inlet/outlet,
was charged with alcohol 3 [9.24 g, 92.3 mmol, 1 equiv] in
anhydrous tetrahydrofuran (166 mL, 18 vol). The solution was cooled
to -10 to -15.degree. C. The catalyst Bu.sub.4NI (3.41 g, 9.23
mmol, 10 mol %) was charged into the reactor followed by benzyl
bromide (19.1 g, 112 mmol, 1.2 equiv). The resulting solution was
stirred for 20 min. Sodium hydride (4.1 g, 1.1 equiv, 60% mineral
oil dispersion) was then added to the batch in portions such that
the batch temperature was maintained at -10 to -15.degree. C. Once
the addition of sodium hydride was complete, the reaction mixture
was stirred for an additional 30 min and then the cold bath was
removed and reaction mixture brought up to ambient temperature and
further stirred for 18 h. The reaction was quenched with aqueous
NaHCO.sub.3 (37 mL, 4 vol) while maintaining the temperature at -5
to 0.degree. C. (ice bath). The resulting solution was diluted with
MTBE (185 mL, 20 vol), the organic layer was washed with water
(2.times.18 mL, 2.times.3 vol), brine (1.times.18 mL, 1.times.3
vol), dried (MgSO.sub.4), filtered, and concentrated under reduced
pressure to obtain crude product as an oil. The synthesis was
repeated on 1.98 g scale of alcohol 3. The crude from both the
reactions were combined and purified via column chromatography
(silica gel column, 2.5-10% MTBE/heptanes) to obtain the desired
benzylated product 4 as an oil [13.96 g, 65%: R.sub.f=0.61 (3:7
MTBE/heptanes)]; .sup.1H NMR (CDCl.sub.3, 500 MHz) .delta.
7.36-7.32 (m, 4H), 7.29-7.26 (m, 1H), 5.83 (ddd, J=17.3, 10.5, 6.7,
1H), 5.36 (td, J=17.3, 1.4 Hz, 1H), 5.31 (td, J=10.5, 1.2 Hz, 1H),
4.63 (ABq, J=12.0 Hz, 2H), 3.62 (ddd, J=, 1H), 3.11-3.08 (m, 1H),
2.78 (t, J=4.4 Hz, 1H), 2.60 (dd, J=5.0, 2.7 Hz, 1H).
Synthesis of Compound 5
A 250-mL round-bottomed flask equipped with a reflux condenser was
charged with alcohol 4 [10 g, 52.5 mmol, 1 equiv], phthalimide
(11.6 g, 78.8 mmol, 1.5 equiv), pyridine (0.85 mL, 10.5 mmol. 20
mol %) and IPA (100 mL, 10 vol) and the resulting solution was
stirred at 80-82.degree. C. for 8 hrs. The reaction mixture was
then cooled to ambient temperature and concentrated on a rotatory
evaporator to dryness. The residue was adsorbed on silica gel (20
g), dried under high vacuum and then purified by flash column
chromatography on silica gel (10-40% MTBE/heptanes) to afford the
desired phthalimide protected amino alcohol 5 as a white tacky
solid [15.85 g, 89%]: R.sub.f=0.34 (1:1 MTBE/heptanes); .sup.1H NMR
(DMSO-d.sub.6, 500 MHz) .delta. 7.84-7.82 (m, 4H), 7.36-7.31 (m,
4H), 7.28-7.25 (m, 1H), 5.93 (ddd, J=17.5, 10.5, 10.1 Hz, 1H),
5.38-5.35 (m, 2H), 5.12 (d, J=5.5 Hz, 1H), 4.53 (d, J=11.9 Hz, 1H),
4.40 (d, J=11.9 Hz, 1H), 3.98 (dddd, J=9.0, 4.5, 4.5, 4.5 Hz, 1H),
3.86 (dd, J=5.8, 4.6 Hz, 1H), 3.67 (dd, J=13.7, 8.9 Hz, 1H), 3.59
(dd, J=13.7, 4.4 Hz, 1H).
Synthesis of Compound 6
A 1-L three-necked round-bottomed flask equipped with an addition
funnel, an overhead mechanical stirrer, and a nitrogen inlet/outlet
was charged with a solution of alcohol 5 [15 g, 44.5 mmol, 1 equiv]
in anhydrous tetrahydrofuran (270 mL, 18 vol). The solution was
cooled to -10 to -15.degree. C., then Bu.sub.4NI (1.64 g, 4.45
mmol, 10 mol %) was charged into the reactor followed by benzyl
bromide (9.2 g, 53.8 mmol, 1.2 equiv). The resulting solution was
stirred for 20 min, then sodium hydride (1.97 g, 1.1 equiv, 60%
mineral oil dispersion) was added to the batch in portions such
that the batch temperature was maintained at -10 to -15.degree. C.
Once the addition of sodium hydride was complete, the reaction
mixture was stirred for an additional 30 min and then brought to
ambient temperature and further stirred for 18 h. The reaction was
quenched with aqueous NaHCO.sub.3 (60 mL, 4 vol) while maintaining
the reaction mixture at -5 to 0.degree. C. (ice bath). The reaction
mixture was then diluted with MTBE (300 mL, 20 vol) and the phases
separated. The organic layer was washed with water (2.times.45 mL,
2.times.3 vol), brine (1.times.45 mL, 1.times.3 vol), dried
(MgSO.sub.4), filtered, and concentrated to obtain the crude
product as an oil. The synthesis was repeated on 1.75 g scale of
alcohol 5. The combined crude products from both reactions were
purified by flash column chromatography on silica gel (5-25%
MTBE/heptanes) to obtain the desired product 6 as a semi solid
[15.1 g, 71%: R.sub.f=0.61 (1:1 MTBE/heptanes)]; .sup.1H NMR
(CDCl.sub.3, 300 MHz) .delta. 7.74-7.71 (m, 2H), 7.67-7.64 (m, 2H),
7.37-7.27 (m, 5H), 7.10-7.07 (m, 2H), 6.98-6.93 (m, 3H), 5.97 (ddd,
J=17.5, 10.4, 10.0 Hz, 1H), 5.42 (d, J=4.38 Hz, 1H), 5.38 (s, 1H),
4.68 (dd, J=12.3, 12.3 Hz, 2H), 4.45 (d, J=5.37 Hz, 1H), 4.41 (d,
J=5.58 Hz, 1H), 3.99-3.82 (m, 3H), 3.65 (dd, J=13.6, 3.2 Hz,
1H).
Synthesis of Aldehyde 7 and Carboxylic Acid 8
A solution of alkene, 6 [1 g, 2.34 mol] in DCM (60 mL, 60 vol) was
sparged with ozone at <-70.degree. C. (dry ice-acetone) for 25
min using house air as oxygen source to generate the ozone. Once
the reaction was deemed compete (TLC, 1:1 MTBE/heptanes), the
solution was sparged with nitrogen for 20 min to remove residual
ozone. The reaction was quenched with dimethyl sulfide (1.7 mL,
23.4 mmol, 10 equiv) while maintaining the reaction mixture at
<-70.degree. C. (dry ice-acetone). The cold bath was removed and
the mixture was allowed to warm to ambient temperature. The
reaction mixture was concentrated under reduced pressure and
further dried under high vacuum to obtain the crude aldehyde as a
thick oil (1.12 g, >99%, R.sub.f=0.36, 1:1 MTBE/heptanes). The
reaction was repeated at 13 g scale of 6. The two lots of crude
aldehyde were combined and subjected to the Pinnick oxidation
without further purification.
The crude aldehyde 7 [14.06 g], was taken into a mixture of
tetrahydrofuran, tBuOH, and water (105 mL, 105 mL, 70 mL, 3:3:2, 20
vol) along with NaH.sub.2PO.sub.4 (15.6 g, 130 mmol, 4 equiv) and
2-methyl-2-butene (34.4 mL, 324 mmol, 10 equiv). The solution was
cooled (15.+-.5.degree. C., water bath). Sodium chlorite (3.9 g, 43
mmol, 1.33 equiv) was added to the batch and the resulting solution
was stirred at ambient temperature for 4 hr. The completion of the
reaction was confirmed by TLC analysis (1:1 MTBE/heptanes and 5%
MeOH in DCM). The reaction was then quenched with brine (280 mL, 20
vol) and the product extracted into DCM (3.times.280 mL, 3.times.20
vol). The organic layers were dried (MgSO.sub.4), concentrated
under reduced pressure to obtain the crude acid as a thick oil. The
crude acid was purified by flash column chromatography over silica
(5-100% MTBE/heptanes followed by 5-20% MeOH/DCM). Fractions
containing the acid were combined and concentrated under reduced
pressure to afford acid 8 as a white solid [2.64 g, 18%:
R.sub.f=0.33, 5:95 MeOH/DCM)]; .sup.1H NMR (CDCl.sub.3, 500 MHz)
.delta. 7.78 (dd, J=5.5, 3.0 Hz, 2H), 7.70 (dd, J=5.5, 3.0 Hz, 2H),
7.43-7.40 (m, 2H), 7.37-7.29 (m, 3H), 7.20-7.19 (m, 2H), 7.14-7.11
(m, 2H), 7.09-7.05 (m, 1H), 4.76 (d, J=11 Hz, 1H), 4.65 (dd,
J=10.9, 9.4 Hz, 2H), 4.55 (d, J=11.8 Hz, 1H), 4.13 (ddd, J=6.2,
6.2, 3.1 Hz, 1H), 4.1 (d, J=3.0 Hz, 1H), 3.98 (dd, J=14.2, 6.2 Hz,
1H), 3.89 (dd, J=14.2, 6.2 Hz, 1H).
Synthesis of Compound 9
A round bottomed flask equipped with a magnetic stirring bar, and a
thermocouple probe was charged with a solution of
phthalimide-protected amino acid 8 [2.5 g, 5.61 mmol, 1.0 equiv] in
THF (28 mL, 11 vol, bulk solvent grade). To the clear, yellow
solution was added deionized water (15 mL, 6 vol) and the resulting
mixture cooled to 5.degree. C. Methylamine solution in water (5.0
mL, 40 wt %, 56.1 mmol, 10 equiv) was then added to the batch,
which was warmed to ambient temperature (21-23.degree. C.) and
stirred for 22.5 hours. Analysis of an aliquot from the reaction
mixture by LCMS indicated the reaction was complete. The reaction
mixture was then concentrated in vacuo to a yellow solid residue,
removing all excess methylamine. The residue was taken up in THF
(60 mL, 24 vol) and water (30 mL, 12 vol), cooled to 0-5.degree.
C., and to the crude amino acid solution was added potassium
carbonate (3.9 g, 28.26 mmol, 5.0 equiv), followed by
benzylchloroformate (1.4 mL, 9.81 mmol, 1.75 equiv). The batch was
warmed to ambient temperature and the reaction allowed to proceed
for 25.5 hours. Analysis of an aliquot at this time point by LCMS
indicated a complete conversion of the amino acid to the carbamate.
The reaction mixture was concentrated under reduced pressure to
remove most of THF, the aqueous residue was diluted with water (30
mL, 12 vol) and the pH adjusted with 2N HCl to approximately pH 5
(pH paper strip). The crude product was extracted with chloroform
(3.times.60 mL), the extracts washed with water (1.times.60 mL) and
with aqueous NaCl (1.times.60 mL), dried (MgSO.sub.4) and
concentrated in vacuo to a yellow, mobile oil (3.52 g) which was
purified by flash column chromatography on silica gel (50 wt.
equiv; elution with 0-5% MeOH in CHCl.sub.3) to afford 9 as a
yellow oil, which partially solidified upon further drying under
high vacuum [2.22 g, 88.1% yield over two steps]. .sup.1H NMR
(DMSO, 500 MHz) .delta. 12.92 (s, 1H), 7.43-7.23 (m, 15H), 5.04 (s,
2H), 4.67 (d, J=11.10 Hz, 1H), 4.58 (d, J=11.10 Hz, 1H), 4.48 (d,
J=11.05 Hz, 1H), 4.42 (d, J=11.05 Hz, 1H), 4.09 (d, J=2.95 Hz, 1H),
3.96 (ddd, J=6.30, 6.30, 3.15 Hz, 1H), 3.29 (dd, J=6.30, 6.30,
2H).
Synthesis of Cyclopropyl Amino Acids
##STR00130##
Ethyl-2-(tert-Butyldimethylsilyloxy)acrylate (2)
A solution of ester 1 (4.00 g, 34.4 mmol) and triethylamine (4.79
mL, 34.4 mmol) in anhydrous dichloromethane (170 mL) was cooled to
0.degree. C. under nitrogen and
tert-butyldimethylsilyltrifluoromethane sulfonate (8.31 mL, 36.2
mmol) was added dropwise. The resulting solution was stirred
vigorously at reflux for 4 h. The solvent was then carefully
evaporated, the residue was dissolved in Et/0 (170 mL), and the
organic phase was washed with water (3.times.50 mL). The organic
phase was dried (Na.sub.2SO.sub.4), filtered, and concentrated. The
residue was purified by silica gel chromatography eluting with
0-20% diethyl ether/hexanes to afford 2 (4.89 g, 62%) as a clear
oil: .sup.1H NMR (500 MHz, CDCl.sub.3) .delta. 5.50 (d, J=1.0 Hz,
1H), 4.85 (d, J=1.0 Hz, 1H). 4.21 (q, J=7.0 Hz, 2H), 1.31 (t, J=7.0
Hz, 3H), 0.95 (s, 9H), 0.16 (s, 6H).
2-tert-Butyl-1-Ethyl-1-(tert-butyldimethylsilyloxy)cyclopropane-1,2-dicarb-
oxylate (3a and 3b)
A mixture of ethyl-2-(tert-butyldimethylsilyloxy)acrylate (2, 500
mg, 2.17 mmol) and Cu(acac).sub.2 (0.011 g, 0.043 mmol) was heated
at 80.degree. C. A solution of tert-butyl diazoacetate (463 mg,
3.25 mmol) in benzene (5 mL) was added to the reaction mixture over
2 h. After this time, the reaction mixture was cooled to room
temperature and concentrated. The residue was purified by silica
gel chromatography eluting with 0-10% diethyl ether/hexanes to
afford both diastereomers 3a (0.119 g, 16%) and 3b (0.235 g, 31%)
as clear oils. 3a: .sup.1H NMR (500 MHz, CDCl.sub.3) .delta.
4.25-1.13 (m, 2H), 2.28 (dd, J=7.5, 2.0 Hz, 1H), 1.73 (dd, J=7.5,
2.0 Hz, 1H), 1.59 (dd, J=9.5, 4.0 Hz, 1H), 1.46 (s, 9H), 1.29 (t,
J=7.5 Hz, 3H), 0.90 (s, 9H), 0.18 (s, 3H), 0.12 (s, 3H); ESI MS m/z
367 [M+Na].sup.+; 3b: .sup.1H NMR (500 MHz, CDCl.sub.3) .delta.
4.23 (dq, J=11.0, 7.0 Hz, 1H), 4.13 (dq, J=11.0, 7.0 Hz, 1H), 2.11
(dd, J=10.0, 1.5 Hz, 1H), 1.85 (dd, J=5.5, 2.5 Hz, 1H), 1.43 (s,
9H), 1.54 (dd, J=10.0, 4.0 Hz, 1H), 1.28 (t, J=7.5 Hz, 3H), 0.86
(s, 9H), 0.19 (s, 3H), 0.18 (s, 3H); ESI MS m/z 367
[M+Na].sup.+.
2-(tert-Butyldimethylsilyloxy)-2-(ethoxycarbonyl)cyclopropanecarboxylic
Acid (4a and 4b)
A mixture of dicarboxylate 3a and 3b (0.385 g, 1.12 mmol, 1:2 ratio
of 3a/3b), trifluoroacetic acid (0.43 mL), and dichloromethane (0.5
mL) was stirred overnight at room temperature. The solids were
filtered, and the filtrate was concentrated. The residue was
purified by silica gel chromatography eluting with 0-100% diethyl
ether/hexanes to afford both diastereomers 4a (0.050 g, 15%) and 4b
(0.078 g, 24%) as off-white solids. 4a: .sup.1H NMR (500 MHz,
CDCl.sub.3) .delta. 4.25-1.17 (m, 2H), 2.38 (dd, J=7.5, 1.5 Hz,
1H), 1.81-1.76 (m, 2H), 1.30 (t, J=7.0 Hz, 3H), 0.90 (s, 9H), 0.21
(s, 3H), 0.13 (s, 3H); ESI MS m/z 289 [M+H].sup.+; 4b: .sup.1H NMR
(500 MHz, CDCl.sub.3) .delta. 4.22 (q, J=7.0 Hz, 1H), 2.21 (dd,
J=10.0, 1.5 Hz, 1H), 1.93 (dd, J=8.0, 2.0 Hz, 1H), 1.52 (dd, J=6.0,
3.5 Hz, 1H), 1.28 (t, J=7.0 Hz, 3H), 0.87 (s, 9H), 0.19 (s, 3H),
0.17 (s, 3H); ESI MS m/z 287 [M-H].sup.-.
Ethyl-2-(Benzyloxycarbonylamino)-1-(tert-butyldimethylsilyloxy)cyclopropan-
ecarboxylate (5b)
A mixture of
2-(tert-butyldimethylsilyloxy)-2-(ethoxycarbonyl)cyclopropanecarboxylic
acid (4b, 0.335 g, 1.16 mmol) in toluene (5 mL) under nitrogen was
treated with Hunig's base (0.260 mL, 1.51 mmol) and the mixture was
cooled to 0.degree. C. After this time, DPPA (0.324 mL. 1.51 mmol)
was added and the mixture was heated at 90.degree. C. for 30 min,
followed by the addition of benzyl alcohol (0.155 mL, 1.51 mmol).
After 15 h, the mixture was cooled, diluted with ethyl acetate (75
mL), and washed sequentially with 10% citric acid (2.times.50 mL),
water (50 mL), and saturated NaHCO.sub.3 (50 mL). The organic phase
was dried (MgSO.sub.4), filtered, and concentrated. The residue was
purified by silica gel chromatography eluting with 10%
EtOAc/hexanes to 100% EtOAc to afford the title compound as a clear
oil (0.146 g, 30%): .sup.1H NMR (300 MHz, CDCl.sub.3) .delta.
7.34-7.30 (m, 5H), 5.40-5.38 (m, 1H), 5.21-5.00 (m, 2H), 4.29-4.18
(m, 2H), 4.16-4.09 (m, 1H), 1.50-1.47 (m, 2H), 1.30 (t, J=7.2 Hz,
3H), 0.88 (s, 9H), 0.26-0.07 (m, 6H); Multimode (APCI+ESI) MS w/z
295 [M+H].sup.+.
Ethyl 2-(Benzyloxycarbonylamino)-1-hydroxycyclopropanecarboxylate
(6b)
To a solution of ethyl
2-(benzyloxycarbonylamino)-1-(tert-butyldimethylsilyloxy)cyclopropanecarb-
oxylate (1.45 g, 3.69 mmol) in THF (35 mL) under N.sub.2 was added
HF.pyridine (1.0 mL, 38 mmol). The reaction mixture was stirred for
5 h. After this time, additional HF.pyridine (1.0 mL, 38 mmol) was
added and stirring was continued for 19 h. The reaction mixture was
then cooled to 0.degree. C. and diluted with Et.sub.2O (150 mL).
The mixture was then carefully quenched with saturated aqueous
NaHCO.sub.3 until gas evolution ceased. At this time, the organic
layer was separated and the remaining aqueous layer was extracted
with Et.sub.2O (300 mL). The combined organic layers were washed
with brine (200 mL), dried (Na.sub.2SO.sub.4), filtered, and
concentrated in vacuo. Purification by silica gel chromatography
eluting with 20%-50% EtOAc/hexanes afforded the title compound
(0.960 g, 93%): .sup.1H NMR (300 MHz, CDCl.sub.3) .delta. 7.34-7.30
(m, 5H), 5.11-4.83 (m, 3H), 4.21 (q, J=7.2 Hz, 2H), 3.37-3.25 (m,
2H), 1.73-1.68 (m, 1H), 1.27 (t, J=7.2 Hz, 3H), 1.14-1.06 (m, 1H);
ESI MS m/z 280 [M+H].sup.+.
2-(Benzyloxycarbonylamino)-1-hydroxycyclopropanecarboxylic acid
(7b)
To a 0.degree. C. solution of ethyl
2-(benzyloxycarbonylamino)-1-hydroxycyclopropanecarboxylate (6b,
12.5 g, 44.7 mmol) in THF (100 mL) was added K.sub.2CO.sub.3 (24.7
g, 179.0 mmol) as a solution in H.sub.2O (300 mL). The reaction was
allowed to warm to room temperature and stirred for 4 h and then
additional H.sub.2O (200 mL) was added. After stifling an
additional 18 h at room temperature the reaction was concentrated
to remove most of the THF. The remaining aqueous solution was
washed with Et.sub.2O (2.times.500 mL), acidified with 2 N HCl to
pH 2, and then extracted with EtOAc (5.times.200 mL). The combined
EtOAc layers were washed with brine (500 mL), dried
(Na.sub.2SO.sub.4), filtered and concentrated in vacuo to afford
the title compounds (7.75 g, 69%) as a mixture of diastereomers.
The mixture was triturated with Et.sub.2O to afford a white solid
as mostly the major diastereomers. The supernatant was concentrated
and then triturated with Et.sub.2O to afford a clean mixture of
both diastereomers. Major Diastereomer: .sup.1H NMR (300 MHz, MeOD)
.delta. 7.50-7.14 (m, 5H), 5.22-4.96 (m, 2H), 3.23-3.10 (m, 1H),
1.60 (dd, J=8.9, 6.3 Hz, 1H), 1.10 (t, J=6.2 Hz, 1H); Multimode
(APCI+ESI) MS m/z 250 [M-H].sup.-. Mixture of Diastereomers:
.sup.1H NMR (300 MHz, MeOD) .delta. 7.45-7.14 (m, 5H), 5.24-5.01
(m, 2H), 3.25-3.15 (m, 0.46H), 3.14-3.01 (m, 0.54H), 1.71-1.53 (m,
1H), 1.42 (dd, J=9.1, 6.4 Hz, 0.54H), 1.12 (t, J=6.2 Hz, 0.46H);
Multimode (APCI+ESI) MS m/z 250 [M-H].sup.-.
Representative Compounds
The following representative compounds may be prepared according to
the foregoing procedures.
##STR00131## ##STR00132## ##STR00133## ##STR00134## ##STR00135##
##STR00136## ##STR00137## ##STR00138## ##STR00139## ##STR00140##
##STR00141## ##STR00142## ##STR00143## ##STR00144## ##STR00145##
##STR00146## ##STR00147## ##STR00148## ##STR00149## ##STR00150##
##STR00151## ##STR00152## ##STR00153## ##STR00154## ##STR00155##
##STR00156##
MIC Assay Protocol
Minimum inhibitory concentrations (MIC) are determined by reference
Clinical and Laboratory Standards Institute (CLSI) broth
microdilution methods per M7-A7 [2006]. Quality control ranges
utilizing E. coli ATCC 25922, P. aeruginosa ATCC 27853 and S.
aureus ATCC 29213, and interpretive criteria for comparator agents
are as published in CLSI M100-S17 [2007]. Briefly, serial two-fold
dilutions of the test compounds are prepared at 2.times.
concentration in Mueller Hinton Broth. The compound dilutions are
mixed in 96-well assay plates in a 1:1 ratio with bacterial
inoculum. The inoculum is prepared by suspension of a colony from
an agar plate that is prepared the previous day. Bacteria are
suspended in sterile saline and added to each assay plate to obtain
a final concentration of 5.times.10.sup.5 CFU/mL. The plates are
incubated at 35.degree. C. for 20 hours in ambient air. The MIC is
determined to be the lowest concentration of the test compound that
resulted in no visible bacterial growth as compared to untreated
control.
In Vivo Efficacy Models
Compounds are tested for in vivo efficacy in a murine septicemia
model of infection. Two models are run on each compound, using E.
coli and P. aeruginosa QC bacterial strains. Both studies employ
the same design. Male CD-1 (CRL)-derived mice (individual body
weight, 24.+-.2 grams) are inoculated IP with the 2.times.LD90-100
dose of E. coli ATCC 25922 (4.5.times.105 CFU/mouse) in 0.5 mL of
BHI broth containing 5% mucin, or the 2.times.LD90-100 dose of P.
aeruginosa ATCC 27853 (5.8.times.104 CFU/0.5 mL/mouse) in BHI broth
containing 5% mucin. At 1 hour after bacterial challenge, the mice
receive a single SC or IV dose of vehicle or test substance to
assess in vivo anti-infective activity. Mortality is recorded once
daily for 7 days after bacterial inoculation.
All of the U.S. patents, U.S. patent application publications, U.S.
patent applications, foreign patents, foreign patent applications
and non-patent publications referred to in this specification are
incorporated herein by reference, in their entirety to the extent
not inconsistent with the present description.
From the foregoing it will be appreciated that, although specific
embodiments of the invention have been described herein for
purposes of illustration, various modifications may be made without
deviating from the spirit and scope of the invention. Accordingly,
the invention is not limited except as by the appended claims.
* * * * *